

**Author Index for 1989**

Abbott, K. 28:279  
Adinoff, B. 30:137  
Adler, L. 27:1  
Agam, G. 27:217  
Ainsworth, B. 28:323  
Aizenberg, D. 27:65  
Akiskal, H.S. 30:21  
Al-Sadir, J. 28:161  
Albala, A.A. 27:161  
Aldenhoff, J.B. 29:221  
Alexson, J. 27:81  
Alphs, L.D. 30:119  
Altamura, C. 30:69  
Altshuler, L. 27:193, 28:145  
Amrung, S. 28:153  
Ancri, D. 29:409  
Anderer, P. 29:387  
Andersen, K.H. 30:77  
Anderson, I.M. 29:161  
Angeleri, F. 29:403  
Angrist, B. 27:1  
Angulo, L.N. 30:155  
Arató, M. 29:235  
Arbisi, P.A. 28:323  
Ardisson, J.-L. 28:263  
Arora, R.C. 30:125  
Aulich, A. 29:361, 29:363  
  
Baerwald, R. 29:341  
Barchas, J.D. 30:111  
Barocka, A. 29:187  
Baron J.-C. 29:357  
Barratt, E.S. 27:5  
Barsi, J. 29:235  
Bartko, J.J. 28:227  
Bartzokis, G. 27:193, 28:117, 28:145  
Baumann, N. 30:107  
Bechter, K. 29:281  
Beck, G. 29:187  
Becker, H. 29:309  
Becker, T. 29:285  
Beckmann, H. 29:391, 29:463  
Beersma, D.G.M. 28:47  
Belkin, B.M. 29:113  
Belugou, J.-L. 28:263  
Benkert, O. 29:221, 30:83  
Berga, S.L. 27:351  
Berger, Y. 29:427  
  
Berglund, M. 27:49  
Berlit, P. 29:459  
Berman, S.R. 28:193  
Besson, J.A.O. 29:291, 29:327, 29:447  
Best, P.V. 29:447  
Biggs, M.M. 27:127  
Black, D.W. 30:243  
Blue, L.D. 27:81  
Bogerts, B. 29:255  
Botsch, H. 29:335  
Bouhuys, A.L. 28:47  
Bourdel, M.-C. 29:409  
Bovier, P. 30:103  
Bracha, H.S. 30:275  
Braden, W. 28:63  
Bratenstein, P. 29:231  
Brawanski, A. 29:307  
Breier, A. 29:177  
Brodie, J.D. 29:453  
Broggini, G. 29:55  
Brown, C.S. 27:5  
Brown, G.M. 28:119  
Brown, W.A. 28:315  
Brunner, R.L. 30:223  
Bryant, S.G. 27:5  
Buchanan, R.W. 27:335, 30:119  
Buehler, B. 29:459  
Buller, R. 29:271  
Burgess, J.W. 30:31  
Burrows, G.D. 30:63  
Buysse, D.J. 28:193  
Byerley, W.F. 30:191  
Bylund, D.B. 27:81  
  
Caillard, V. 29:357  
Caligiuri, M.P. 30:275  
Cameron, O.G. 28:25  
Campanini, T. 28:89  
Campbell, J.L. 27:5  
Campbell, S.S. 27:23  
Camurcu, S. 29:151  
Candito, M. 28:263  
Capone, C. 29:425  
Carpenter, W.T., Jr. 30:119  
Carroll, B.J. 27:161  
Carson, S.W. 30:217  
Carstens, M.E. 27:101  
Casacchia, M. 29:261

Cassano, G.B. 30:21  
 Cazzullo, C.L. 29:257  
 Ceccoli, S. 29:261  
 Chang, W.-H. 30:45  
 Charles, G. 29:199  
 Charney, D.S. 27:173  
 Chen, T.-Y. 30:45  
 Chicz-DeMet, A. 30:231  
 Chiodera, P. 28:89  
 Chris Heh, C.W. 30:313  
 Christie, W. 29:375  
 Classen, W. 29:267, 29:421  
 Cleghorn, J.M. 28:119  
 Coffman, J.A. 27:233  
 Coger, R.W. 28:117  
 Coggiano, M.A. 30:259  
 Cohen, B. 28:181  
 Cohen, L.S. 28:345  
 Coiro, V. 28:89  
 Colter, N. 29:247  
 Comaty, J. 28:97  
 Conte, H.R. 27:71, 28:215  
 Cook, B. 30:53  
 Cooper, P.W. 29:137  
 Cooper, T.B. 28:1  
 Corchoran, C. 27:81  
 Cordes, M. 29:341  
 Cordovana, V. 29:265  
 Cornblatt, B.A. 29:65  
 Cornes, C. 27:225  
 Cottraux, J.A. 27:31  
 Courtney, P. 27:313  
 Cowdry, R.W. 27:111  
 Cowen, P.J. 29:161  
 Cowley, D.S. 27:357  
 Coryell, W.H. 30:243  
 Costa, J. 30:313  
 Crawford, J.R. 29:447  
 Crook, W.S. 29:161  
 Crow, T.J. 29:247  
 Csernansky, J.G. 28:135, 30:111  
 Cummings, J.L. 27:193, 28:145  
 Cummings, K.L. 27:351  
 Cummings, M.A. 27:351  
 Curtis, G.C. 28:25  
 Czecze, E. 29:235  
 D'Albenzio, L. 29:261  
 Dager, S.R. 27:357  
 Dains, K. 29:55  
 Daniel, D.G. 27:55  
 Daniels, S. 30:223  
 Darcourt, G. 28:263  
 Darko, D.F. 28:355  
 Davidson, J. 29:327  
 Davies, S.L. 29:87  
 Davis, C.M. 28:153, 29:123, 30:45  
 Davis, J.M. 28:73, 28:97  
 Davous, P. 28:289  
 Deering, W.M. 29:407  
 Deisenhammer, E. 29:337, 29:443  
 DeJong, J. 30:137  
 de la Fuente, J.R. 30:155  
 de Leon, M.J. 29:359  
 de Maertelaere, V. 27:277  
 Demer, J.L. 29:123  
 DeMet, E. 30:231  
 De Mol, J. 27:277  
 Deng, H.-C. 30:45  
 Denoroy, L. 27:31  
 Depue, R.A. 28:323  
 DeReuter, J. 29:55  
 Derouesne, C. 29:409  
 de Villiers, A.S. 27:101  
 Devlin, M.J. 28:11  
 Dieci, M. 29:257  
 Diehl, B.J.M. 29:317  
 Diekmann, V. 29:395  
 Dierks, T. 29:399, 29:413, 29:417, 29:419,  
       29:433, 29:435, 29:439, 29:449  
 Dietz, H. 29:287, 29:309  
 Dillon, D.J. 29:207  
 Di Michele, V. 29:261  
 Donner, A. 28:41  
 Doran, A. 29:177  
 Dressler, D. 29:457  
 Drochner, R. 29:323  
 Dubois, G. 30:107  
 Duffy, F.H. 29:379  
 Dumlao, M.S. 29:169  
 Duncan, E. 27:1  
 Duncan, W.C. 30:285  
 Dunner, D.L. 27:357  
 Easton, C. 28:161  
 Ebmeier, K.P. 29:291, 29:327, 29:447  
 Edell, W.S. 30:265  
 Ehlers, C.L. 27:13, 30:165  
 Ehrenheim, Ch. 29:283, 29:287  
 Eilles, C. 29:449

Eillies, C. 29:347  
 Eiser, A.S. 27:359  
 Elger, C.E. 29:369  
 Emrich, D. 29:457  
 Endicott, J. 27:183  
 Ereshefsky, L. 30:45  
 Erlenmeyer-Kimling, L. 29:65  
 Esser, A.H. 28:279  
 Etzel, B.A. 27:127  
 Evans, N.T.S. 29:327  
  
 Faienza, C. 29:425  
 Faraone, S.V. 28:243, 28:315  
 Farrell, M. 30:223  
 Fasullo, S. 29:265  
 Faull, K.F. 28:97, 30:111  
 Faustman, W.O. 28:135  
 Fava, M. 28:345  
 Feather, J.N. 29:11  
 Feenstra, A. 30:259  
 Feer, H. 27:287  
 Feinendegen, L.E. 29:361, 29:363  
 Feitel, B. 28:279  
 Feldmann, M. 29:457  
 Felthous, A.R. 27:5  
 Ferraro, T. 30:137  
 Ferris, S.H. 29:359  
 Fidone, G.S. 28:153  
 Filipovic, S. 29:409  
 Firnau, G. 28:119  
 Fischer, C. 27:241  
 Flügel, D. 29:231  
 Flynn, J.M. 29:407  
 Folts, D.J. 29:11  
 Frackowiak, R.S.J. 29:353  
 Frances, A. 28:31  
 Frank, E. 27:225  
 Frankel, F. 27:81  
 Franssen, E. 29:359  
 Freeman, W.J. 29:239  
 Frey, M. 29:377  
 Friberg, L. 29:319  
 Friedhoff, A. 28:1  
 Fristad, M.A. 29:215  
 Frith, C.D. 29:247  
 Fritze, J. 29:267, 29:419, 29:421  
 Frlich, L. 29:347, 29:399, 29:449  
 Frommberger, U. 29:271  
 Fuenfgeld, E.W. 29:411  
 Fuenfgeld, M. 29:335  
  
 Futtersak, W. 29:55  
 Fyer, A.J. 28:181, 28:171, 29:207  
 Fyer, M. 27:183  
  
 Gaab, M.R. 29:309  
 Gaillard, J.-M. 30:103  
 Galanter, M. 30:217  
 Galaske, R.G. 29:343  
 Gallyas, F. 29:463  
 Galzin, A.-M. 28:289  
 Garcia, M. 27:137  
 Gardner, D.L. 27:111  
 Garnett, E.W. 28:119  
 Gartside, S.E. 29:161  
 Garvey, M. 30:53  
 Gaudel, G. 27:149  
 Gay, N. 27:31  
 Gay, T.L. 30:1  
 Gebetsberger, B. 29:337  
 Gemmell, H.G. 29:327, 29:447  
 Gentsch, C. 27:287  
 George, A.E. 29:359  
 Georgi, P. 29:331  
 Georgotas, A. 28:1  
 Gerlach, L. 29:341  
 Gershon, S. 29:169  
 Gevedon, R.M. 27:5  
 Giannini, A.J. 29:11  
 Gibb, C. 30:95  
 Giles, D.E. 27:127  
 Gilleard, C.J. 27:313  
 Giller, E.L., Jr. 30:265  
 Gilles, C. 27:277  
 Gillin, J.C. 27:23, 27:253, 27:351  
 Giobbio, M. 29:257  
 Giordano, P.L. 29:265  
 Glass, R.M. 28:161  
 Glassman, A.H. 28:11  
 Glover, V. 30:95  
 Gnudi, A. 28:89  
 Goetz, R.G. 29:207  
 Gold, M.S. 29:113  
 Gold, P. 30:137  
 Goldstein, J.M. 28:243  
 Golshan, S. 27:351  
 Gorman, J.M. 27:183, 28:171, 28:181, 29:207  
 Gottesman, I.I. 29:37  
 Govi, A. 28:89  
 Graf von Keyserlingk, D. 29:461  
 Greden, J.F. 27:359

Griffin, M.L. 28:335  
 Groezinger, B. 29:395  
 Grota, L.J. 29:29  
 Gruenberger, J. 29:387  
 Gubarev, N. 29:303  
 Gueguen, B. 29:409  
 Guenther, W. 29:453  
 Guercetti, G. 30:69  
 Guidi, M. 29:403  
 Gunreben, G. 29:307  
 Gupta, K. 29:29  
 Gur, R.C. 27:325  
 Gur, R.E. 27:325  
 Gurevich, D. 29:169  
 Haas, S. 29:463  
 Haier, R.J. 28:63  
 Halbreich, U. 30:217  
 Hale, A.S. 29:87  
 Halmi, K.A. 29:105  
 Halsband, U. 29:363  
 Hanin, I. 29:45  
 Harrington, A. 29:335  
 Harris, W.R. 27:241  
 Harrison, W.M. 27:183  
 Haskett, R.F. 27:161  
 Haubitz, I. 29:293  
 Haviland, M.G. 27:351  
 Hedde, J.-P. 29:323  
 Heimann, H. 29:277  
 Heinrichs, D.W. 27:199, 27:335  
 Heinsen, H. 29:391, 29:463  
 Heinsen, Y.L. 29:463  
 Heintz, P. 29:283, 29:287  
 Heiss, W.-D. 29:351  
 Hemdal, P. 27:1  
 Heninger, G.R. 27:173  
 Hennerici, M. 29:363  
 Henze, Th. 29:457  
 Herholz, K. 29:351  
 Hermesh, H. 27:65  
 Hermle, L. 29:335  
 Hernandez, J.M. 28:153  
 Herrera, J. 28:307  
 Herzog, H. 29:361, 29:363  
 Herzog, S. 29:281  
 Heun, R. 29:295  
 Heuser, I. 29:221, 30:83  
 Heyer, R. 29:343  
 Hill, J.L. 29:1  
 Hill, M.A. 27:193, 28:145  
 Himle, J.A. 28:25  
 Hinrichs, H. 29:431  
 Hirsch, M. 28:345  
 Hirschowitz, J. 29:55  
 Hitzemann, B. 29:55  
 Hitzemann, R. 29:55  
 Hoell, K. 29:337, 29:443  
 Hoke, M. 29:369  
 Holl, K. 29:309  
 Hollander, E. 28:171, 29:181, 29:207  
 Horrobin, D.F. 27:313  
 Horton, R.W. 29:87  
 Hundeshagen, H. 29:283, 29:287, 29:367  
 Huret, J.D. 29:357  
 Ihl, R. 29:299, 29:347, 29:413, 29:417, 29:421,  
     29:449  
 Isenhart, R. 30:313  
 Imber, S. 27:225  
 Jacobsen, F.M. 29:1  
 Jaffe, J.H. 27:117  
 Janicak, P.G. 28:97, 28:73  
 Jann, M.W. 28:153, 30:45  
 Janowsky, D.S. 27:23, 27:253  
 Janz, D. 29:375  
 Jauch, D. 27:199  
 Javaid, J.I. 28:73, 28:97  
 Javors, M.A. 27:241  
 Jeste, D.V. 29:45  
 Jin, Y. 30:313  
 Joffe, R.T. 30:213  
 Johnstone, E.C. 29:247  
 Jones, S.B. 27:81  
 Joseph, K.C. 28:255  
 Joseph, R. 30:95  
 Judd, F.K. 30:63  
 Jutai, J.W. 27:207  
 Kafka, M.S. 30:181  
 Kaiya, H. 30:11  
 Kaplan, R. 28:119  
 Kappos, L. 29:293, 29:295  
 Karege, F. 30:103  
 Karp, L. 27:65  
 Kaschka, W.P. 29:231  
 Kasper, S. 28:227  
 Kathol, R.G. 30:77  
 Katona, C.L.E. 29:87

Mathew, R.J. 27:55, 28:241  
 Matsushima, E. 28:307  
 Matuzas, W. 28:161  
 Maurer, K. 29:239, 29:299, 29:347, 29:391,  
   29:413, 29:417, 29:419, 29:421, 29:433,  
   29:435, 29:439, 29:449, 29:461  
 May, P.R.A. 27:193, 28:145  
 Mays, W. 30:223  
 Mazoyer, B.M. 29:357  
 McAdam, D. 27:297  
 McCue, R.E. 28:1  
 McIntyre, I.M. 30:63  
 McKenney, P.D. 30:119  
 McLaughlin, J.A. 27:233  
 McPhee, K. 28:25  
 Meinig, G. 29:317  
 Meixensberger, J. 29:307  
 Mellow, A.M. 29:1  
 Meltzer, H.L. 27:267  
 Meltzer, H.Y. 30:125  
 Mendelson, W.B. 30:285  
 Mendlewicz, J. 27:277  
 Meyer, G.J. 29:367  
 Meyer, H.K. 29:317  
 Miller, N.S. 29:113  
 Mirin, S.M. 28:335  
 Molchan, S.E. 29:1  
 Monk, T.H. 27:89, 28:193  
 Morrison, S.L. 29:137  
 Morycz, R.K. 27:225  
 Moser, E. 29:453  
 Moses, J.A., Jr. 28:135  
 Mubrin, Z. 29:303  
 Mueller, E.A. 29:1  
 Mueller, T. 29:419  
 Mukherjee, S. 29:17  
 Munitz, H. 27:65  
 Murphy, D.L. 29:1  
 Nagachandran, N. 28:1  
 Nahmias, C. 28:119  
 Nasrallah, H.A. 27:233  
 Nathan, R.S. 30:165  
 Nee, J. 27:183  
 Negele-Anetsberger, J. 29:231  
 Nelson, J. 30:231  
 Nemati, M.N. 29:309  
 Neufeld, M.Y. 29:427  
 Newman, M.M. 29:105  
 Newsholme, E.A. 29:161  
 Newton, R. 29:327  
 Niedermeier, T. 29:331  
 Niemann, K. 29:461  
 Noder, M. 29:187  
 Norman, T.R. 30:63  
 Noyes, R., Jr. 30:53, 30:243  
 Nunes, E.V. 28:105  
 Nutt, D.J. 28:351  
 Oepen, G. 29:335  
 Olson, S.C. 27:233  
 Oltmanns, T.F. 27:199  
 Opitz, H. 29:277  
 Orpen, G. 30:305  
 Owens, D.G.C. 29:247  
 Oxenkrug, G.F. 29:169  
 Öztaş, B. 29:151  
 Pandey, G.N. 28:73  
 Pantev, C. 29:369  
 Papp, L.A. 28:171, 28:181, 29:207  
 Parker, D.M. 29:447  
 Parry, B.L. 30:285  
 Parry-Billings, M. 29:161  
 Pawlik, G. 29:351  
 Paykel, E.S. 29:87  
 Percudani, M. 30:69  
 Perel, J.M. 27:225, 30:165  
 Perisic, I. 29:399, 29:449  
 Peron-Magnan, P. 29:357  
 Perry, P.J. 30:77  
 Peters, J.L. 27:297  
 Petersen, D. 29:277, 29:285  
 Petryshen, P. 28:41  
 Petsch, R. 29:453  
 Philipp, M. 29:221, 30:83  
 Picard, S. 27:71  
 Pickar, D. 27:111, 29:177  
 Pirke, K.-M. 27:39  
 Piscani, K. 29:55  
 Placidi, G.F. 30:21  
 Plancon, D. 29:409  
 Plutchik, R. 27:71, 28:215  
 Pogacnik, T. 29:313  
 Poirier, M.-F. 28:289  
 Pollack, M.H. 28:345  
 Pollock, B.G. 30:165  
 Porter, F.I. 29:123  
 Potkin, S.G. 28:307, 30:313  
 Prasad, A. 30:95  
 Prati, G. 29:425

Katz, J.L. 28:11  
 Kaye, H. 29:137  
 Kelley, J.S. 29:87  
 Kelly, M.W. 30:243  
 Kent, T.A. 27:5  
 Kerry, S.M. 29:87  
 Kharazmi, M. 28:307  
 King, R.J. 30:111  
 Kirby, J. 27:81  
 Kirkpatrick, B. 27:199, 30:119  
 Klahr, A.L. 29:113  
 Klein, D.F. 28:105, 28:171, 28:181, 29:207  
 Klose, U. 29:289  
 Kluger, A. 29:359  
 Knezevic, S. 29:303  
 Koerner, R. 29:283  
 Kojima, T. 28:307  
 Kopp, N. 27:31  
 Kopp, U. 29:45  
 Korczyn, A.D. 29:427  
 Korn, M. 27:71  
 Kornhuber, H.H. 29:395  
 Koschorke, S. 29:273  
 Kovasznay, B. 29:55  
 Krajewski, K. 29:123  
 Krebs, B. 28:263  
 Kretzschmar, K. 29:221  
 Krieg, J.-C. 27:39  
 Kripke, D.F. 27:23, 27:253, 27:351  
 Kruesi, M.J.P. 28:115  
 Kruse, J. 29:29  
 Kumor, K.M. 27:117  
 Kunkel, K. 29:431  
 Kunz, U. 29:283, 29:287  
 Kupfer, D.J. 27:127, 27:13, 27:225, 28:193,  
     30:165  
 Kutcher, S.P. 29:137, 30:213  
 Kuwert, T. 29:361, 29:363

LaGrone, H. 29:55  
 Lajos, J. 29:235  
 Lamour, Y. 28:289  
 Lanczik, M. 29:347, 29:421  
 Lange, H.W. 29:361  
 Langen, K.-J. 29:361  
 Langer, S.Z. 28:289  
 Lauer, C. 27:39  
 Lawlor, B.A. 29:1  
 Lawson, W.B. 29:45  
 Leblhuber, F. 29:337, 29:443  
 Lefebre, C. 29:375  
 Lehmann, D. 29:385  
 Lehnertz, K. 29:369  
 Leibing, U. 29:395

Lejoyeux, M. 30:107  
 Lempérière, T. 30:107  
 Lenzenweger, M.F. 29:65  
 Leon, A. 28:323  
 Lichtsteiner, M. 27:287  
 Liebowitz, M.R. 28:171, 28:181, 29:207  
 Linkie, D.M. 28:11  
 Linnoila, M. 27:297, 30:137  
 Lista, A.L. 30:253  
 Little, K.Y. 30:1  
 Littlewood, J. 30:95  
 Livne, A. 27:217  
 Lohr, J.B. 30:275  
 Lohr, N.E. 27:161  
 Lombard, C.J. 27:101  
 Loo, H. 29:357  
 Lucas, P.B. 27:111  
 Luetkenhoener, B. 29:369  
 Lung, F.-W. 30:45

Maas, J.W. 27:241  
 MacDonald, C. 30:213  
 Macedo, C.A. 27:241  
 Machowski, R. 29:199  
 MacLaughlin, R.A. 28:345  
 Mahajan, S. 29:55  
 Maier, W. 29:221, 30:83  
 Maier-Hauff, K. 29:341  
 Mallard, J.R. 29:327  
 Malloy, P. 28:63  
 Maloney, M.J. 30:223  
 Mamelak, M. 29:137  
 Manku, M.S. 27:313  
 Mann, K. 29:277  
 Mann, U. 29:293  
 Marazziti, D. 30:21  
 Marchesi, C. 28:89  
 Marienhagen, J. 29:231  
 Markow, T.A. 29:37  
 Marks, G. 27:137  
 Markut, H. 29:443  
 Marshall, L.E. 28:295  
 Martin, P. 27:149  
 Martinez, J.M. 28:171  
 Martinot, J.L. 29:357  
 Massol, J. 27:149

Preskorn, S.H. 29:215  
 Pringuey, D. 28:263  
 Prohovnik, I. 27:49, 29:301  
 Puehringer, W. 29:337

Quitkin, F.M. 28:105

Rasmussen, S. 28:63

Rea, M.M. 28:31  
 Reed, M.K. 29:429  
 Rees, J. 29:395  
 Reich, J. 30:145  
 Reimherr, F.W. 30:191  
 Reischies, F.M. 29:323  
 Reisecker, F. 29:337, 29:443  
 Resnick, S.M. 27:325  
 Reynolds, C.F. III 27:13, 27:225, 28:193  
 Rice, D.M. 30:313  
 Richards, A.L. 30:45  
 Riederer, P. 29:187, 29:391  
 Rihmer, Z. 29:235  
 Ringelstein, E.B. 29:273  
 Risberg, J. 27:49, 29:297, 29:303  
 Risch, S.C. 27:23, 27:253  
 Roeda, D. 29:327  
 Roffwarg, H.P. 27:127  
 Rogeness, G.A. 27:241  
 Rohrbach, E. 29:295  
 Roose, S.P. 28:11  
 Rose, F.C. 30:95  
 Rose, R.M. 27:5  
 Rosen, J. 27:297  
 Rosenbaum, J.F. 28:345  
 Ross, D. 28:171  
 Rossi, A. 29:261  
 Roth, S.D. 29:17  
 Rotrosen, J. 27:1  
 Rott, R. 29:281  
 Roudier, M. 28:289  
 Roy, A. 29:177, 30:137, 30:181  
 Rubino, M.A. 29:265  
 Rubinow, D. 30:137  
 Rupprecht, C. 29:187  
 Rupprecht, M. 29:187  
 Rupprecht, R. 29:187, 29:417, 29:435  
 Rush, A.J. 27:127  
 Russell, V.A. 27:101  
 Ryckaert, P. 27:277  
 Rzesacz, E. 29:309  
 Sacchetti, E. 29:257  
 Sack, D.A. 30:285  
 Sacks, W. 28:279  
 Saklad, S.R. 30:45  
 Saletu, B. 29:387  
 Salin-Pascual, R.J. 30:155  
 Salvati, E. 28:263  
 Sandberg, D. 27:183  
 Sandler, M. 30:95  
 Sandman, C.A. 30:313  
 Sandyk, R. 29:17  
 Sangdahl, C. 30:231  
 Sani, E. 29:425  
 Sauer, H. 29:331  
 Scarpino, O. 29:403  
 Scharff, G. 29:463  
 Scherb, W. 29:395  
 Schiazza, G. 29:261  
 Schittecatte, M. 29:199  
 Schlecht, A. 29:231  
 Schlegel, S. 29:221, 29:271, 30:83  
 Schnabel, M. 29:377  
 Schneider, R. 29:273  
 Schnur, D.B. 29:17  
 Schober, O. 29:343, 29:367  
 Schroeder, J. 29:331  
 Schroth, G. 29:277, 29:289  
 Schüler, P. 29:377  
 Schüttler, R. 29:281  
 Schwarzkopf, S.B. 27:233  
 Searson, J.A. 27:101  
 Seggie, J. 30:305  
 Seidel, J.W. 29:367  
 Serafetinides, E.A. 28:117  
 Sharma, R. 28:97  
 Sharp, P.F. 29:327, 29:447  
 Shekim, W.O. 27:81  
 Sherer, M.A. 27:117  
 Sherman, A.D. 30:77  
 Shimazono, Y. 28:307  
 Shipley, J.E. 27:359  
 Shrout, P.E. 30:201  
 Siegel, B. 29:169  
 Simon, G. 29:431  
 Sitaram, N. 28:255  
 Skodol, A.E. 30:201  
 Slotnick, V. 27:1  
 Smith, F.W. 29:291, 29:327, 29:447  
 Snow, W.G. 29:137  
 Sofic, E. 29:187  
 Solomon, C.M. 28:31  
 Soubrié, P. 27:149  
 Souetré, E. 28:263  
 Southwick, S.M. 30:265  
 Spilich, G. 29:303  
 Spoont, M.R. 28:323  
 Sramek, J. 30:313  
 Staedt, D. 29:293, 29:295  
 Stein, M.K. 33:231  
 Steinberg, R. 29:453  
 Steiner, M. 30:305  
 Steinhaeusel, H. 29:443  
 Steinmetz, H. 29:363  
 Stolke, D. 29:287  
 Stoppe, G. 29:367

Stratta, P. 29:261  
 Strauss, M.E. 27:199  
 Streck, P. 29:453  
 Sullivan, B.S. 29:11  
 Summerfelt, A. 27:199  
 Sunderland, T. 29:1  
 Sweeney, J.A. 28:31  
 Syrota, A. 29:357  
 Szalai, J.P. 29:137  
 Szechtman, B. 28:119  
 Szechtman, H. 28:119  
 Szelies, B. 29:351  
  
 Taljaard, J.J.F. 27:101  
 Tampieri, E. 28:89  
 Tandon, R. 27:359  
 Targum, S.D. 28:295  
 Tartaro, A. 29:261  
 Teitlebaum, L. 29:55  
 Tesar, G.E. 28:345  
 Theodorou, A.E. 29:87  
 Thornton, J. 27:225  
 Tissot, R. 30:103  
 Tollefson, G. 30:53  
 Tommasi, M. 27:31  
 Tran, C. 30:231  
 Trenkler, E. 29:337  
 Trenkler, J. 29:443  
 Tsuang, M.T. 28:243  
 Turpin, J.-C. 30:107  
  
 Uematsu, M. 30:11  
 Uhlenhuth, E.H. 28:161  
 Ullrich, O.W. 29:307  
 Ulrich, I. 29:123  
 Ulrich, P. 29:317  
 Uy, J. 27:183  
  
 Vaddadi, K.S. 27:313  
 Valvassori, G. 29:257  
 van den Hoofdakker, R.H. 28:47  
 Vande Wiele, R. 28:11  
 van Kammen, D.P. 27:297  
 van Kammen, W.B. 27:297  
 van Praag, H.M. 27:71, 28:215  
 Van Toller, S. 29:429  
 van Zyl, A.M. 27:101  
 Varga, M. 29:235  
 Vieth, J. 29:377  
  
 Villani, D. 29:425  
 Vita, A. 29:257  
 Volkow, N.D. 29:123  
 Vore, M. 30:1  
 Voth, E. 29:457  
 Vucinic, G. 29:303  
  
 Walsh, B.T. 28:11  
 Walsh, V. 28:31  
 Waltrip, R.W. II 27:199  
 Wannenmacher, W. 29:303  
 Ward, M.F. 30:191  
 Wasel, J. 29:461  
 Wehr, T.A. 30:285  
 Weiss, R.D. 28:335  
 Weller, E.B. 29:215  
 Weller, R.A. 29:215  
 Wense, A.V.D. 29:293  
 Westphal, K.P. 29:395  
 Wetzel, E. 29:459  
 White, P.A. 28:135  
 Wiedemann, K. 30:83  
 Wienhard, K. 29:351  
 Wiethoelter, H. 29:285  
 Wildhagen, K. 29:367  
 Wilhelm, K.R. 29:331  
 Williamson, P.C. 29:137  
 Willinsky, R.A. 29:137  
 Wilmotte, J. 29:199  
 Wilson, W.H. 27:55, 28:241  
 Wirshing, W. 27:193, 28:145  
 Wolf, A.P. 29:359  
 Wolkowitz, O.M. 29:177  
 Woods, S.W. 27:173  
 Wright, L. 28:11  
 Wright, N. 30:305  
 Wyatt, R.J. 29:45, 30:259  
  
 Yao, J.K. 27:297  
 Yaylayan, S.A. 29:215  
 Yeh, C.-M. 30:217  
 Yehuda, R. 30:265  
 Yerevanian, B.I. 29:29  
 Young, A.S. 28:315  
  
 Zacher, A. 29:433  
 Zborowski, L. 29:29  
 Zhang, Y. 27:267  
 Zis, A.P. 27:161

## Subject Index for 1989

### Abnormal Involuntary Movement Scale

electromechanical measures, observer ratings, tardive dyskinesia, 27:193  
observer ratings, electromechanical measures, tardive dyskinesia, 27:193  
tardive dyskinesia, electromechanical measures, observer ratings, 27:193

### Acetazolamide

anxiety, carbon dioxide, cerebral blood flow, 28:241  
carbon dioxide, anxiety, cerebral blood flow, 28:241  
cerebral blood flow, anxiety, carbon dioxide, 28:241  
pyruvate dehydrogenase, schizophrenia, thiamine, 28:279  
schizophrenia, pyruvate dehydrogenase, thiamine, 28:279  
thiamine, pyruvate dehydrogenase, schizophrenia, 28:279

### Activity

menstrual cycle, premenstrual syndrome, sleep, temperature, 30:285  
premenstrual syndrome, sleep, temperature, 30:285  
sleep, menstrual cycle, premenstrual syndrome, temperature, 30:285  
temperature, menstrual cycle, premenstrual syndrome, sleep, 30:285

### Acute Panic Inventory

affective disorder, lactate, panic, 27:357  
carbon dioxide inhalation, panic, premenstrual dysphoria, 27:183  
lactate, affective disorder, panic, 27:357  
lactate, panic disorder, somatic symptoms, 29:207  
panic, affective disorder, 27:357  
panic, carbon dioxide inhalation, 27:183  
panic disorder, lactate, somatic symptoms, 29:207  
panic, lactate, 27:357  
panic, premenstrual dysphoria, 27:183  
premenstrual dysphoria, carbon dioxide inhalation, panic, 27:183  
somatic symptoms, lactate, panic disorder, 29:207

### Adenosine

caffeine, panic disorder, posttraumatic stress disorder, taste test, 30:231  
panic disorder, caffeine, posttraumatic stress disorder, taste test, 30:231  
posttraumatic stress disorder, caffeine, panic disorder, taste test, 30:231  
taste test, caffeine, panic disorder, posttraumatic stress disorder, 30:231

**Adenosine monophosphate.** See cyclic adenosine monophosphate

### Adolescence

affective disorder, cortisol, 27:101  
affective disorder, 3-methoxy-4-hydroxyphenylglycol, 27:101  
affective disorder, norepinephrine, 27:101  
cortisol, affective disorder, 27:101  
cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:101  
cortisol, norepinephrine, 27:101  
3-methoxy-4-hydroxyphenylglycol, affective disorder, 27:101  
3-methoxy-4-hydroxyphenylglycol, cortisol, 27:101  
3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:101  
norepinephrine, affective disorder, 27:101  
norepinephrine, cortisol, 27:101  
norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:101

### Affective disorder

Acute Panic Inventory, lactate, 27:357  
adolescents, cortisol, 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:101

Albert Einstein College of Medicine

Suicide Intent Scale, 27:71

age of onset, 3-methoxy-4-hydroxyphenylglycol, 30:103

Alzheimer's disease, clonidine, growth hormone, 27:277

Alzheimer's disease, EEG mapping, evoked potentials, 29:403

ankyrin, bipolar subtype, lithium, red blood cell membrane, 27:267

**Affective Disorder** continued

- antidepressants, clonidine binding in platelets, 28:73
- antidepressants, diagnostic criteria, 30:83
- antidepressants, geriatric depression, 28:1
- antidepressants, lithium, 28:73
- antidepressants, nortriptyline, 28:1
- antidepressants, phenelzine, 28:1
- antidepressants, schizophrenia, 28:73
- antidepressants, treatment response, 30:83
- antisocial personality disorder, borderline, 30:265
- antisocial personality disorder, monoamine oxidase, 30:265
- antisocial personality disorder, 30:265
- attention, continuous performance test, laterality, schizophrenia, 29:65
- bipolar depression, circadian rhythm, sleep, temperature, 27:23
- bipolar subtype, ankyrin, lithium, red blood cell membrane, 27:267
- borderline personality disorder, platelet monoamine oxidase, 30:265
- Center for Epidemiologic Studies Depression Scale, Mexican-Americans, 27:137
- cerebral blood flow, SPECT, 29:323, 29:331
- children, cholesterol, 29:215
- children, dexamethasone suppression test, 29:215
- children, glucose, 29:215
- children, potassium, 29:215
- children, sodium, 29:215
- cholesterol, children, 29:215
- cholesterol, dexamethasone suppression test, 29:215
- cholesterol, glucose, 29:215
- cholesterol, potassium, 29:215
- cholesterol, sodium, 29:215
- circadian rhythms, bipolar depression, 27:23
- circadian rhythms, cortisol, 28:263
- circadian rhythms, global vigor and affect, 27:89
- circadian rhythms, melatonin, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, sleep, temperature, 27:23, 28:263
- circadian rhythms, thyroid stimulating hormone, 28:263
- circadian rhythms, Visual Analogue Scale, 27:89
- circannual rhythms, dexamethasone suppression test, 29:87

**Affective Disorder** continued

- circannual rhythms, platelet imipramine binding, 29:87, 30:21
- clomipramine, interview behavior, 28:47
- clomipramine, sleep, 30:165
- clomipramine, sleep deprivation, 28:47
- clonidine, Alzheimer's disease, 27:277
- clonidine, binding in platelets, lithium, 28:73
- clonidine, binding in platelets, schizophrenia, 28:73
- clonidine, growth hormone, 27:277, 29:199
- clonidine, lithium, 28:73
- clonidine, schizophrenia, 28:73
- cluster analysis, seasonal affective disorder, 28:227
- cocaine, comorbidity, 28:105, 28:335
- cocaine, substance abuse, 28:105, 28:335
- comorbidity, cocaine, substance abuse, 28:105, 28:335
- computed tomography, psychotic symptoms, 29:221
- computed tomography, symptomatology, 29:271
- computed tomography, ventricle-brain ratio, 29:271
- continuous performance test, attention, laterality, schizophrenia, 29:65
- cortisol, adolescents, 27:101
- cortisol, circadian rhythms, 28:263
- cortisol, cyclic adenosine monophosphate, 30:181
- cortisol, dexamethasone suppression test, 27:161, 29:187
- cortisol, dihydroergocryptine, 30:181
- cortisol, dopamine, 29:187
- cortisol, epinephrine, 29:187
- cortisol, melatonin, 28:263
- cortisol, 3-methoxy-4-hydroxy-phenylglycol, 27:101
- cortisol, norepinephrine, 27:101, 28:263, 29:187
- cortisol, prostaglandin, 30:181
- cortisol, temperature, 28:263
- cortisol, thyroid stimulating hormone, 28:263
- cyclic adenosine monophosphate, 30:181
- dexamethasone suppression test, children, 29:215
- dexamethasone suppression test, cholesterol, 29:215
- dexamethasone suppression test, circannual rhythms, 29:87
- dexamethasone suppression test, cortisol, 27:161, 29:187

**Affective Disorder** continued

dexamethasone suppression test,  
dopamine, 29:187  
dexamethasone suppression test,  
epinephrine, 29:187  
dexamethasone suppression test,  
glucose, 29:215  
dexamethasone suppression test,  
homovanillic acid, 29:177  
dexamethasone suppression test,  
imipramine binding, 29:87  
dexamethasone suppression test,  
norepinephrine, 29:187  
dexamethasone suppression test,  
potassium, 29:215  
dexamethasone suppression test, sodium,  
29:215  
diagnostic criteria, antidepressants, 30:83  
diagnostic criteria, treatment response,  
30:83  
diagnostic specificity, imipramine binding,  
30:21  
dihydroergocryptine binding, 30:181  
dopamine, cortisol, 29:187  
dopamine, dexamethasone suppression  
test, 29:187  
dopamine, epinephrine, 29:187  
dopamine, norepinephrine, 29:187  
EEG mapping, Alzheimer's disease, 29:403  
EEG mapping, evoked potentials, 29:403  
elderly subjects, EEG mapping, 29:403  
elderly subjects, evoked potentials, 29:403  
epinephrine, cortisol, 29:187  
epinephrine, dexamethasone suppression  
test, 29:187  
epinephrine, dopamine, 29:187  
epinephrine, norepinephrine, 29:187  
evoked potentials, Alzheimer's disease,  
29:403  
evoked potentials, EEG mapping, 29:403  
evoked potentials, elderly subjects, 29:403  
fluoxetine, Hamilton Rating Scale for  
Depression, 30:191  
fluoxetine, imipramine, 30:191  
fluoxetine, placebo washout, 30:191  
generalized anxiety disorder,  
norepinephrine, 30:253  
generalized anxiety disorder,  
time sampling, 30:253  
geriatric depression,  
antidepressants, 28:1  
geriatric depression, maintenance  
pharmacotherapy, 27:225  
geriatric depression, nortriptyline,  
27:225, 28:1

**Affective Disorder** continued

geriatric depression, phenelzine, 28:1  
geriatric depression, sleep, 27:13  
geriatric depression, survival analysis,  
27:225  
global vigor and affect, circadian rhythm,  
27:89  
global vigor and affect, Visual Analogue  
Scale, 27:89  
glucose, children, 29:215  
glucose, cholesterol, 29:215  
glucose, dexamethasone suppression test,  
29:215  
glucose, potassium, 29:215  
glucose, sodium, 29:215  
growth hormone, Alzheimer's disease,  
27:277  
growth hormone, clonidine, 27:277, 29:199  
Hamilton Rating Scale for Depression,  
fluoxetine, 30:191  
Hamilton Rating Scale for Depression,  
imipramine, 30:191  
Hamilton Rating Scale for Depression,  
placebo washout, 30:191  
homovanillic acid, dexamethasone  
suppression test, 29:177  
5-hydroxyindolacetic acid, 30:181  
imipramine, fluoxetine, 30:191  
imipramine, Hamilton Rating Scale  
for Depression, 30:191  
imipramine, placebo washout, 30:191  
imipramine binding, circannual rhythms,  
29:87, 30:21  
imipramine binding, diagnostic specificity,  
30:21  
imipramine binding, dexamethasone  
suppression test, 29:87  
immune function, mania, 29:235  
interview behavior, clomipramine, 28:47  
interview behavior, sleep deprivation,  
28:47  
lactate, Acute Panic Inventory, 27:357  
laterality, attention, continuous  
performance test, 29:65  
laterality, schizophrenia, 29:65  
life events, mania, 30:213  
life events, Psychiatric Epidemiology  
Research Interview, 30:213  
life events, stressors, 30:213  
light, melatonin, 27:351  
light therapy, seasonal affective  
disorder, 29:29  
lithium, ankyrin, 27:267  
lithium, antidepressants, 28:73  
lithium, bipolar subtype, 27:267

**Affective Disorder** continued

lithium, clonidine binding in platelets, 28:73  
 lithium, red blood cell membrane, 27:267  
 lithium, schizophrenia, 28:73  
 maintenance pharmacotherapy, geriatric depression, 27:225  
 maintenance pharmacotherapy, nortriptyline, 27:225  
 maintenance pharmacotherapy, survival analysis, 27:225  
 mania, immune function, 29:235  
 mania, life events, 30:213  
 mania, stressors, 30:213  
 melatonin, circadian rhythms, 28:263  
 melatonin, light, 27:351  
 melatonin, temperature, 28:263  
 3-methoxy-4-hydroxyphenylglycol, adolescents, 27:101  
 3-methoxy-4-hydroxyphenylglycol, age of onset, 30:103  
 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:101  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:101  
 Mexican-Americans, Center for Epidemiologic Studies Depression Scale, 27:137  
 monoamine oxidase, borderline personality disorder, 30:265  
 monoamine oxidase, antisocial personality disorder, 30:265  
 naps, sleep deprivation, 27:253  
 neuroleptics, schizophrenia, 28:315  
 neuroleptics, tardive dyskinesia, 28:315  
 norepinephrine, adolescents, 27:101  
 norepinephrine, circadian rhythms, 28:263  
 norepinephrine, cortisol, 27:101, 28:263, 29:187  
 norepinephrine, dexamethasone suppression test, 29:187  
 norepinephrine, dopamine, 29:187  
 norepinephrine, epinephrine, 29:187  
 norepinephrine, generalized anxiety disorder, 30:253  
 norepinephrine, melatonin, 28:263  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:101  
 norepinephrine, temperature, 28:263  
 norepinephrine, thyroid stimulating hormone, 28:263  
 norepinephrine, time sampling, 30:253

**Affective Disorder** continued

nortriptyline, geriatric depression, 27:225, 28:1  
 nortriptyline, maintenance pharmacotherapy, 27:225  
 nortriptyline, phenelzine, 28:1  
 nortriptyline, survival analysis, 27:225  
 panic, Acute Panic Inventory, 27:357  
 panic, lactate, 27:357  
 personality disorder, antisocial personality disorder, 30:265  
 personality disorder, borderline, 30:265  
 personality disorder, monoamine oxidase, 30:265  
 phenelzine, geriatric depression, 28:1  
 phenelzine, nortriptyline, 28:1  
 Pittsburgh Sleep Quality Index, 28:193  
 placebo washout, fluoxetine, 30:191  
 placebo washout, imipramine, 30:191  
 placebo washout, Hamilton Rating Scale for Depression, 30:191  
 potassium, children, 29:215  
 potassium, cholesterol, 29:215  
 potassium, dexamethasone suppression test, 29:215  
 potassium, glucose, 29:215  
 potassium, sodium, 29:215  
 prostaglandin, 30:181  
 Psychiatric Epidemiology Research Interview, life events, 30:213  
 psychotic symptoms, computed tomography, 29:221  
 red blood cell membrane, ankyrin, 27:267  
 red blood cell membrane, bipolar subtype, 27:267  
 red blood cell membrane, lithium, 27:267  
 relatives of unipolars, REM latency, sleep, 27:127  
 schizophrenia, antidepressants, 28:73  
 schizophrenia, attention, 29:65  
 schizophrenia, clonidine binding in platelets, 28:73  
 schizophrenia, continuous performance test, 29:65  
 schizophrenia, laterality, 29:65  
 schizophrenia, lithium, 28:73  
 schizophrenia, neuroleptics, 28:315  
 schizophrenia, tardive dyskinesia, 28:315  
 seasonal affective disorder, cluster analysis, 28:227  
 seasonal affective disorder, light therapy, 29:29  
 seasonal affective disorder, temperature, 28:323

**Affective Disorder** continued

serotonin uptake, 30:181  
 single photon emission computed tomography, cerebral blood flow, 29:323, 29:331  
 sleep, bipolar depression, 27:23  
 sleep, circadian rhythm, 27:23  
 sleep, clomipramine, 30:165  
 sleep deprivation, clomipramine, 28:47  
 sleep deprivation, interview behavior, 28:47  
 sleep deprivation, naps, 27:253  
 sleep deprivation, thyroid stimulating hormone, 29:231  
 sleep deprivation, triiodothyronine, 29:231  
 sleep, geriatric depression, 27:13  
 sleep, Pittsburgh Sleep Quality Index, 28:193  
 sleep, relatives of unipolars, 27:127  
 sleep, REM latency, 27:127  
 sleep, temperature, 27:23  
 sodium, children, 29:215  
 statistics, cluster analysis, 28:227  
 statistics, seasonal affective disorder, 28:227  
 stressors, life events, 30:213  
 stressors, mania, 30:213  
 substance abuse, cocaine, 28:105, 28:335  
 substance abuse, comorbidity, 28:105, 28:335  
 suicide, Albert Einstein College of Medicine Suicide Intent Scale, 27:71  
 survival analysis, nortriptyline, 27:225  
 survival analysis, geriatric depression, 27:225  
 survival analysis, maintenance pharmacotherapy, 27:225  
 symptomatology, computed tomography, 29:271  
 symptomatology, ventricle-brain ratio, 29:271  
 tardive dyskinesia, neuroleptics, 28:315  
 tardive dyskinesia, schizophrenia, 28:315  
 temperature, bipolar depression, 27:23  
 temperature, circadian rhythms, 27:23, 28:263  
 temperature, cortisol, 28:263  
 temperature, melatonin, 28:263  
 temperature, norepinephrine, 28:263  
 temperature, seasonal affective disorder, 28:323  
 temperature, sleep, 27:23  
 temperature, thyroid stimulating hormone, 28:263

**Affective Disorder** continued

thyroid stimulating hormone, circadian rhythms, 28:263  
 thyroid stimulating hormone, cortisol, 28:263  
 thyroid stimulating hormone, melatonin, 28:263  
 thyroid stimulating hormone, norepinephrine, 28:263  
 thyroid stimulating hormone, sleep deprivation, 29:231  
 thyroid stimulating hormone, temperature, 28:263  
 thyroid stimulating hormone, triiodothyronine, 29:231  
 time sampling, norepinephrine, 30:253  
 treatment response, antidepressants, 30:83  
 treatment response, diagnostic criteria, 30:83  
 triiodothyronine, sleep deprivation, 29:231  
 triiodothyronine, thyroid stimulating hormone, 29:231  
 ventricle-brain ratio, computed tomography, 29:271  
 ventricle-brain ratio, symptomatology, 29:271  
 Visual Analogue Scale, circadian rhythms, 27:89  
 Visual Analogue Scale, global vigor and affect, 27:89

**Age**

chlorophenylpiperazine, 29:1  
 cortisol, 29:1  
 mental retardation, social group formation, 30:31  
 prolactin, 29:1  
 serotonin, 29:1  
 social group formation, mental retardation, 30:31

**Agoraphobia.** See Panic disorder

**Aggression.** See also Violence  
 impulsivity, serotonin, 27:5  
 serotonin, impulsivity, 27:5

**Akathisia**

beta blocker, posttraumatic stress disorder, 27:1  
 beta blocker, schizophrenia, 27:1  
 neuroleptic side effect, propranolol, 27:1  
 posttraumatic stress disorder, beta blocker, 27:1  
 posttraumatic stress disorder, schizophrenia, 27:1  
 propranolol, neuroleptic side effects, 27:1  
 schizophrenia, beta blocker, 27:1

**Akathisia** continued

- schizophrenia, posttraumatic stress disorder, 27:1

**Alcoholism**

- blackout, cerebral blood flow, 27:49
- cerebral blood flow, blackout, 27:49
- cocaine, comorbidity, 29:113
- cocaine, genetics, 29:113
- comorbidity, cocaine, 29:113
- comorbidity, genetics, 29:113
- comorbidity, substance abuse, 29:113
- computed tomography, cerebrospinal fluid volumetry, 29:277
- computed tomography, growth hormone, 28:89
- computed tomography, magnetic resonance imaging, 29:277
- computed tomography, prolactin, 28:89
- computed tomography, thyroid stimulating hormone, 28:89
- computed tomography, thyrotropin releasing hormone test, 28:89
- cortisol, dexamethasone suppression test, 30:217
- cortisol, liver function, 30:217
- cerebrospinal fluid volumetry, computed tomography, 29:277
- cerebrospinal fluid volumetry, magnetic resonance imaging, 29:277
- dexamethasone suppression test, cortisol, 30:217
- dexamethasone suppression test, liver function, 30:217
- genetics, cocaine, 29:113
- genetics, comorbidity, 29:113
- genetics, substance abuse, 29:113
- growth hormone, computed tomography, 28:89
- growth hormone, prolactin, 28:89
- growth hormone, thyroid stimulating hormone, 28:89
- growth hormone, thyrotropin releasing hormone test, 28:89
- lithium, prolactin, 29:55
- lithium, red blood cells, 29:55
- liver function, cortisol, 30:217
- liver function, dexamethasone suppression test, 30:217
- magnetic resonance imaging, computed tomography, 29:277
- magnetic resonance imaging, cerebrospinal fluid volumetry, 29:277
- prolactin, computed tomography, 28:89
- prolactin, growth hormone, 28:89

**Alcoholism**, continued

- prolactin, lithium, 29:55
- prolactin, red blood cells, 29:55
- prolactin, thyroid stimulating hormone, 28:89
- prolactin, thyrotropin releasing hormone test, 28:89
- red blood cells, lithium, 29:55
- red blood cells, prolactin, 29:55
- substance abuse, cocaine, 29:113
- substance abuse, comorbidity, 29:113
- substance abuse, genetics, 29:113
- thyroid stimulating hormone, computed tomography, 28:89
- thyroid stimulating hormone, growth hormone, 28:89
- thyroid stimulating hormone, prolactin, 28:89
- thyrotropin releasing hormone test, computed tomography, 28:89
- thyrotropin releasing hormone test, growth hormone, 28:89
- thyrotropin releasing hormone test, prolactin, 28:89

**Albert Einstein College of Medicine****Suicide Intent Scale**

- affective disorders, suicide, 27:71
- suicide, affective disorders, 27:71

**Alprazolam**

- diazepam, 3-methoxy-4-hydroxyphenylglycol, 30:53
- diazepam, panic disorder, 30:53
- diazepam, treatment response, 30:53
- 3-methoxy-4-hydroxyphenylglycol, panic disorder, 30:53
- 3-methoxy-4-hydroxyphenylglycol, treatment response, 30:53
- panic disorder, 3-methoxy-4-hydroxyphenylglycol, 30:53
- panic disorder, treatment response, 30:53
- treatment response, diazepam, 30:53
- treatment response, panic disorder, 30:53

**Alzheimer's disease.** See also **Dementia**

- affective disorder, clonidine, 27:277
- affective disorder, growth hormone, 27:277
- affective disorder, EEG mapping, 29:403
- affective disorders, elderly subjects, 29:403
- affective disorders, evoked potentials, 29:403
- cerebral blood flow, magnetic resonance imaging, 29:447
- cerebral blood flow, parietotemporal deficit, 29:301
- cerebral blood flow, pyritinol, 29:303

**Alzheimer's disease** continued

cerebral blood flow, single photon emission computed tomography, 29:347  
 clonidine, affective disorder, 27:277  
 clonidine, growth hormone, 27:277  
 cognitive impairment, EEG mapping, 29:409  
 computed tomography, dementia, 29:445  
 computed tomography, positron emission tomography, 29:359  
 computed tomography, single photon emission computed tomography, 29:445  
 computed tomography, white matter, 29:359  
 cortisol, dexamethasone suppression test, 29:169  
 cortisol, gender, 29:169  
 dementia, computed tomography, 29:445  
 dementia, single photon emission computed tomography, 29:445  
 deoxyglucose, positron emission tomography, 29:351  
 dexamethasone suppression test, cortisol, 29:169  
 dexamethasone suppression test, gender, 29:169  
 disease severity, EEG mapping, 29:399  
 EEG mapping, affective disorders, 29:403  
 EEG mapping, cognitive impairment, 29:409  
 EEG mapping, disease severity, 29:399  
 EEG mapping, elderly subjects, 29:403  
 EEG mapping, evoked potentials, 29:403  
 EEG mapping, phosphatidylserine, 29:411  
 EEG mapping, single photon emission computed tomography, 29:449  
 elderly subjects, affective disorders, 29:403  
 elderly subjects, EEG mapping, 29:403  
 elderly subjects, evoked potentials, 29:403  
 evoked potentials, affective disorders, 29:403  
 evoked potentials, EEG mapping, 29:403  
 evoked potentials, elderly subjects, 29:403  
 gallyas impregnation, neuropathology, 29:463  
 gender, cortisol, 29:169  
 gender, dexamethasone suppression test, 29:169  
 growth hormone, affective disorder, 27:277  
 growth hormone, clonidine, 27:277  
 imipramine binding, platelet, 28:289  
 magnetic resonance imaging, cerebral blood flow, 29:447  
 neuropathology, gallyas impregnation, 29:463

**Alzheimer's disease** continued

parietotemporal deficit, cerebral blood flow, 29:301  
 phosphatidylserine, EEG mapping, 29:411  
 platelet, imipramine binding, 28:289  
 positron emission tomography, computed tomography, 29:359  
 positron emission tomography, deoxyglucose, 29:351  
 pyritinol, cerebral blood flow, 29:303  
 single photon emission computed tomography, cerebral blood flow, 29:347  
 single photon emission computed tomography, computed tomography, 29:445  
 single photon emission computed tomography, dementia, 29:445  
 single photon emission computed tomography, EEG mapping, 29:449  
 white matter, computed tomography, 29:359

**Amantadine**

bromocriptine, cocaine, 29:11  
 bromocriptine, substance abuse, 29:11  
 bromocriptine, withdrawal, 29:11  
 cocaine, bromocriptine, 29:11  
 cocaine, withdrawal, 29:11  
 substance abuse, bromocriptine, 29:11  
 substance abuse, withdrawal, 29:11  
 withdrawal, bromocriptine, 29:11  
 withdrawal, cocaine, 29:11

**Ankyrin**

affective disorder, bipolar, 27:267  
 affective disorder, lithium, 27:267  
 affective disorder, red blood cell membrane, 27:267  
 bipolar affective disorder, 27:267  
 bipolar, lithium, 27:267  
 bipolar, red blood cell membrane, 27:267  
 lithium, affective disorder, 27:267  
 lithium, bipolar, 27:267  
 lithium, red blood cell membrane, 27:267  
 red blood cell membrane, affective disorder, 27:267  
 red blood cell membrane, bipolar, 27:267  
 red blood cell membrane, lithium, 27:267

**Anorexia nervosa.** See *Eating disorders***Anticonvulsants**

neuroleptics, plasma concentration, 28:153  
 plasma concentration, neuroleptics, 28:153

**Antidepressants**

affective disorder, diagnostic criteria, 30:83  
 affective disorder, schizophrenia, 28:73  
 affective disorder, treatment response, 30:83

**Antidepressants** continued

clonidine binding in platelets, affective disorder, 28:73  
 clonidine binding in platelets, schizophrenia, 28:73  
 clonidine, lithium, 28:73  
 diagnostic criteria, affective disorder, 30:83  
 diagnostic criteria, treatment response, 30:83  
 food intake, learned helplessness, 27:149  
 food intake, rats, 27:149  
 food intake, triiodothyronine, 27:149  
 geriatric depression, nortriptyline, 28:1  
 geriatric depression, phenelzine, 28:1  
 learned helplessness, food intake, 27:149  
 learned helplessness, rats, 27:149  
 learned helplessness, triiodothyronine, 27:149  
 lithium, affective disorder, 28:73  
 lithium, clonidine binding in platelets, 28:73  
 lithium, schizophrenia, 28:73  
 nortriptyline, affective disorder, 28:1  
 nortriptyline, geriatric depression, 28:1  
 phenelzine, affective disorder, 28:1  
 phenelzine, geriatric depression, 28:1  
 rats, food intake, 27:149  
 rats, learned helplessness, 27:149  
 rats, triiodothyronine, 27:149  
 schizophrenia, affective disorder, 28:73  
 schizophrenia, clonidine binding in platelets, 28:73  
 schizophrenia, lithium, 28:73  
 treatment response, affective disorders, 30:83  
 treatment response, diagnostic criteria, 30:83  
 triiodothyronine, food intake, 27:149  
 triiodothyronine, learned helplessness, 27:149  
 triiodothyronine, rats, 27:149

**Anxiety**

acetazolamide, cerebral blood flow, 28:241  
 carbon dioxide, cerebral blood flow, 28:241  
 cerebral blood flow, acetazolamide, 28:241  
 cerebral blood flow, carbon dioxide, 28:241  
 depressed mood, headache, 30:95  
 depressed mood, migraine, 30:95  
 depressed mood, monoamine oxidase, 30:95  
 depressed mood, obsessive-compulsive disorder, 27:65

**Anxiety** continued

depressed mood, pseudocholinesterase, 27:65  
 depressed mood, tribulin, 30:95  
 fenfluramine, panic disorder, 28:295  
 fenfluramine, serotonin, 28:295  
 headache, depressed mood, 30:95  
 headache, monoamine oxidase, 30:95  
 headache, tribulin, 30:95  
 migraine, depressed mood, 30:95  
 migraine, monoamine oxidase, 30:95  
 migraine, tribulin, 30:95  
 monoamine oxidase, depressed mood, 30:95  
 monoamine oxidase, headache, 30:95  
 monoamine oxidase, migraine, 30:95  
 monoamine oxidase, tribulin, 30:95  
 obsessive-compulsive disorder, depressed mood, 27:65  
 obsessive-compulsive disorder, pseudocholinesterase, 27:65  
 panic disorder, fenfluramine, 28:295  
 panic disorder, serotonin, 28:295  
 pseudocholinesterase, depressed mood, 27:65  
 pseudocholinesterase, obsessive-compulsive disorder, 27:65  
 serotonin, fenfluramine, 28:295  
 serotonin, panic disorder, 28:295  
 tribulin, depressed mood, 30:95  
 tribulin, headache, 30:95  
 tribulin, migraine, 30:95  
 tribulin, monoamine oxidase, 30:95

**Arylsulfatase A**

metachromatic leucodystrophy, schizophrenia, 30:107  
 schizophrenia, metachromatic leucodystrophy, 30:107

**Attention**

affective disorder, continuous performance test, 29:65  
 affective disorder, laterality, 29:65  
 affective disorder, schizophrenia, 29:65  
 clinical stabilization, eye movements, 28:31  
 clinical stabilization, schizophrenia, 28:31  
 college students, Perceptual Aberration-Magical Ideation, 27:207  
 college students, Physical Anhedonia, 27:207  
 college students, psychosis proneness, 27:207  
 college students, risk factors, 27:207  
 computed tomography, laterality, 29:267  
 computed tomography, schizophrenia, 29:267

**Attention** continued

- computed tomography, ventricle-brain ratio, 29:267
- continuous performance test, affective disorder, 29:65
- continuous performance test, laterality, 29:65
- continuous performance test, schizophrenia, 29:65
- eye movements, clinical stabilization, 28:31
- eye movements, schizophrenia, 28:31
- laterality, affective disorder, 29:65
- laterality, computed tomography, 29:267
- laterality, continuous performance test, 29:65
- laterality, schizophrenia, 29:65, 29:267
- laterality, ventricle-brain ratio, 29:267
- Perceptual Aberration-Magical Ideation Scale**, psychosis, 27:207
- Physical Anhedonia Scale**, college students, 27:207
- Physical Anhedonia Scale**, psychosis proneness, 27:207
- Physical Anhedonia Scale**, risk factors, 27:207
- psychosis proneness, college students, 27:207
- psychosis proneness, **Perceptual Aberration-Magical Ideation** psychosis proneness, **Physical Anhedonia Scale**, 27:207
- psychosis proneness, risk factors, 27:207
- risk factors, college students, 27:207
- risk factors, **Perceptual Aberration-Magical Ideation Scale**, 27:207
- risk factors, **Physical Anhedonia Scale**, 27:207
- risk factors, psychosis proneness, 27:207
- schizophrenia, affective disorder, 29:65
- schizophrenia, clinical stabilization, 28:31
- schizophrenia, computed tomography, 29:267
- schizophrenia, continuous performance test, 29:65
- schizophrenia, eye movements, 28:31
- schizophrenia, laterality, 29:65, 29:267
- schizophrenia, ventricle-brain ratio, 29:267
- ventricle-brain ratio, computed tomography, 29:267
- ventricle-brain ratio, laterality, 29:267
- ventricle-brain ratio, schizophrenia, 29:267

**Attention deficit disorder**

- catecholamines, conduct disorder, 27:241
- conduct disorder, catecholamines, 27:241

**Attention deficit disorder** continued

- conduct disorder, dopamine-beta-hydroxylase, 27:241
- conduct disorder, 3-methoxy-4-hydroxyphenylglycol, 27:241
- conduct disorder, norepinephrine, 27:241
- dopamine-beta-hydroxylase, conduct disorder, 27:241
- dopamine-beta-hydroxylase, norepinephrine, 27:241
- 3-methoxy-4-hydroxyphenylglycol, conduct disorder, 27:241
- norepinephrine, conduct disorder, 27:241
- norepinephrine, dopamine-beta-hydroxylase, 27:241

**Beta blockers**

- akathisia, posttraumatic stress disorder, 27:1
- akathisia, schizophrenia, 27:1
- posttraumatic stress disorder, akathisia, 27:1
- schizophrenia, akathisia, 27:1

**Beta-hydroxybutyric acid**

- computed tomography, cortisol, 27:39
- computed tomography, eating disorders, 27:39
- computed tomography, triiodothyronine, 27:39
- computed tomography, ventricle-brain ratio, 27:39
- cortisol, computed tomography, 27:39
- cortisol, eating disorders, 27:39
- cortisol, triiodothyronine, 27:39
- cortisol, ventricle-brain ratio, 27:39
- eating disorders, computed tomography, 27:39
- eating disorders, cortisol, 27:39
- eating disorders, triiodothyronine, 27:39
- eating disorders, ventricle-brain ratio, 27:39
- triiodothyronine, computed tomography, 27:39
- triiodothyronine, cortisol, 27:39
- triiodothyronine, eating disorders, 27:39
- triiodothyronine, ventricle-brain ratio, 27:39
- ventricle-brain ratio, computed tomography, 27:39
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, eating disorders, 27:39
- ventricle-brain ratio, triiodothyronine, 27:39

**Blood-brain barrier**

- electroconvulsive seizure, hypoglycemia, 29:151

**Blood-brain barrier** continued

- hypoglycemia, electroconvulsive seizure, 29:151
- rats, electroconvulsive seizure, 29:151

**Blood pressure**

- cocaine, haloperidol, 27:117
- cocaine, heart rate, 27:117
- cocaine, subjective effects, 27:117
- cortisol, generalized anxiety disorder, 27:173
- cortisol, heart rate, 27:173
- cortisol, 3-methoxy-4-hydroxyphenyl glycol, 27:173
- cortisol, norepinephrine, 27:173
- cortisol, yohimbine, 27:173
- eating disorders, heart rate, 30:223
- eating disorders, stressors, 30:223
- eating disorders, Type A behavior, 30:223
- generalized anxiety disorder, cortisol, 27:173
- generalized anxiety disorder, heart rate, 27:173
- generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173
- generalized anxiety disorder, norepinephrine, 27:173
- generalized anxiety disorder, yohimbine, 27:173
- haloperidol, cocaine, 27:117
- haloperidol, heart rate, 27:117
- haloperidol, subjective effects, 27:117
- haloperidol, substance abuse, 27:117
- heart rate, cocaine, 27:117
- heart rate, cortisol, 27:173
- heart rate, eating disorders, 30:223
- heart rate, generalized anxiety disorder, 27:173
- heart rate, haloperidol, 27:117
- heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173
- heart rate, norepinephrine, 27:173
- heart rate, premenstrual dysphoria, 27:183
- heart rate, stressors, 30:223
- heart rate, subjective effects, 27:117
- heart rate, substance abuse, 27:117
- heart rate, Type A behavior, 30:223
- heart rate, yohimbine, 27:173
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:173
- 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173
- 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:173

**Blood pressure** continued

- 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173
- norepinephrine, cortisol, 27:173
- norepinephrine, generalized anxiety disorder, 27:173
- norepinephrine, heart rate, 27:173
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:173
- norepinephrine, yohimbine, 27:173
- premenstrual dysphoria, heart rate, 27:183
- stressors, eating disorders, 30:223
- stressors, heart rate, 30:223
- stressors, Type A behavior, 30:223
- subjective effects, cocaine, 27:117
- subjective effects, haloperidol, 27:117
- subjective effects, heart rate, 27:117
- subjective effects, substance abuse, 27:117
- substance abuse, cocaine, 27:117
- substance abuse, haloperidol, 27:117
- substance abuse, heart rate, 27:117
- substance abuse, subjective effects, 27:117
- Type A behavior, eating disorders, 30:223
- Type A behavior, heart rate, 30:223
- Type A behavior, stressors, 30:223
- yohimbine, cortisol, 27:173
- yohimbine, generalized anxiety disorder, 27:173
- yohimbine, heart rate, 27:173
- yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173
- yohimbine, norepinephrine, 27:173

**Borderline personality disorder.** See also **Personality disorder**

- computed tomography, 27:111
- third ventricle size, gender differences, 27:111

**Borna disease**

- magnetic resonance imaging, psychiatric patients, 29:281
- psychiatric patients, magnetic resonance imaging, 29:281

**Brain imaging.** See also **Cerebral blood flow, Computed tomography, EEG topography, Magnetic resonance imaging,**

- Magnetoencephalography, Positron emission tomography, Single photon emission computed tomography**
- acetazolamide, anxiety, 28:241
- affective disorder, Alzheimer's disease, 29:403
- affective disorder, computed tomography, 29:221, 29:271
- affective disorder, evoked potentials, 29:403
- affective disorder, psychotic symptoms, 29:221

**Brain imaging** continued

affective disorder, single photon emission computed tomography, 29:323, 29:331  
 affective disorder, symptomatology, 29:271  
 affective disorder, ventricle-brain ratio, 29:271  
 alcoholism, blackout, 27:49  
 alcoholism, cerebral blood flow, 27:49  
 alcoholism, cerebrospinal fluid volumetry, 29:277  
 alcoholism, computed tomography, 28:89  
 alcoholism, magnetic resonance imaging, 29:277  
 algorithm, spatial interpolation, 29:431  
 Alzheimer's disease, affective disorders, 29:403  
 Alzheimer's disease, cerebral blood flow, 29:447  
 Alzheimer's disease, cognitive impairment, 29:409  
 Alzheimer's disease, computed tomography, 29:359  
 Alzheimer's disease, dementia, 29:445  
 Alzheimer's disease, deoxyglucose, 29:351  
 Alzheimer's disease, disease severity, 29:399  
 Alzheimer's disease, elderly subjects, 29:403  
 Alzheimer's disease, evoked potentials, 29:403  
 Alzheimer's disease, magnetic resonance imaging, 29:447  
 Alzheimer's disease, parietotemporal deficit, 29:301  
 Alzheimer's disease, positron emission tomography, 29:359  
 Alzheimer's disease, pyritinol, 29:303  
 Alzheimer's disease, single photon emission computed tomography, 29:347, 29:445, 29:449  
 Alzheimer's disease, white matter, 29:359  
 anxiety, acetazolamide, 28:241  
 anxiety, carbon dioxide, 28:241  
 arachnoid cyst, evoked potentials, 29:421  
 arachnoid cyst, P300, 29:421  
 arachnoid cyst, schizophrenia, 29:421  
 atherosclerosis, operative therapy, 29:309  
 attention, laterality, 29:267  
 attention, schizophrenia, 29:267  
 attention, ventricle-brain ratio, 29:267  
 auditory and visual paradigm, evoked potential, 29:439

**Brain imaging** continued

auditory and visual paradigm, P300, 29:439  
 auditory and visual paradigm, semantic tasks, 29:439  
 autogenic training, beta reduction, 29:433  
 autogenic training, hypnosis, 29:317  
 autogenic training, laterality, 29:317  
 beta-hydroxybutyric acid, computed tomography, 27:39  
 beta-hydroxybutyric acid, ventricle-brain ratio, 27:39  
 beta reduction, autogenic training, 29:433  
 blackout, alcoholism, 27:49  
 blackout, cerebral blood flow, 27:49  
 borderline personality disorder, computed tomography, 27:111  
 Borna disease, magnetic resonance imaging, 29:281  
 brain atlas, computed tomography, 29:461  
 brain atlas, EEG mapping, 29:461  
 brain tumors, SPECT, 29:341  
 bromospiperone, dopamine receptors, 29:357  
 bromospiperone, schizophrenia, 29:357  
 carbon dioxide, anxiety, 28:241  
 cerebral blood flow, alcoholism, 27:49  
 cerebral blood flow, Alzheimer's disease, 29:447  
 cerebral blood flow, blackout, 27:49  
 cerebral blood flow, corpus callosum, 29:453  
 cerebral blood flow, gender, 27:55  
 cerebral blood flow, laterality, 27:325  
 cerebral blood flow, positron emission tomography, 27:325  
 cerebral blood flow, schizophrenia, 27:325, 29:453  
 cerebral blood flow, sex role orientation, 27:55  
 cerebral blood flow, single photon emission computed tomography, 29:319  
 cerebral ischemia, single photon emission computed tomography, 29:457  
 cerebrospinal fluid flow, magnetic resonance imaging, 29:289  
 cerebrospinal fluid flow, normal pressure hydrocephalus, 29:289  
 cerebrospinal fluid volumetry, alcoholism, 29:277  
 cerebrospinal fluid volumetry, computed tomography, 29:277  
 cerebrospinal fluid volumetry, magnetic resonance imaging, 29:277

**Brain imaging** continued

clonidine, evoked potentials, 28:255  
 clonidine, P300, 28:255  
 cognitive function, electro-  
 encephalography, 29:385  
 cognitive function, pyritinol, 29:387  
 cognitive impairment, Alzheimer's disease,  
 29:409  
 computed tomography, affective disorder,  
 29:221, 29:271  
 computed tomography, alcoholism, 28:89,  
 29:277  
 computed tomography, Alzheimer's  
 disease, 29:359  
 computed tomography, beta-hydroxy-  
 butyric acid, 27:39  
 computed tomography, borderline  
 personality disorder, 27:111  
 computed tomography, brain atlas, 29:461  
 computed tomography, cerebrospinal fluid  
 volumetry, 29:277  
 computed tomography, cortisol, 27:39  
 computed tomography, diencephalic  
 lesions, 29:285  
 computed tomography, eating disorders,  
 27:39  
 computed tomography, electro-  
 encephalogram, 29:137  
 computed tomography, electro-  
 encephalographic focus, 29:459  
 computed tomography, frontal lobe,  
 29:137  
 computed tomography, laterality, 29:247  
 computed tomography, limbic system,  
 29:255  
 computed tomography, lupus  
 erythematosus, 29:367  
 computed tomography, magnetic  
 resonance imaging, 29:277, 29:363,  
 29:367  
 computed tomography, positron emission  
 tomography, 29:363, 29:367  
 computed tomography, psychotic  
 symptoms, 29:221  
 computed tomography, schizophrenia,  
 29:137, 29:247, 29:255, 29:257, 29:265  
 computed tomography, seizures, 29:459  
 computed tomography, single photon  
 emission computed tomography, 29:457,  
 29:459  
 computed tomography, symptomatology,  
 29:271  
 computed tomography, thalamic  
 infarction, 29:363

**Brain imaging** continued

computed tomography, ventricle-brain  
 ratio, 27:39, 29:257, 29:265, 29:271  
 computed tomography, white matter,  
 29:359  
 computed tomography, Wisconsin Card  
 Sort Test, 29:137  
 computerized brains, historical  
 background, 29:239  
 corpus callosum, cerebral blood flow,  
 29:453  
 corpus callosum, magnetic resonance  
 imaging, 29:453  
 corpus callosum, schizophrenia, 29:453  
 cortisol, ventricle-brain ratio, 27:39  
 dementia, Alzheimer's disease, 29:445  
 dementia, deoxyglucose, 29:353  
 dementia, evoked potentials, 29:391  
 dementia, P300, 29:391  
 dementia, schizophrenia, 29:391  
 dementia, single photon emission  
 computed tomography, 29:327, 29:445  
 dementia, xenon inhalation, 29:297  
 deoxyglucose, Alzheimer's disease, 29:351  
 deoxyglucose, dementia, 29:353  
 diencephalic lesions, computed  
 tomography, 29:285  
 diencephalic lesions, magnetic resonance  
 imaging, 29:285  
 disease severity, Alzheimer's disease,  
 29:399  
 dopamine receptors, bromospiperone,  
 29:357  
 dopamine receptors, schizophrenia, 29:357  
 dyslexic children, dyslexia, 29:407  
 dyslexia, dyslexic children, 29:407  
 eating disorders, computed tomography,  
 27:39  
 eating disorders, ventricle-brain ratio,  
 27:39  
 EEG focus, computed tomography, 29:459  
 EEG focus, magnetic resonance imaging,  
 29:459  
 EEG focus, seizures, 29:459  
 EEG focus, single photon emission  
 computed tomography, 29:459  
 EEG mapping, brain atlas, 29:461  
 elderly subjects, affective disorders, 29:403  
 elderly subjects, Alzheimer's disease,  
 29:403  
 elderly subjects, evoked potentials, 29:403  
 electroencephalogram, brain imaging, 29:137  
 electroencephalogram, cognitive functions,  
 29:385

**Brain imaging** continued

electroencephalogram, computed tomography, 29:137  
 electroencephalogram, evoked potentials, 29:379  
 electroencephalogram, frontal lobe, 29:137  
 electroencephalogram, schizophrenia, 29:137  
 electroencephalogram, Wisconsin Card Sort Test, 29:137  
 embolic mechanisms, stroke, 29:273  
 evoked potentials, affective disorders, 29:403  
 evoked potentials, Alzheimer's disease, 29:403  
 evoked potentials, arachnoid cyst, 29:421  
 evoked potentials, auditory and visual paradigm, 29:439  
 evoked potentials, clonidine, 28:255  
 evoked potentials, dementia, 29:391  
 evoked potentials, elderly subjects, 29:403  
 evoked potentials, electroencephalography, 29:379  
 evoked potentials, frontal lobe, 28:63  
 evoked potentials, obsessive-compulsive disorder, 28:63  
 evoked potentials, P300, 28:63, 28:255, 29:391, 29:413, 29:421, 29:439  
 evoked potentials, pyritinol, 29:413  
 evoked potentials, schizophrenia, 29:391, 29:421  
 evoked potentials, semantic tasks, 29:439  
 frontal lobe, electroencephalogram, 29:137  
 frontal lobe, evoked potentials, 28:63  
 frontal lobe, head injury, 29:313  
 frontal lobe, obsessive-compulsive disorder, 28:63  
 frontal lobe, P300, 28:63  
 frontal lobe reduction, schizophrenia, 29:331  
 frontal lobe reduction, single photon emission computed tomography, 29:331  
 frontal lobe, schizophrenia, 29:137  
 frontal lobe size, magnetic resonance imaging, 30:11  
 frontal lobe size, negative symptoms, 30:11  
 frontal lobe size, saggital morphology, 30:11  
 frontal lobe size, schizophrenia, 30:11  
 frontal lobe, Wisconsin Card Sort Test, 29:137  
 frontal lobes, parietal lobes, 28:119  
 frontal lobes, positron emission tomography, 28:119

**Brain imaging** continued

frontal lobes, schizophrenia, 28:119  
 gender, cerebral blood flow, 27:55  
 gender, sex role orientation, 27:55  
 Gilles de la Tourette syndrome, normal comparison, 29:427  
 head injury, frontal lobe, 29:313  
 historical background, computerized brains, 29:239  
 Huntington's chorea, psychiatric symptoms, 29:361  
 hypnosis, laterality, 29:317  
 intracranial pressure, low pressure hydrocephalus, 29:307  
 K complex, sleep, 29:435  
 laterality, attention, 29:267  
 laterality, autogenic training, 29:317  
 laterality, cerebral blood flow, 27:325  
 laterality, computed tomography, 29:247  
 laterality, hypnosis, 29:317  
 laterality, positron emission tomography, 27:325  
 laterality, schizophrenia, 27:325, 29:247, 29:267  
 laterality, ventricle-brain ratio, 29:267  
 limbic system, computed tomography, 29:255  
 limbic system, schizophrenia, 29:255  
 low pressure hydrocephalus, intracranial pressure, 29:307  
 lupus erythematosus, computed tomography, 29:367  
 lupus erythematosus, magnetic resonance imaging, 29:367  
 lupus erythematosus, positron emission tomography, 29:367  
 magnetic resonance imaging, alcoholism, 29:277  
 magnetic resonance imaging, Alzheimer's disease, 29:447  
 magnetic resonance imaging, Borna disease, 29:281  
 magnetic resonance imaging, cerebrospinal fluid flow, 29:289  
 magnetic resonance imaging, cerebrospinal fluid volumetry, 29:277  
 magnetic resonance imaging, computed tomography, 29:277, 29:363, 29:367  
 magnetic resonance imaging, corpus callosum, 29:453  
 magnetic resonance imaging, diencephalic lesions, 29:285  
 magnetic resonance imaging, EEG focus, 29:459

**Brain imaging** continued

magnetic resonance imaging, frontal lobe size, 30:11  
 magnetic resonance imaging, lupus erythematosus, 29:367  
 magnetic resonance imaging, negative symptoms, 30:11  
 magnetic resonance imaging, normal pressure hydrocephalus, 29:287, 29:289  
 magnetic resonance imaging, pituitary tumors, 29:283  
 magnetic resonance imaging, positron emission tomography, 29:363, 29:367  
 magnetic resonance imaging, psychiatric patients, 29:281  
 magnetic resonance imaging, saggital morphology, 30:11  
 magnetic resonance imaging, schizophrenia, 29:261, 29:265, 29:453, 30:11  
 magnetic resonance imaging, seizures, 29:459  
 magnetic resonance imaging, single photon emission computed tomography, 29:459  
 magnetic resonance imaging, subcaudate tractotomy lesions, 29:291  
 magnetic resonance imaging, temporal lobe, 29:261  
 magnetic resonance imaging, thalamic infarction, 29:363  
 magnetic resonance imaging, ventricle-brain ratio, 29:265  
 multiple sclerosis, neuropsychology, 29:293  
 multiple sclerosis, optic neuritis, 29:295  
 negative symptoms, frontal lobe size, 30:11  
 negative symptoms, magnetic resonance imaging, 30:11  
 negative symptoms, saggital morphology, 30:11  
 negative symptoms, schizophrenia, 30:11  
 neuropsychology, multiple sclerosis, 29:293  
 normal comparison, Gilles de la Tourette syndrome, 29:427  
 normal pressure hydrocephalus, cerebro spinal fluid flow, 29:289  
 normal pressure hydrocephalus, magnetic resonance imaging, 29:287, 29:289  
 normal volunteers, phosphatidylserine, 29:417  
 obsessive-compulsive disorder, evoked potentials, 28:63  
 obsessive-compulsive disorder, frontal lobe, 28:63

**Brain imaging** continued

obsessive-compulsive disorder, P300, 28:63  
 olfactory stimulation, trigeminal stimulants, 29:429  
 operative therapy, atherosclerosis, 29:309  
 optic neuritis, multiple sclerosis, 29:295  
 P300, arachnoid cyst, 29:421  
 P300, auditory and visual paradigm, 29:439  
 P300, clonidine, 28:255  
 P300, dementia, 29:391  
 P300, frontal lobe, 28:63  
 P300, obsessive-compulsive disorder, 28:63  
 P300, pyritinol, 29:413  
 P300, schizophrenia, 29:391, 29:421  
 P300, semantic tasks, 29:439  
 parietal lobes, frontal lobes, 28:119  
 parietal lobes, positron emission tomography, 28:119  
 parietal lobes, schizophrenia, 28:119  
 parietotemporal deficit, Alzheimer's disease, 29:301  
 phosphatidylserine, Alzheimer's disease, 29:411  
 phosphatidylserine, normal volunteers, 29:417  
 pituitary tumors, magnetic resonance imaging, 29:283  
 positron emission tomography, Alzheimer's disease, 29:359  
 positron emission tomography, cerebral blood flow, 27:325  
 positron emission tomography, computed tomography, 29:363, 29:367  
 positron emission tomography, frontal lobes, 28:119  
 positron emission tomography, laterality, 27:325  
 positron emission tomography, lupus erythematosus, 29:367  
 positron emission tomography, magnetic resonance imaging, 29:363, 29:367  
 positron emission tomography, parietal lobes, 28:119  
 positron emission tomography, schizophrenia, 27:325, 28:119  
 positron emission tomography, thalamic infarction, 29:363  
 positron emission tomography, white matter, 29:359  
 prolactin, computed tomography, 28:89  
 psychiatric patients, Borna disease, 29:281  
 psychiatric patients, magnetic resonance imaging, 29:281

**Brain imaging continued**

psychiatric symptoms, Huntington's chorea, 29:361  
 psychotic symptoms, affective disorder, 29:221  
 psychotic symptoms, computed tomography, 29:221  
 pyritinol, Alzheimer's disease, 29:303  
 pyritinol, cognitive function, 29:387  
 pyritinol, evoked potentials, 29:413  
 pyritinol, P300, 29:413  
 Rett syndrome, theta activity, 29:425  
 saggital morphology, frontal lobe size, 30:11  
 saggital morphology, magnetic resonance imaging, 30:11  
 saggital morphology, negative symptoms, 30:11  
 saggital morphology, schizophrenia, 30:11  
 Scale for the Assessment of Negative Symptoms, schizophrenia, 29:137  
 schizophrenia, arachnoid cyst, 29:421  
 schizophrenia, attention, 29:267  
 schizophrenia, bromospiperone, 29:357  
 schizophrenia, cerebral blood flow, 27:325, 29:453  
 schizophrenia, computed tomography, 29:137, 29:247, 29:255, 29:257, 29:265  
 schizophrenia, corpus callosum, 29:453  
 schizophrenia, dementia, 29:391  
 schizophrenia, dopamine receptors, 29:357  
 schizophrenia, electroencephalogram, 29:137  
 schizophrenia, evoked potentials, 29:391, 29:421  
 schizophrenia, frontal lobe, 28:119, 29:137, 29:331, 30:11  
 schizophrenia, laterality, 27:325, 29:247, 29:267  
 schizophrenia, limbic system, 29:255  
 schizophrenia, magnetic resonance imaging, 29:261, 29:265, 29:453, 30:11  
 schizophrenia, negative symptoms, 30:11  
 schizophrenia, P300, 29:391, 29:421  
 schizophrenia, parietal lobes, 28:119  
 schizophrenia, positron emission tomography, 27:325, 28:119  
 schizophrenia, saggital morphology, 30:11  
 schizophrenia, Scale for the Assessment of Negative Symptoms, 29:137  
 schizophrenia, single photon emission computed tomography, 29:331  
 schizophrenia, temporal lobe, 29:261  
 schizophrenia, temporal lobe beta, 29:419

**Brain imaging continued**

schizophrenia, ventricle-brain ratio, 29:257, 29:265, 29:267  
 schizophrenia, Wisconsin Card Sort Test, 29:137  
 seizures, computed tomography, 29:459  
 seizures, EEG focus, 29:459  
 seizures, magnetic resonance imaging, 29:459  
 seizures, single photon emission computed tomography, 29:459  
 semantic tasks, auditory and visual paradigm, 29:439  
 semantic tasks, evoked potential, 29:439  
 semantic tasks, P300, 29:439  
 sex role orientation, cerebral blood flow, 27:55  
 sex role orientation, gender, 27:55  
 single photon emission computed tomography, affective disorder, 29:331, 29:323  
 single photon emission computed tomography, Alzheimer's disease, 29:347, 29:445, 29:449  
 single photon emission computed tomography, brain tumors, 29:341  
 single photon emission computed tomography, cerebral blood flow, 29:319  
 single photon emission computed tomography, cerebral ischemia, 29:457  
 single photon emission computed tomography, computed tomography, 29:457, 29:459  
 single photon emission computed tomography, dementia, 29:327, 29:445  
 single photon emission computed tomography, EEG focus, 29:459  
 single photon emission computed tomography, frontal lobe reduction, 29:331  
 single photon emission computed tomography, magnetic resonance imaging, 29:459  
 single photon emission computed tomography, schizophrenia, 29:331  
 single photon emission computed tomography, seizures, 29:459  
 sleep, K complex, 29:435  
 spatial interpolation, algorithm, 29:431  
 stroke, embolic mechanisms, 29:273  
 subcaudate tractotomy lesions, brain imaging, 29:291  
 subcaudate tractotomy lesions, magnetic resonance imaging, 29:291

**Brain imaging** continued

- symptomatology, affective disorders, 29:271
- symptomatology, computed tomography, 29:271
- symptomatology, ventricle-brain ratio, 29:271
- temporal lobe beta, schizophrenia, 29:419
- temporal lobe, magnetic resonance imaging, 29:261
- temporal lobe, schizophrenia, 29:261
- thalamic infarction, computed tomography, 29:363
- thalamic infarction, magnetic resonance imaging, 29:363
- thalamic infarction, positron emission tomography, 29:363
- theta activity, Rett syndrome, 29:425
- thyroid stimulating hormone, computed tomography, 28:89
- thyrotropin releasing hormone test, computed tomography, 28:89
- trigeminal stimulants, olfactory stimulation, 29:429
- triiodothyronine, computed tomography, 27:39
- triiodothyronine, ventricle-brain ratio, 27:39
- ventricle-brain ratio, affective disorders, 29:271
- ventricle-brain ratio, attention, 29:267
- ventricle-brain ratio, beta-hydroxybutyric acid, 27:39
- ventricle-brain ratio, computed tomography, 27:39, 29:257, 29:265, 29:271
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, eating disorders, 27:39
- ventricle-brain ratio, laterality, 29:267
- ventricle-brain ratio, magnetic resonance imaging, 29:265
- ventricle-brain ratio, schizophrenia, 29:257, 29:265, 29:267
- ventricle-brain ratio, symptomatology, 29:271
- ventricle-brain ratio, triiodothyronine, 27:39
- white matter, Alzheimer's disease, 29:359
- white matter, computed tomography, 29:359
- white matter, positron emission tomography, 29:359
- Wisconsin Card Sort Test, computed tomography, 29:137

**Brain imaging** continued

- Wisconsin Card Sort Test, electroencephalogram, 29:137
- Wisconsin Card Sort Test, frontal lobe, 29:137
- Wisconsin Card Sort Test, schizophrenia, 29:137
- xenon inhalation, dementia, 29:297

**Brief Psychiatric Rating Scale**

- Minnesota Multiphasic Personality Inventory, 28:135, schizoaffective disorder, schizophrenia, 28:135
- schizophrenia, Minnesota Multiphasic Personality Inventory, 28:135

**Bromocriptine**

- amantadine, cocaine withdrawal, 29:11
- cocaine withdrawal, 29:11
- withdrawal, cocaine, 29:11

**Bulimia.** See *Eating disorders***Butaclamol**

- dopamine, lymphocytes, 30:259
- dopamine, spiperone binding, 30:259
- lymphocytes, dopamine, 30:259
- lymphocytes, spiperone binding, 30:259
- spiperone binding, dopamine, 30:259
- spiperone binding, lymphocytes, 30:259

**Caffeine**

- adenosine, panic disorder, 30:231
- adenosine, posttraumatic stress disorder, 30:231
- adenosine, taste test, 30:231
- panic disorder, adenosine, 30:231
- panic disorder, taste test, 30:231
- posttraumatic stress disorder, adenosine, 30:231
- posttraumatic stress disorder, taste test, 30:231
- taste test, panic disorder, 30:231
- taste test, posttraumatic stress disorder, 30:231

**Cyclic adenosine monophosphate**

- affective disorder, cortisol, 30:181
- affective disorder, dihydroergocryptine binding, 30:181
- affective disorder, 5-hydroxyindolacetic acid, 30:181
- affective disorder, prostaglandin, 30:181
- affective disorder, serotonin uptake, 30:181
- cortisol, affective disorder, 30:181
- dihydroergocryptine binding, affective disorder, 30:181
- 5-hydroxyindolacetic acid, affective disorders, 30:181

**Cyclic adenosine monophosphate**  
continued  
prostaglandin, affective disorders, 30:181  
serotonin uptake, affective disorders, 30:181

**Carbon dioxide**  
acetazolamide, anxiety, 28:241  
Acute Panic Inventory, premenstrual dysphoria, 27:183  
anxiety, cerebral blood flow, 28:241  
cerebral blood flow, acetazolamide, 28:241  
cerebral blood flow, anxiety, 28:241  
panic, premenstrual dysphoria, 27:183  
premenstrual dysphoria, Acute Panic Inventory, 27:183  
premenstrual dysphoria, panic, 27:183

**Cardiovascular function.** See Blood pressure, Heart rate

**Center for Epidemiological Studies Depression Scale**  
affective disorder, Mexican-Americans, 27:137

**Cerebral blood flow**  
acetazolamide, anxiety, 28:241  
acetazolamide, carbon dioxide, 28:241  
affective disorder, single photon emission computed tomography, 29:331 29:323  
alcoholism, blackout, 27:49  
Alzheimer's disease, magnetic resonance imaging, 29:447  
Alzheimer's disease, parietotemporal deficit, 29:301  
Alzheimer's disease, pyritinol, 29:303  
Alzheimer's disease, single photon emission computed tomography, 29:347  
anxiety, acetazolamide, 28:241  
anxiety, carbon dioxide, 28:241  
atherosclerosis, operative therapy, 29:309  
autogenic training, hypnosis, 29:317  
autogenic training, laterality, 29:317  
blackout, alcoholism, 27:49  
brain tumors, single photon emission computed tomography, 29:341  
carbon dioxide, acetazolamide, 28:241  
carbon dioxide, anxiety, 28:241  
computed tomography, single photon emission computed tomography, 29:457  
corpus callosum, magnetic resonance imaging, 29:453  
corpus callosum, schizophrenia, 29:453  
dementia, single photon emission computed tomography, 29:327  
dementia, xenon inhalation, 29:297  
frontal lobe, head injury, 29:313

**Cerebral blood flow** continued  
frontal lobe reduction, schizophrenia, 29:331  
frontal lobe reduction, single photon emission computed tomography, 29:331  
gender, sex role orientation, 27:55  
head injury, frontal lobe, 29:313  
hypnosis, autogenic training, 29:317  
hypnosis, laterality, 29:317  
intracranial pressure, low pressure hydrocephalus, 29:307  
laterality, autogenic training, 29:317  
laterality, hypnosis, 29:317  
laterality, positron emission tomography, 27:325  
laterality, schizophrenia, 27:325  
low pressure hydrocephalus, intracranial pressure, 29:307  
magnetic resonance imaging, Alzheimer's disease, 29:447  
magnetic resonance imaging, corpus callosum, 29:453  
magnetic resonance imaging, schizophrenia, 29:453  
operative therapy, atherosclerosis, 29:309  
parietotemporal deficit, Alzheimer's disease, 29:301  
positron emission tomography, laterality, 27:325  
positron emission tomography, schizophrenia, 27:325  
pyritinol, Alzheimer's disease, 29:303  
schizophrenia, corpus callosum, 29:453  
schizophrenia, frontal lobe reduction, 29:331  
schizophrenia, laterality, 27:325  
schizophrenia, magnetic resonance imaging, 29:453  
schizophrenia, positron emission tomography, 27:325  
schizophrenia, single photon emission computed tomography, 29:331  
sex role orientation, gender, 27:55  
single photon emission computed tomography, affective disorder, 29:323, 29:331, 29:323  
single photon emission computed tomography, Alzheimer's disease, 29:347  
single photon emission computed tomography, brain tumors, 29:341  
single photon emission computed tomography, computed tomography, 29:457

**Cerebral blood flow** continued

- single photon emission computed tomography, dementia, 29:327
- single photon emission computed tomography, frontal lobe reduction, 29:331
- single photon emission computed tomography, schizophrenia, 29:331
- xenon inhalation, dementia, 29:297

**m-Chlorophenylpiperazine**

- age, 29:1
- cortisol, 29:1
- prolactin, 29:1
- serotonin, 29:1

**Cholesterol**

- affective disorder, children, 29:215
- children, affective disorder, 29:215
- dexamethasone suppression test, 29:215
- glucose, 29:215
- potassium, 29:215
- sodium, 29:215

**Choline**

- neuroleptics, red blood cells, schizophrenia, tardive dyskinesia, 29:45
- red blood cells, neuroleptics, schizophrenia, tardive dyskinesia, 29:45
- schizophrenia, neuroleptics, red blood cells, tardive dyskinesia, 29:45
- tardive dyskinesia, neuroleptics, red blood cells, schizophrenia, 29:45

**Circadian rhythms**

- affective disorder, bipolar depression, 27:23
- affective disorder, cortisol, 28:263
- affective disorder, global vigor and affect, 27:89
- affective disorder, melatonin, 28:263
- affective disorder, norepinephrine, 28:263
- affective disorder, sleep, 27:23
- affective disorder, temperature, 27:23, 28:263
- affective disorder, thyroid stimulating hormone, 28:263
- affective disorder, Visual Analogue Scale, 27:89
- bipolar depression, sleep, 27:23
- bipolar depression, temperature, 27:23
- cortisol, affective disorder, 28:263
- cortisol, melatonin, 28:263
- cortisol, norepinephrine, 28:263
- cortisol, temperature, 28:263
- cortisol, thyroid stimulating hormone, 28:263
- global vigor and affect, affective disorder, 27:89

**Circadian rhythms** continued

- global vigor and affect, Visual Analogue Scale, 27:89
- melatonin, affective disorder, 28:263
- melatonin, cortisol, 28:263
- melatonin, norepinephrine, 28:263
- melatonin, temperature, 28:263
- melatonin, thyroid stimulating hormone, 28:263
- norepinephrine, affective disorder, 28:263
- norepinephrine, cortisol, 28:263
- norepinephrine, melatonin, 28:263
- norepinephrine, temperature, 28:263
- norepinephrine, thyroid stimulating hormone, 28:263
- sleep, affective disorder, 27:23
- sleep, bipolar depression, 27:23
- sleep, temperature, 27:23
- temperature, affective disorder, 27:23, 28:263
- temperature, bipolar depression, 27:23
- temperature, cortisol, 28:263
- temperature, melatonin, 28:263
- temperature, norepinephrine, 28:263
- temperature, sleep, 27:23
- temperature, thyroid stimulating hormone, 28:263
- thyroid stimulating hormone, affective disorder, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, melatonin, 28:263
- thyroid stimulating hormone, norepinephrine, 28:263
- thyroid stimulating hormone, temperature, 28:263
- Visual Analogue Scale, affective disorder, 27:89
- Visual Analogue Scale, global vigor and affect, 27:89

**Circannual rhythms**

- affective disorder, dexamethasone suppression test, 29:87
- affective disorder, imipramine binding, 29:87, 30:21
- dexamethasone suppression test, affective disorder, 29:87
- dexamethasone suppression test, imipramine binding, 29:87
- imipramine binding, affective disorder, 29:87, 30:21
- imipramine binding, dexamethasone suppression test, 29:87
- serotonin, platelet uptake, 27:5

**Clenbuterol**

- clomipramine, food restriction, rats, 27:149
- desipramine, food restriction, rats, 27:149
- food restriction, clomipramine, desipramine, indalpine, nialamide, rats, 27:149
- indalpine, food restriction, rats, 27:149
- nialamide, food restriction, rats, 27:149

**Clomipramine**

- affective disorder, interview behavior, 28:47
- affective disorders, sleep, 30:165
- affective disorder, sleep deprivation, 28:47
- clenbuterol, food restriction, rats, 27:149
- desipramine, food restriction, rats, 27:149
- food restriction, rats, 27:149
- indalpine, food restriction, rats, 27:149
- interview behavior, affective disorder, 28:47
- interview behavior, sleep deprivation, 28:47
- nialamide, food restriction, rats, 27:149
- sleep, affective disorder, 30:165
- sleep deprivation, affective disorder, 28:47
- sleep deprivation, interview behavior, 28:47

**Clonidine**

- affective disorder, Alzheimer's disease, 27:277
- affective disorder, antidepressants, 28:73
- affective disorder, growth hormone, 27:277
- affective disorder, growth hormone, 29:199
- affective disorder, lithium, 28:73
- affective disorder, schizophrenia, 28:73
- Alzheimer's disease, affective disorder, 27:277
- Alzheimer's disease, growth hormone, 27:277
- antidepressants, affective disorder, 28:73
- antidepressants, lithium, 28:73
- antidepressants, schizophrenia, 28:73
- binding in platelets, 28:73
- evoked potentials, 28:255
- growth hormone, affective disorder, 27:277, 29:199
- growth hormone, Alzheimer's disease, 27:277
- growth hormone, 3-methoxy-4-hydroxy-phenylglycol, 27:297
- growth hormone, norepinephrine, 27:297
- growth hormone, schizophrenia, 27:297
- growth hormone, treatment response prediction, 27:297
- lithium, affective disorder, 28:73

**Clonidine continued**

- lithium, antidepressants, 28:73
- lithium, schizophrenia, 28:73
- 3-methoxy-4-hydroxyphenylglycol, growth hormone, 27:297
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:297
- 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 27:297
- 3-methoxy-4-hydroxyphenylglycol, treatment response prediction, 27:297
- norepinephrine, growth hormone, 27:297
- norepinephrine, 3-methoxy-4-hydroxy-phenylglycol, 27:297
- norepinephrine, schizophrenia, 27:297
- norepinephrine, treatment response prediction, 27:297
- P300, evoked potentials, 28:255
- schizophrenia, affective disorder, 28:73
- schizophrenia, antidepressants, 28:73
- schizophrenia, growth hormone, 27:297
- schizophrenia, lithium, 28:73
- schizophrenia, 3-methoxy-4-hydroxy-phenylglycol, 27:297
- schizophrenia, norepinephrine, 27:297
- schizophrenia, treatment response prediction, 27:297
- treatment response prediction, growth hormone, 27:297
- treatment response prediction, 3-methoxy-4-hydroxyphenylglycol, 27:297
- treatment response prediction, norepinephrine, 27:297
- treatment response prediction, schizophrenia, 27:297
- Cocaine**
- affective disorder, comorbidity, 28:105, 28:335
- alcoholism, comorbidity, 29:113
- alcoholism, genetics, 29:113
- amantadine, bromocriptine, 29:11
- amantadine, withdrawal, 29:11
- blood pressure, haloperidol, 27:117
- blood pressure, heart rate, 27:117
- blood pressure, subjective effects, 27:117
- blood pressure, substance abuse, 27:117
- bromocriptine, amantadine, 29:11
- bromocriptine, withdrawal, 29:11
- comorbidity, affective disorder, 28:105, 28:335
- comorbidity, alcoholism, 29:113
- comorbidity, genetics, 29:113
- eye movements, 3-methoxy-4-hydroxy-phenylglycol, 29:123
- genetics, alcoholism, 29:113

**Cocaine** continued

- genetics, comorbidity, 29:113
- haloperidol, blood pressure, 27:117
- haloperidol, heart rate, 27:117
- haloperidol, subjective effects, 27:117
- heart rate, blood pressure, 27:117
- heart rate, haloperidol, 27:117
- heart rate, subjective effects, 27:117
- 3-methoxy-4-hydroxyphenylglycol, eye movements, 29:123
- subjective effects, blood pressure, 27:117
- subjective effects, haloperidol, 27:117
- subjective effects, heart rate, 27:117
- withdrawal, amantadine, 29:11
- withdrawal, bromocriptine, 29:11

**Computed tomography**

- affective disorder, psychotic symptoms, 29:221
- affective disorder, symptomatology, 29:271
- affective disorder, ventricle-brain ratio, 29:271
- alcoholism, cerebrospinal fluid volumetry, 29:277
- alcoholism, growth hormone, 28:89
- alcoholism, magnetic resonance imaging, 29:277
- Alzheimer's disease, dementia, 29:445
- Alzheimer's disease, positron emission tomography, 29:359
- Alzheimer's disease, single photon emission computed tomography, 29:445
- Alzheimer's disease, white matter, 29:359
- attention, laterality, 29:267
- attention, schizophrenia, 29:267
- attention, ventricle-brain ratio, 29:267
- beta-hydroxybutyric acid, ventricle-brain ratio, 27:39
- borderline personality disorder, 27:111
- brain atlas, EEG mapping, 29:461
- bulimia nervosa, 27:39
- cerebral ischemia, single photon emission computed tomography, 29:457
- cortisol, ventricle-brain ratio, 27:39
- cerebrospinal fluid volumetry, alcoholism, 29:277
- cerebrospinal fluid volumetry, magnetic resonance imaging, 29:277
- dementia, Alzheimer's disease, 29:445
- dementia, single photon emission computed tomography, 29:445
- diencephalic lesions, magnetic resonance imaging, 29:285
- eating disorders, ventricle-brain ratio, 27:39

**Computed tomography** continued

- EEG focus, magnetic resonance imaging, 29:459
- EEG focus, seizures, 29:459
- EEG focus, single photon emission computed tomography, 29:459
- EEG mapping, brain atlas, 29:461
- electroencephalogram, frontal lobe, 29:137
- electroencephalogram, schizophrenia, 29:137
- electroencephalogram, Wisconsin Card Sort Test, 29:137
- embolic mechanisms, stroke, 29:273
- frontal lobe, electroencephalogram, 29:137
- frontal lobe, schizophrenia, 29:137
- frontal lobe, Wisconsin Card Sort Test, 29:137
- laterality, attention, 29:267
- laterality, schizophrenia, 29:247, 29:267
- laterality, ventricle-brain ratio, 29:267
- limbic system, schizophrenia, 29:255
- lupus erythematosus, magnetic resonance imaging, 29:367
- lupus erythematosus, positron emission tomography, 29:367
- magnetic resonance imaging, alcoholism, 29:277
- magnetic resonance imaging, cerebrospinal fluid volumetry, 29:277
- magnetic resonance imaging, diencephalic lesions, 29:285
- magnetic resonance imaging, EEG focus, 29:459
- magnetic resonance imaging, lupus erythematosus, 29:367
- magnetic resonance imaging, positron emission tomography, 29:363, 29:367
- magnetic resonance imaging, schizophrenia, 29:265
- magnetic resonance imaging, seizures, 29:459
- magnetic resonance imaging, single photon emission computed tomography, 29:459
- magnetic resonance imaging, thalamic infarction, 29:363
- magnetic resonance imaging, ventricle-brain ratio, 29:265
- positron emission tomography, Alzheimer's disease, 29:359
- positron emission tomography, lupus erythematosus, 29:367
- positron emission tomography, magnetic resonance imaging, 29:363, 29:367
- positron emission tomography, thalamic infarction, 29:363

**Computed tomography** continued

- positron emission tomography, white matter, 29:359
- psychotic symptoms, affective disorder, 29:221
- schizophrenia, attention, 29:267
- schizophrenia, electroencephalogram, 29:137
- schizophrenia, frontal lobe, 29:137
- schizophrenia, laterality, 29:247, 29:267
- schizophrenia, limbic system, 29:255
- schizophrenia, magnetic resonance imaging, 29:265
- schizophrenia, ventricle-brain ratio, 29:257, 29:265, 29:267
- schizophrenia, Wisconsin Card Sort Test, 29:137
- seizures, EEG focus, 29:459
- seizures, magnetic resonance imaging, 29:459
- seizures, single photon emission computed tomography, 29:459
- single photon emission computed tomography, Alzheimer's disease, 29:445
- single photon emission computed tomography, cerebral ischemia, 29:457
- single photon emission computed tomography, dementia, 29:445
- single photon emission computed tomography, EEG focus, 29:459
- single photon emission computed tomography, magnetic resonance imaging, 29:459
- single photon emission computed tomography, seizures, 29:459
- stroke, embolic mechanisms, 29:273
- symptomatology, affective disorders, 29:271
- symptomatology, ventricle-brain ratio, 29:271
- thalamic infarction, magnetic resonance imaging, 29:363
- thalamic infarction, positron emission tomography, 29:363
- third ventricle size, borderline personality disorder, 27:111
- triiodothyronine, ventricle-brain ratio, 27:39
- ventricle-brain ratio, affective disorders, 29:271
- ventricle-brain ratio, attention, 29:267
- ventricle-brain ratio, beta-hydroxybutyric acid, 27:39
- ventricle-brain ratio, borderline personality disorder, 27:111

**Computed tomography** continued

- ventricle-brain ratio, bulimia nervosa, 27:39
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, eating disorders, 27:39
- ventricle-brain ratio, laterality, 29:267
- ventricle-brain ratio, magnetic resonance imaging, 29:265
- ventricle-brain ratio, schizophrenia, 29:257, 29:265, 29:267
- ventricle-brain ratio, symptomatology, 29:271
- ventricle-brain ratio, triiodothyronine, 27:39
- Wisconsin Card Sort Test, electroencephalogram, 29:137
- Wisconsin Card Sort Test, frontal lobe, 29:137
- Wisconsin Card Sort Test, schizophrenia, 29:137
- white matter, Alzheimer's disease, 29:359
- white matter, positron emission tomography, 29:359

**Conduct disorder.** See also Attention deficit disorder

- attention deficit disorder, catecholamines, 27:241
- attention deficit disorder, dopamine-beta-hydroxylase, 27:241
- attention deficit disorder, 3-methoxy-4-hydroxyphenylglycol, 27:241
- attention deficit disorder, norepinephrine, 27:241
- case report, 5-hydroxyindolacetic acid, 28:115
- case report, cruelty to animals, 28:115
- catecholamines, attention deficit disorder, 27:241
- catecholamines, dopamine-beta-hydroxylase, 27:241
- catecholamines, norepinephrine, 27:241
- cruelty to animals, 5-hydroxyindolacetic acid, 28:115
- cruelty to animals, case report, 28:115
- dopamine-beta-hydroxylase, attention deficit disorder, 27:241
- dopamine-beta-hydroxylase, catecholamines, 27:241
- dopamine-beta-hydroxylase, norepinephrine, 27:241
- 5-hydroxyindole acetic acid, case report, 28:115
- 5-hydroxyindole acetic acid, cruelty to animals, 28:115

**Conduct disorder** continued

- 3-methoxy-4-hydroxyphenylglycol, attention deficit disorder, 27:241
- norepinephrine, attention deficit disorder, 27:241
- norepinephrine, catecholamines, 27:241
- norepinephrine, dopamine-beta-hydroxylase, 27:241

**Continuous performance test**

- affective disorder, attention, 29:65
- affective disorder, laterality, 29:65
- affective disorder, schizophrenia, 29:65
- laterality, affective disorder, 29:65
- laterality, attention, 29:65
- laterality, schizophrenia, 29:65
- schizophrenia, attention, 29:65
- schizophrenia, laterality, 29:65

**Corticotropin releasing hormone**

- gamma-aminobutyric acid, gambling, 30:137
- gamma-aminobutyric acid, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gamma-aminobutyric acid, neuropeptides, 30:137
- gamma-aminobutyric acid, norepinephrine, 30:137
- gambling, gamma-aminobutyric acid, 30:137
- gambling, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gambling, neuropeptides, 30:137
- gambling, norepinephrine, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gambling, 30:137
- 3-methoxy-4-hydroxyphenylglycol, neuropeptides, 30:137
- neuropeptides, gamma-aminobutyric acid, 30:137
- neuropeptides, gambling, 30:137
- neuropeptides, 3-methoxy-4-hydroxyphenylglycol, 30:137
- neuropeptides, norepinephrine, 30:137
- norepinephrine, gambling, 30:137

**Cortisol**

- adolescents, affective disorder, 27:101
- adolescents, 3-methoxy-4-hydroxyphenylglycol, 27:101
- adolescents, norepinephrine, 27:101
- affective disorder, adolescents, 27:101
- affective disorder, dexamethasone suppression test, 27:161, 29:187
- affective disorder, dopamine, 29:187
- affective disorder, epinephrine, 29:187
- affective disorder, 3-methoxy-4-hydroxyphenylglycol, 27:101

**Cortisol** continued

- affective disorder, norepinephrine, 27:101, 29:187
- affective disorders, circadian rhythms, 28:263
- affective disorders, cyclic adenosine monophosphate, 30:181
- affective disorders, dihydroergocryptine, 30:181
- affective disorders, melatonin, 28:263
- affective disorders, norepinephrine, 28:263
- affective disorders, prostaglandin, 30:181
- affective disorders, temperature, 28:263
- affective disorders, thyroid stimulating hormone, 28:263
- age, chlorophenylpiperazine, 29:1
- age, prolactin, 29:1
- age, serotonin, 29:1
- alcoholism, dexamethasone suppression test, 30:217
- alcoholism, liver function, 30:217
- Alzheimer's disease, dexamethasone suppression test, 29:169
- Alzheimer's disease, gender, 29:169
- beta-hydroxybutyric acid, computed tomography, 27:39
- beta-hydroxybutyric acid, eating disorders, 27:39
- beta-hydroxybutyric acid, triiodothyronine, 27:39
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, heart rate, 27:173
- blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173
- blood pressure, norepinephrine, 27:173
- blood pressure, yohimbine, 27:173
- chlorophenylpiperazine, age, 29:1
- chlorophenylpiperazine, prolactin, 29:1
- chlorophenylpiperazine, serotonin, 29:1
- circadian rhythms, affective disorders, 28:263
- circadian rhythms, melatonin, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, temperature, 28:263
- circadian rhythms, thyroid stimulating hormone, 28:263
- computed tomography, beta-hydroxybutyric acid, 27:39
- computed tomography, eating disorders, 27:39
- computed tomography, triiodothyronine, 27:39
- computed tomography, ventricle-brain ratio, 27:39

**Cortisol** continued

cyclic adenosine monophosphate, affective disorders, dihydroergocryptine, prostaglandin, 30:181  
 dehydroepiandrosterone, panic disorder, 28:345  
 dexamethasone suppression test, affective disorder, 27:161, 29:187  
 dexamethasone suppression test, alcoholism, 30:217  
 dexamethasone suppression test, Alzheimer's disease, 29:169  
 dexamethasone suppression test, dopamine, 29:187  
 dexamethasone suppression test, epinephrine, 29:187  
 dexamethasone suppression test, gender, 29:169  
 dexamethasone suppression test, liver function, 30:217  
 dexamethasone suppression test, negative symptoms, 30:69  
 dexamethasone suppression test, norepinephrine, 29:187  
 dexamethasone suppression test, obsessive-compulsive, 30:243, dexamethasone suppression test, panic disorder, 30:243  
 dexamethasone suppression test, schizophrenia, 30:69  
 dihydroergocryptine, affective disorders, 30:181  
 dihydroergocryptine, cyclic adenosine monophosphate, 30:181  
 dihydroergocryptine, prostaglandin, 30:181  
 dopamine, affective disorder, 29:187  
 dopamine, dexamethasone suppression test, 29:187  
 dopamine, epinephrine, 29:187  
 dopamine, norepinephrine, 29:187  
 eating disorders, beta-hydroxybutyric acid, 27:39  
 eating disorders, computed tomography, 27:39  
 eating disorders, estradiol, 29:105  
 eating disorders, osteoporosis, 29:105  
 eating disorders, triiodothyronine, 27:39  
 eating disorders, ventricle-brain ratio, 27:39  
 epinephrine, affective disorder, 29:187  
 epinephrine, dexamethasone suppression test, 29:187  
 epinephrine, dopamine, 29:187  
 epinephrine, norepinephrine, 29:187  
 estradiol, eating disorders, 29:105

**Cortisol** continued

estradiol, osteoporosis, 29:105  
 gender, Alzheimer's disease, 29:169  
 gender, dexamethasone suppression test, 29:169  
 generalized anxiety disorder, blood pressure, 27:173  
 generalized anxiety disorder, heart rate, 27:173  
 generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 generalized anxiety disorder, norepinephrine, 27:173  
 generalized anxiety disorder, yohimbine, 27:173  
 growth hormone, panic disorder, 28:351  
 growth hormone, prolactin, 28:351  
 growth hormone, syncope, 28:351  
 heart rate, blood pressure, 27:173  
 heart rate, generalized anxiety disorder, 27:173  
 heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 heart rate, norepinephrine, 27:173  
 heart rate, yohimbine, 27:173  
 liver function, alcoholism, 30:217  
 liver function, dexamethasone suppression test, 30:217  
 melatonin, affective disorders, 28:263  
 melatonin, circadian rhythms, 28:263  
 melatonin, norepinephrine, 28:263  
 melatonin, temperature, 28:263  
 melatonin, thyroid stimulating hormone, 28:263  
 3-methoxy-4-hydroxyphenylglycol, adolescents, 27:101  
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 27:101  
 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173  
 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173  
 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:101, 27:173  
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173  
 negative symptoms, dexamethasone suppression test, 30:69  
 negative symptoms, schizophrenia, 30:69  
 norepinephrine, adolescents, 27:101  
 norepinephrine, affective disorder, 27:101, 28:263, 29:187  
 norepinephrine, blood pressure, 27:173

**Cortisol** continued

norepinephrine, circadian rhythms, 28:263  
 norepinephrine, dexamethasone suppression test, 29:187  
 norepinephrine, dopamine, 29:187  
 norepinephrine, epinephrine, 29:187  
 norepinephrine, generalized anxiety disorder, 27:173  
 norepinephrine, heart rate, 27:173  
 norepinephrine, melatonin, 28:263  
 norepinephrine, 3-methoxy-4-hydroxy-phenylglycol, 27:101, 27:173  
 norepinephrine, temperature, 28:263  
 norepinephrine, thyroid stimulating hormone, 28:263  
 norepinephrine, yohimbine, 27:173  
 obsessive-compulsive disorder, dexamethasone suppression test, 30:243  
 osteoporosis, eating disorders, 29:105  
 osteoporosis, estradiol, 29:105  
 panic disorder, dehydroepiandrosterone, 28:345  
 panic disorder, dexamethasone suppression test, 30:243  
 panic disorder, growth hormone, 28:351  
 panic disorder, prolactin, 28:351  
 panic disorder, syncope, 28:351  
 prolactin, age, 29:1  
 prolactin, chlorophenylpiperazine, 29:1  
 prolactin, growth hormone, 28:351  
 prolactin, panic disorder, 28:351  
 prolactin, serotonin, 29:1  
 prolactin, syncope, 28:351  
 prostaglandin, affective disorders, 30:181  
 prostaglandin, cyclic adenosine monophosphate, 30:181  
 prostaglandin, dihydroergocryptine, 30:181  
 schizophrenia, dexamethasone suppression test, 30:69  
 schizophrenia, negative symptoms, 30:69  
 serotonin, age, 29:1  
 serotonin, chlorophenylpiperazine, 29:1  
 serotonin, prolactin, 29:1  
 syncope, growth hormone, 28:351  
 syncope, panic disorder, 28:351  
 syncope, prolactin, 28:351  
 temperature, affective disorder, 28:263  
 temperature, circadian rhythms, 28:263  
 temperature, melatonin, 28:263  
 temperature, norepinephrine, 28:263  
 temperature, thyroid stimulating hormone, 28:263  
 thyroid stimulating hormone, affective disorder, 28:263

**Cortisol** continued

thyroid stimulating hormone, circadian rhythms, 28:263  
 thyroid stimulating hormone, melatonin, 28:263  
 thyroid stimulating hormone, norepinephrine, 28:263  
 thyroid stimulating hormone, temperature, 28:263  
 triiodothyronine, beta-hydroxybutyric acid, 27:39  
 triiodothyronine, computed tomography, 27:39  
 triiodothyronine, eating disorders, 27:39  
 triiodothyronine, ventricle-brain ratio, 27:39  
 ventricle-brain ratio, beta-hydroxybutyric acid, 27:39  
 ventricle-brain ratio, computed tomography, 27:39  
 ventricle-brain ratio, eating disorders, 27:39  
 ventricle-brain ratio, triiodothyronine, 27:39  
 yohimbine, blood pressure, 27:173  
 yohimbine, generalized anxiety disorder, 27:173  
 yohimbine, heart rate, 27:173  
 yohimbine, 3-methoxy-4-hydroxy-phenylglycol, 27:173  
 yohimbine, norepinephrine, 27:173  
**Dehydroepiandrosterone-sulfate**  
 panic disorder, cortisol, 28:345  
**Dementia.** See also *Alzheimer's disease*  
*Alzheimer's disease*, computed tomography, 29:445  
*Alzheimer's disease*, single photon emission computed tomography, 29:445  
 cerebral blood flow, single photon emission computed tomography, 29:327  
 cerebral blood flow, xenon inhalation, 29:297  
 computed tomography, *Alzheimer's disease*, 29:445  
 computed tomography, single photon emission computed tomography, 29:445  
 deoxyglucose, positron emission tomography, 29:353  
 EEG mapping, evoked potentials, 29:391  
 EEG mapping, P300, 29:391  
 EEG mapping, schizophrenia, 29:391  
 evoked potentials, EEG mapping, 29:391  
 evoked potentials, P300, 29:391  
 evoked potentials, schizophrenia, 29:391

**Dementia** continued

- P300, EEG mapping, 29:391
- P300, evoked potentials, 29:391
- P300, schizophrenia, 29:391
- positron emission tomography, deoxyglucose, 29:353
- schizophrenia, EEG mapping, 29:391
- schizophrenia, evoked potentials, 29:391
- schizophrenia, P300, 29:391
- single photon emission computed tomography, Alzheimer's disease, 29:445
- single photon emission computed tomography, cerebral blood flow, 29:327
- single photon emission computed tomography, computed tomography, 29:445
- xenon inhalation, cerebral blood flow, 29:297

**Dermatoglyphics**

- genetics, schizophrenia, 29:37
- schizophrenia, genetics, 29:37
- schizophrenia, twins, 29:37
- twins, schizophrenia, 29:37

**Desipramine**

- clenbuterol, food restriction, rats, 27:149
- clomipramine, food restriction, rats, 27:149
- food restriction, rats, 27:149
- frontal lobe, imipramine binding, 30:125
- frontal lobe, serotonin, 30:125
- frontal lobe, suicide, 30:125
- imipramine binding, frontal lobe, 30:125
- imipramine binding, serotonin, 30:125
- imipramine binding, suicide, 30:125
- indalpine, food restriction, rats, 27:149
- nialamide, food restriction, rats, 27:149
- serotonin, frontal lobe, 30:125
- serotonin, imipramine binding, 30:125
- serotonin, suicide, 30:125
- suicide, frontal lobe, 30:125
- suicide, imipramine binding, 30:125

**Dexamethasone suppression test**

- affective disorder, children, 29:215
- affective disorder, cholesterol, 29:215
- affective disorder, circannual rhythms, 29:87
- affective disorder, cortisol, 27:161, 29:187
- affective disorder, dopamine, 29:187
- affective disorder, epinephrine, 29:187
- affective disorder, glucose, 29:215
- affective disorder, homovanillic acid, 29:177
- affective disorder, imipramine binding, 29:87
- affective disorder, norepinephrine, 29:187

**Dexamethasone suppression test**

- continued
- affective disorder, potassium, 29:215
- affective disorder, sodium, 29:215
- alcoholism, cortisol, 30:217
- alcoholism, liver function, 30:217
- Alzheimer's disease, cortisol, 29:169
- Alzheimer's disease, gender, 29:169
- children, affective disorder, 29:215
- children, cholesterol, 29:215
- children, glucose, 29:215
- children, potassium, 29:215
- children, sodium, 29:215
- cholesterol, affective disorder, 29:215
- cholesterol, children, 29:215
- cholesterol, glucose, 29:215
- circannual rhythms, affective disorder, 29:87
- circannual rhythms, imipramine binding, 29:87
- cortisol, affective disorder, 27:161, 29:187
- cortisol, alcoholism, 30:217
- cortisol, Alzheimer's disease, 29:169
- cortisol, dopamine, 29:187
- cortisol, epinephrine, 29:187
- cortisol, gender, 29:169
- cortisol, liver function, 30:217
- cortisol, negative symptoms, 30:69
- cortisol, norepinephrine, 29:187
- cortisol, obsessive-compulsive disorder, 30:243
- cortisol, panic disorder, 30:243
- cortisol, schizophrenia, 30:69
- dopamine, affective disorder, 29:187
- dopamine, cortisol, 29:187
- dopamine, epinephrine, 29:187
- dopamine, norepinephrine, 29:187
- epinephrine, affective disorder, 29:187
- epinephrine, cortisol, 29:187
- epinephrine, dopamine, 29:187
- epinephrine, norepinephrine, 29:187
- gender, Alzheimer's disease, 29:169
- gender, cortisol, 29:169
- glucose, affective disorder, 29:215
- glucose, children, 29:215
- glucose, cholesterol, 29:215
- homovanillic acid, affective disorder, 29:177
- imipramine binding, affective disorder, 29:87
- imipramine binding, circannual rhythms, 29:87
- liver function, alcoholism, 30:217
- liver function, cortisol, 30:217
- negative symptoms, cortisol, 30:69

**Dexamethasone suppression test**

continued

- negative symptoms, schizophrenia, 30:69
- norepinephrine, affective disorder, 29:187
- norepinephrine, cortisol, 29:187
- norepinephrine, dopamine, 29:187
- obsessive-compulsive disorder, cortisol, 30:243
- panic disorder, cortisol, 30:243
- potassium, affective disorder, 29:215
- potassium, children, 29:215
- potassium, cholesterol, 29:215
- potassium, glucose, 29:215
- schizophrenia, cortisol, 30:69
- schizophrenia, negative symptoms, 30:69
- sodium, affective disorder, 29:215
- sodium, children, 29:215

**Diabetes**

- glucose tolerance, haloperidol, 29:17
- glucose tolerance, schizophrenia, 29:17
- glucose tolerance, tardive dyskinesia, 29:17
- haloperidol, glucose tolerance, 29:17
- haloperidol, schizophrenia, 29:17
- haloperidol, tardive dyskinesia, 29:17
- schizophrenia, glucose tolerance, 29:17
- schizophrenia, haloperidol, 29:17
- schizophrenia, tardive dyskinesia, 29:17
- tardive dyskinesia, glucose tolerance, 29:17
- tardive dyskinesia, haloperidol, 29:17
- tardive dyskinesia, schizophrenia, 29:17

**Diagnostic criteria**

- affective disorders, antidepressants, 30:83
- affective disorders, treatment response, 30:83
- antidepressants, affective disorders, 30:83
- antidepressants, treatment response, 30:83
- Axis IV, DSM-III, 30:201
- Axis IV, stressors, 30:201
- DSM-III, Axis IV, 30:201
- DSM-III, stressors, 30:201
- personality disorder, self-defeating, 30:145
- self-defeating personality disorder, 30:145
- stressors, Axis IV, 30:201
- stressors, DSM-III, 30:201
- treatment response, affective disorders, 30:83
- treatment response, antidepressants, 30:83

**Diazepam**

- alprazolam, 3-methoxy-4-hydroxy-phenylglycol, 30:53
- alprazolam, panic disorder, 30:53
- alprazolam, treatment response, 30:53
- 3-methoxy-4-hydroxyphenylglycol, panic disorder, 30:53

**Diazepam** continued

- 3-methoxy-4-hydroxyphenylglycol, treatment response, 30:53
- panic disorder, 3-methoxy-4-hydroxy-phenylglycol, 30:53
- panic disorder, treatment response, 30:53
- treatment response, 3-methoxy-4-hydroxy-phenylglycol, 30:53
- treatment response, panic disorder, 30:53

**Dihydroergocryptine**

- affective disorders, cyclic adenosine monophosphate, 30:181
- affective disorders, cortisol, 30:181
- affective disorders, 5-hydroxyindolacetic acid, 30:181
- affective disorders, prostaglandin, 30:181
- affective disorders, serotonin uptake, 30:181
- cortisol, affective disorders, 30:181
- cortisol, cyclic adenosine monophosphate, 30:181
- cortisol, prostaglandin, 30:181
- cyclic adenosine monophosphate, affective disorders, 30:181
- cyclic adenosine monophosphate, cortisol, 30:181
- cyclic adenosine monophosphate, 5-hydroxyindolacetic acid, 30:181
- cyclic adenosine monophosphate, prostaglandin, 30:181
- cyclic adenosine monophosphate, serotonin uptake, 30:181
- 5-hydroxyindolacetic acid, affective disorders, 30:181
- 5-hydroxyindolacetic acid, cyclic adenosine monophosphate, 30:181
- 5-hydroxyindolacetic acid, serotonin uptake, 30:181
- prostaglandin, affective disorders, 30:181
- prostaglandin, cyclic adenosine monophosphate, 30:181
- prostaglandin, cortisol, 30:181
- serotonin uptake, affective disorders, 30:181
- serotonin uptake, cyclic adenosine monophosphate, 30:181
- serotonin uptake, 5-hydroxyindolacetic acid, 30:181

**Dopamine**

- affective disorder, cortisol, 29:187
- affective disorder, dexamethasone suppression test, 29:187
- affective disorder, epinephrine, 29:187
- affective disorder, norepinephrine, 29:187

**Dopamine** continued

attention deficit disorder, catecholamines, 27:241  
 attention deficit disorder, conduct disorder, 27:241  
 attention deficit disorder, norepinephrine, 27:241  
 bromospiperone, positron emission tomography, 29:357  
 bromospiperone, schizophrenia, 29:357  
 butaclarol, lymphocytes, 30:259  
 butaclarol, spiperone binding, 30:259  
 catecholamines, attention deficit disorder, 27:241  
 catecholamines, conduct disorder, 27:241  
 catecholamines, norepinephrine, 27:241  
 conduct disorder, attention deficit disorder, 27:241  
 conduct disorder, catecholamines, 27:241  
 conduct disorder, norepinephrine, 27:241  
 cortisol, affective disorder, 29:187  
 cortisol, dexamethasone suppression test, 29:187  
 cortisol, epinephrine, 29:187  
 cortisol, norepinephrine, 29:187  
 dexamethasone suppression test, affective disorder, 29:187  
 dexamethasone suppression test, cortisol, 29:187  
 dexamethasone suppression test, epinephrine, 29:187  
 dexamethasone suppression test, norepinephrine, 29:187  
 epinephrine, affective disorder, 29:187  
 epinephrine, cortisol, 29:187  
 epinephrine, dexamethasone suppression test, 29:187  
 epinephrine, norepinephrine, 29:187  
 locus ceruleus, paranoid subtype, 27:31  
 locus ceruleus, post-mortem study, 27:31  
 locus ceruleus, schizophrenia, 27:31  
 lymphocytes, butaclarol, 30:259  
 lymphocytes, spiperone binding, 30:259  
 norepinephrine, affective disorder, 29:187  
 norepinephrine, attention deficit disorder, 27:241  
 norepinephrine, catecholamines, 27:241  
 norepinephrine, conduct disorder, 27:241  
 norepinephrine, cortisol, 29:187  
 norepinephrine, epinephrine, 29:187  
 paranoid subtype, locus ceruleus, 27:31  
 paranoid subtype, post-mortem study, 27:31  
 paranoid subtype, schizophrenia, 27:31

**Dopamine** continued

positron emission tomography, bromospiperone, 29:357  
 positron emission tomography, schizophrenia, 29:357  
 post-mortem study, locus ceruleus, 27:31  
 post-mortem study, paranoid subtype, 27:31  
 post-mortem study, schizophrenia, 27:31  
 schizophrenia, bromospiperone, 29:357  
 schizophrenia, locus ceruleus, 27:31  
 schizophrenia, paranoid subtype, 27:31  
 schizophrenia, positron emission tomography, 29:357  
 schizophrenia, post-mortem study, 27:31  
 spiperone binding, butaclarol, 30:259  
 spiperone binding, lymphocytes, 30:259

**DSM-III**

Axis IV, diagnostic criteria, 30:201  
 Axis IV, stressors, 30:201  
 diagnostic criteria, Axis IV, 30:201  
 diagnostic criteria, stressors, 30:201  
 life events, *Psychiatric Epidemiology Research Interview*, 30:201  
*Psychiatric Epidemiology Research Interview*, life events, 30:201  
 stressors, Axis IV, 30:201  
 stressors, diagnostic criteria, 30:201

**Dyslexia**

dyseidetic children, EEG mapping, 29:407  
 EEG mapping, dyseidetic children, 29:407

**Eating disorders**

beta-hydroxybutyric acid, computed tomography, 27:39  
 beta-hydroxybutyric acid, cortisol, 27:39  
 beta-hydroxybutyric acid, triiodothyronine, 27:39  
 beta-hydroxybutyric acid, ventricle-brain ratio, 27:39  
 blood pressure, heart rate, 30:223  
 blood pressure, stressors, 30:223  
 blood pressure, Type A behavior, 30:223  
 cocaine, comorbidity, 28:105  
 comorbidity, cocaine, 28:105  
 computed tomography, beta-hydroxybutyric acid, 27:39  
 computed tomography, cortisol, 27:39  
 computed tomography, triiodothyronine, 27:39  
 computed tomography, ventricle-brain ratio, 27:39  
 cortisol, beta-hydroxybutyric acid, 27:39  
 cortisol, computed tomography, 27:39  
 cortisol, estradiol, 29:105

**Eating disorders** continued

cortisol, osteoporosis, 29:105  
 cortisol, triiodothyronine, 27:39  
 cortisol, ventricle-brain ratio, 27:39  
 estradiol, cortisol, 29:105  
 estradiol, osteoporosis, 29:105  
 follicle stimulating hormone, luteinizing hormone, 28:11  
 gonadotropin releasing hormone, luteinizing hormone, 28:11  
 gonadotropin releasing hormone, menstrual cycle, 28:11  
 heart rate, blood pressure, 30:223  
 heart rate, stressors, 30:223  
 heart rate, Type A behavior, 30:223  
 imipramine binding, platelet, 30:21  
 luteinizing hormone, follicle stimulating hormone, 28:11  
 luteinizing hormone, gonadotropin releasing hormone, 28:11  
 luteinizing hormone, menstrual cycle, 28:11  
 menstrual cycle, gonadotropin releasing hormone, 28:11  
 menstrual cycle, luteinizing hormone, 28:11  
 osteoporosis, cortisol, 29:105  
 osteoporosis, estradiol, 29:105  
 stressors, blood pressure, 30:223  
 stressors, heart rate, 30:223  
 stressors, Type A behavior, 30:223  
 triiodothyronine, beta-hydroxybutyric acid, 27:39  
 triiodothyronine, computed tomography, 27:39  
 triiodothyronine, cortisol, 27:39  
 triiodothyronine, ventricle-brain ratio, 27:39  
 Type A behavior, blood pressure, 30:223  
 Type A behavior, heart rate, 30:223  
 Type A behavior, stressors, 30:223  
 ventricle-brain ratio, beta-hydroxybutyric acid, 27:39  
 ventricle-brain ratio, computed tomography, 27:39  
 ventricle-brain ratio, cortisol, 27:39  
 ventricle-brain ratio, triiodothyronine, 27:39

**Electroencephalogram**

alpha, photic driving, 30:313  
 alpha, schizophrenia, 30:313  
 brain electrical activity mapping, cognitive functions, 29:385

**Electroencephalogram** continued

brain electrical activity mapping, evoked potentials, 29:379  
 cognitive functions, brain electrical activity mapping, 29:385  
 computed tomography, frontal lobe, 29:137  
 computed tomography, schizophrenia, 29:137  
 computed tomography, Wisconsin Card Sort Test, 29:137  
 evoked potentials, brain electrical activity mapping, 29:379  
 frontal lobe, computed tomography, 29:137  
 frontal lobe, schizophrenia, 29:137  
 frontal lobe, Wisconsin Card Sort Test, 29:137  
 neuroleptics, schizophrenia, 29:395  
 photic driving, schizophrenia, 30:313  
 schizophrenia, alpha, 30:313  
 schizophrenia, computed tomography, 29:137  
 schizophrenia, frontal lobe, 29:137  
 schizophrenia, neuroleptics, 29:395  
 schizophrenia, photic driving, 30:313  
 schizophrenia, thalamus, 30:313  
 schizophrenia, Wisconsin Card Sort Test, 29:137  
 thalamus, alpha, 30:313  
 thalamus, schizophrenia, 30:313  
 Wisconsin Card Sort Test, computed tomography, 29:137  
 Wisconsin Card Sort Test, frontal lobe, 29:137  
 Wisconsin Card Sort Test, schizophrenia, 29:137

**Electroencephalographic (EEG)****topography**

affective disorders, Alzheimer's disease, 29:403  
 affective disorders, evoked potentials, 29:403  
 algorithm, spatial interpolation, 29:431  
 Alzheimer's disease, affective disorders, 29:403  
 Alzheimer's disease, cognitive impairment, 29:409  
 Alzheimer's disease, disease severity, 29:399  
 Alzheimer's disease, evoked potentials, 29:403  
 Alzheimer's disease, phosphatidylserine, 29:411

**Electroencephalographic (EEG) topography** continued

Alzheimer's disease, single photon emission computed tomography, 29:449  
 arachnoid cyst, evoked potentials, P300, 29:421  
 arachnoid cyst, schizophrenia, 29:421  
 auditory and visual paradigm, evoked potentials, P300, 29:439  
 auditory and visual paradigm, semantic tasks, 29:439  
 autogenic training, beta reduction, 29:433  
 beta reduction, autogenic training, 29:433  
 brain atlas, computed tomography, 29:461  
 cognitive function, electroencephalography, 29:385  
 cognitive function, pyritinol, 29:387  
 cognitive impairment, Alzheimer's disease, 29:409  
 computed tomography, brain atlas, 29:461  
 dementia, evoked potentials, P300, 29:391  
 dementia, schizophrenia, 29:391  
 disease severity, Alzheimer's disease, 29:399  
 dyslexic children, dyslexia, 29:407  
 dyslexia, dyslexic children, 29:407  
 elderly subjects, affective disorders, 29:403  
 elderly subjects, Alzheimer's disease, 29:403  
 elderly subjects, evoked potentials, 29:403  
 electroencephalography, cognitive function, 29:385  
 electroencephalography, evoked potentials, 29:379  
 evoked potentials, affective disorders, 29:403  
 evoked potentials, Alzheimer's disease, 29:403  
 evoked potentials, arachnoid cyst, 29:421  
 evoked potentials, auditory and visual paradigm, 29:439  
 evoked potentials, dementia, 29:391  
 evoked potentials, elderly subjects, 29:403  
 evoked potentials, electroencephalography, 29:379  
 evoked potentials, P300, 29:391, 29:413, 29:421, 29:439  
 evoked potentials, pyritinol, 29:413  
 evoked potentials, schizophrenia, 29:391, 29:421  
 evoked potentials, semantic tasks, 29:439  
 Gilles de la Tourette syndrome, normal comparison, 29:427  
 K complex, sleep, 29:435

**Electroencephalographic (EEG) topography** continued

normal volunteers, phosphatidylserine, 29:417  
 normal comparison, Gilles de la Tourette syndrome, 29:427  
 olfactory stimulation, trigeminal stimulants, 29:429  
 P300, arachnoid cyst, 29:421  
 P300, auditory and visual paradigm, 29:439  
 P300, dementia, 29:391  
 P300, evoked potentials, 29:391, 29:413, 29:421, 29:439  
 P300, pyritinol, 29:413  
 P300, schizophrenia, 29:391, 29:421  
 P300, semantic tasks, 29:439  
 phosphatidylserine, Alzheimer's disease, 29:411  
 phosphatidylserine, normal volunteers, 29:417  
 pyritinol, cognitive function, 29:387  
 pyritinol, evoked potentials, P300, 29:413  
 Rett syndrome, theta activity, 29:425  
 Scale for the Assessment of Negative Symptoms, schizophrenia, 29:137  
 schizophrenia, arachnoid cyst, 29:421  
 schizophrenia, dementia, 29:391  
 schizophrenia, evoked potentials, 29:391, 29:421  
 schizophrenia, P300, 29:391, 29:421  
 schizophrenia, temporal lobe beta, 29:419  
 schizophrenia, Scale for the Assessment of Negative Symptoms, 29:137  
 semantic tasks, auditory and visual paradigm, 29:439  
 semantic tasks, evoked potential, 29:439  
 semantic tasks, P300, 29:439  
 sleep, K complex, 29:435  
 spatial interpolation, algorithm, 29:431  
 single photon emission computed tomography, Alzheimer's disease, 29:449  
 temporal lobe beta, schizophrenia, 29:419  
 theta activity, Rett syndrome, 29:425  
 trigeminal stimulants, olfactory stimulation, 29:429

**Electroconvulsive therapy**  
 blood-brain barrier, hypoglycemia, rats, 29:151  
 hypoglycemia, blood-brain barrier, rats, 29:151

**Epinephrine**  
 affective disorder, cortisol, 29:187  
 affective disorder, dexamethasone suppression test, 29:187

**Epinephrine** continued

- affective disorder, dopamine, 29:187
- affective disorder, norepinephrine, 29:187
- cortisol, affective disorder, 29:187
- cortisol, dexamethasone suppression test, 29:187
- cortisol, dopamine, 29:187
- cortisol, norepinephrine, 29:187
- dexamethasone suppression test, affective disorder, 29:187
- dexamethasone suppression test, cortisol, 29:187
- dexamethasone suppression test, norepinephrine, 29:187
- dopamine, affective disorder, 29:187
- dopamine, dexamethasone suppression test, 29:187
- dopamine, norepinephrine, 29:187
- norepinephrine, affective disorder, 29:187
- norepinephrine, cortisol, 29:187
- norepinephrine, dexamethasone suppression test, 29:187

**Essential fatty acids**

- linoleic acid, tardive dyskinesia, 27:313
- tardive dyskinesia, linoleic acid, 27:313

**Estradiol**

- cortisol, eating disorders, 29:105
- cortisol, osteoporosis, 29:105
- eating disorders, cortisol, 29:105
- osteoporosis, eating disorders, 29:105

**Evoked potentials**

- affective disorders, Alzheimer's disease, 29:403
- affective disorders, EEG mapping, 29:403
- affective disorders, elderly subjects, 29:403
- Alzheimer's disease, affective disorders, 29:403
- Alzheimer's disease, EEG mapping, 29:403
- Alzheimer's disease, elderly subjects, 29:403
- arachnoid cyst, EEG mapping, 29:421
- arachnoid cyst, P300, 29:421
- arachnoid cyst, schizophrenia, 29:421
- auditory and visual paradigm, EEG mapping, 29:439
- auditory and visual paradigm, P300, 29:439
- auditory and visual paradigm, semantic tasks, 29:439
- auditory stimuli, magnetoencephalography, 29:369
- brain electrical activity mapping, electroencephalography, 29:379
- clonidine, P300, 28:255
- dementia, EEG mapping, 29:391
- dementia, P300, 29:391
- dementia, schizophrenia, 29:391
- EEG mapping, affective disorder, 29:403
- EEG mapping, Alzheimer's disease, 29:403
- EEG mapping, arachnoid cyst, 29:421
- EEG mapping, auditory and visual paradigm, 29:439
- EEG mapping, dementia, 29:391
- EEG mapping, elderly subjects, 29:403
- EEG mapping, P300, 29:391, 29:413, 29:421, 29:439
- EEG mapping, pyritinol, 29:413
- EEG mapping, schizophrenia, 29:391, 29:421
- EEG mapping, semantic tasks, 29:439
- elderly subjects, affective disorders, 29:403
- elderly subjects, Alzheimer's disease, 29:403
- elderly subjects, EEG mapping, 29:403
- electroencephalography, brain electrical activity mapping, 29:379
- frontal lobe, obsessive-compulsive disorder, 28:63
- frontal lobe, P300, 28:63
- magnetoencephalography, auditory stimuli, 29:369
- obsessive-compulsive disorder, frontal lobe, 28:63
- obsessive-compulsive disorder, P300, 28:63
- P300, arachnoid cyst, 29:421
- P300, auditory and visual paradigm, 29:439
- P300, clonidine, 28:255
- P300, dementia, 29:391
- P300, EEG mapping, 29:391, 29:413, 29:421, 29:439
- P300, frontal lobe, 28:63
- P300, obsessive-compulsive disorder, 28:63
- P300, pyritinol, 29:413
- P300, schizophrenia, 29:391, 29:421
- P300, semantic tasks, 29:439
- pyritinol, EEG mapping, 29:413
- pyritinol, P300, 29:413
- schizophrenia, arachnoid cyst, 29:421
- schizophrenia, dementia, 29:391
- schizophrenia, EEG mapping, 29:391, 29:421
- schizophrenia, P300, 29:391, 29:421
- schizophrenia, tardive dyskinesia, 28:117
- semantic tasks, auditory and visual paradigm, 29:439
- semantic tasks, EEG mapping, 29:439
- semantic tasks, P300, 29:439
- tardive dyskinesia, schizophrenia, 28:117

**Eye movements**

- attention, clinical stabilization, 28:31
- attention, schizophrenia, 28:31
- clinical stabilization, schizophrenia, 28:31
- cocaine, 3-methoxy-4-hydroxyphenylglycol, 29:123
- 3-methoxy-4-hydroxyphenylglycol, cocaine, 29:123
- 3-methoxy-4-hydroxyphenylglycol, substance abuse, 29:123
- neuroleptics, schizophrenia, 28:307
- schizophrenia, attention, 28:31
- schizophrenia, clinical stabilization, 28:31
- schizophrenia, neuroleptics, 28:307
- substance abuse, 3-methoxy-4-hydroxyphenylglycol, 29:123

**Fenfluramine**

- anxiety, serotonin, 28:295
- panic disorder, anxiety, 28:295
- panic disorder, serotonin, 28:295
- serotonin, panic disorder, 28:295

**Fluoxetine**

- affective disorder, Hamilton Rating Scale for Depression, 30:191
- affective disorder, imipramine, 30:191
- affective disorder, placebo washout, 30:191
- Hamilton Rating Scale for Depression, imipramine, 30:191
- Hamilton Rating Scale for Depression, placebo washout, 30:191
- imipramine, placebo washout, 30:191
- placebo washout, affective disorder, 30:191
- placebo washout, imipramine, 30:191

**Follicle stimulating hormone**

- eating disorders, luteinizing hormone, 28:11
- luteinizing hormone, eating disorders, 28:11

**Food intake**

- antidepressants, learned helplessness, 27:149
- antidepressants, rats, 27:149
- antidepressants, triiodothyronine, 27:149
- learned helplessness, antidepressants, 27:149
- learned helplessness, triiodothyronine, 27:149
- triiodothyronine, antidepressants, 27:149
- triiodothyronine, learned helplessness, 27:149
- triiodothyronine, rats, 27:149

**Frontal lobe**

- cerebral blood flow, head injury, 29:313
- cerebral blood flow, schizophrenia, 29:331
- cerebral blood flow, single photon emission computed tomography, 29:331

**Frontal lobe** continued

- computed tomography, electroencephalogram, 29:137
- computed tomography, schizophrenia, 29:137
- computed tomography, Wisconsin Card Sort Test, 29:137
- desipramine, imipramine binding, 30:125
- desipramine, serotonin, 30:125
- desipramine, suicide, 30:125
- electroencephalogram, computed tomography, 29:137
- electroencephalogram, schizophrenia, 29:137
- electroencephalogram, Wisconsin Card Sort Test, 29:137
- evoked potentials, obsessive-compulsive disorder, 28:63
- evoked potentials, P300, 28:63
- head injury, cerebral blood flow, 29:313
- imipramine binding, desipramine, 30:125
- imipramine binding, serotonin, 30:125
- imipramine binding, suicide, 30:125
- magnetic resonance imaging, negative symptoms, 30:11
- magnetic resonance imaging, sagittal morphology, 30:11
- magnetic resonance imaging, schizophrenia, 30:11
- negative symptoms, magnetic resonance imaging, 30:11
- negative symptoms, sagittal morphology, 30:11
- negative symptoms, schizophrenia, 30:11
- obsessive-compulsive disorder, evoked potentials, 28:63
- obsessive-compulsive disorder, P300, 28:63
- P300, evoked potentials, 28:63
- P300, obsessive-compulsive disorder, 28:63
- parietal lobes, positron emission tomography, 28:119
- parietal lobes, schizophrenia, 28:119
- positron emission tomography, parietal lobes, 28:119
- positron emission tomography, schizophrenia, 28:119
- sagittal morphology, magnetic resonance imaging, 30:11
- sagittal morphology, negative symptoms, 30:11
- sagittal morphology, schizophrenia, 30:11
- schizophrenia, cerebral blood flow, 29:331
- schizophrenia, computed tomography, 29:137

**Frontal lobe** continued

- schizophrenia, electroencephalogram, 29:137
- schizophrenia, magnetic resonance imaging, 30:11
- schizophrenia, negative symptoms, 30:11
- schizophrenia, parietal lobes, 28:119
- schizophrenia, positron emission tomography, 28:119
- schizophrenia, sagittal morphology, 30:11
- schizophrenia, single photon emission computed tomography, 29:331
- schizophrenia, Wisconsin Card Sort Test, 29:137
- serotonin, desipramine, 30:125
- serotonin, imipramine binding, 30:125
- serotonin, suicide, 30:125
- single photon emission computed tomography, cerebral blood flow, 29:331
- single photon emission computed tomography, schizophrenia, 29:331
- suicide, desipramine, 30:125
- suicide, imipramine binding, 30:125
- suicide, serotonin, 30:125
- Wisconsin Card Sort Test, computed tomography, 29:137
- Wisconsin Card Sort Test, electroencephalogram, 29:137
- Wisconsin Card Sort Test, schizophrenia, 29:137

**Gamma-aminobutyric acid**

- corticotropin releasing hormone, gambling, 30:137
- corticotropin releasing hormone, 3-methoxy-4-hydroxyphenylglycol, 30:137
- corticotropin releasing hormone, neuropeptides, 30:137
- corticotropin releasing hormone, norepinephrine, 30:137
- gambling, corticotropin releasing hormone, 30:137
- gambling, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gambling, neuropeptides, 30:137
- gambling, norepinephrine, 30:137
- 3-methoxy-4-hydroxyphenylglycol, corticotropin releasing hormone, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gambling, 30:137
- 3-methoxy-4-hydroxyphenylglycol, neuropeptides, 30:137
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 30:137

**Gamma-aminobutyric acid** continued

- neuropeptides, corticotropin releasing hormone, 30:137
- neuropeptides, gambling, 30:137
- neuropeptides, norepinephrine, 30:137
- norepinephrine, corticotropin releasing hormone, 30:137
- norepinephrine, gambling, 30:137
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 30:137
- norepinephrine, neuropeptides, 30:137

**Gambling**

- corticotropin releasing hormone, gamma-aminobutyric acid, 30:137
- corticotropin releasing hormone, 3-methoxy-4-hydroxyphenylglycol, 30:137
- corticotropin releasing hormone, neuropeptides, 30:137
- corticotropin releasing hormone, norepinephrine, 30:137
- gamma-aminobutyric acid, corticotropin releasing hormone, 30:137
- gamma-aminobutyric acid, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gamma-aminobutyric acid, neuropeptides, 30:137
- gamma-aminobutyric acid, norepinephrine, 30:137
- 3-methoxy-4-hydroxyphenylglycol, corticotropin releasing hormone, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gamma-aminobutyric acid, 30:137
- 3-methoxy-4-hydroxyphenylglycol, neuropeptides, 30:137
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 30:137
- neuropeptides, corticotropin releasing hormone, 30:137
- neuropeptides, gamma-aminobutyric acid, 30:137
- neuropeptides, 3-methoxy-4-hydroxyphenylglycol, 30:137
- neuropeptides, norepinephrine, 30:137
- norepinephrine, corticotropin releasing hormone, 30:137
- norepinephrine, gamma-aminobutyric acid, 30:137
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 30:137
- norepinephrine, neuropeptides, 30:137

**Gender**

- Alzheimer's disease, cortisol, 29:169

**Gender** continued

Alzheimer's disease, dexamethasone suppression test, 29:169  
 borderline personality, 27:111  
 cerebral blood flow, sex role orientation, 27:55  
 cortisol, Alzheimer's disease, 29:169  
 cortisol, dexamethasone suppression test, 29:169  
 dexamethasone suppression test, Alzheimer's disease, 29:169  
 dexamethasone suppression test, cortisol, 29:169  
 genetics, heterogeneity, 28:243  
 genetics, schizophrenia, 28:243  
 heterogeneity, genetics, 28:243  
 heterogeneity, schizophrenia, 28:243  
 schizophrenia, genetics, 28:243  
 schizophrenia, heterogeneity, 28:243  
 sex role orientation, cerebral blood flow, 27:55

**Generalized anxiety disorder**

affective disorders, norepinephrine, 30:253  
 affective disorders, time sampling, 30:253  
 blood pressure, cortisol, 27:173  
 blood pressure, heart rate, 27:173  
 blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 blood pressure, norepinephrine, 27:173  
 blood pressure, yohimbine, 27:173  
 cortisol, blood pressure, 27:173  
 cortisol, heart rate, 27:173  
 cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 cortisol, norepinephrine, 27:173  
 cortisol, yohimbine, 27:173  
 heart rate, blood pressure, 27:173  
 heart rate, cortisol, 27:173  
 heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 heart rate, norepinephrine, 27:173  
 heart rate, yohimbine, 27:173  
 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173  
 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:173  
 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:173  
 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173  
 norepinephrine, affective disorders, 30:253  
 norepinephrine, blood pressure, 27:173  
 norepinephrine, cortisol, 27:173

**Generalized anxiety disorder** continued

norepinephrine, heart rate, 27:173  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 norepinephrine, time sampling, 30:253  
 norepinephrine, yohimbine, 27:173  
 time sampling, affective disorders, 30:253  
 time sampling, norepinephrine, 30:253  
 yohimbine, blood pressure, 27:173  
 yohimbine, cortisol, 27:173  
 yohimbine, heart rate, 27:173  
 yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 yohimbine, norepinephrine, 27:173

**Genetics**

alcoholism, cocaine, 29:113  
 alcoholism, comorbidity, 29:113  
 cocaine, alcoholism, 29:113  
 cocaine, comorbidity, 29:113  
 comorbidity, alcoholism, 29:113  
 comorbidity, cocaine, 29:113  
 dermatoglyphics, schizophrenia, 29:37  
 dermatoglyphics, twins, 29:37  
 gender, heterogeneity, 28:243  
 gender, schizophrenia, 28:243  
 heterogeneity, gender, 28:243  
 heterogeneity, schizophrenia, 28:243  
 imipramine binding, platelet, 27:287  
 imipramine binding, rats, 27:287  
 perinatal complications, schizophrenia, 27:233  
 schizophrenia, dermatoglyphics, 29:37  
 schizophrenia, gender, 28:243  
 schizophrenia, heterogeneity, 28:243  
 schizophrenia, perinatal complications, 27:233  
 schizophrenia, twins, 29:37  
 substance abuse, comorbidity, 29:113  
 twins, dermatoglyphics, 29:37  
 twins, schizophrenia, 29:37

**Geriatric depression**

affective disorder, antidepressants, 28:1  
 affective disorder, maintenance pharmacotherapy, 27:225  
 affective disorder, nortriptyline, 27:225, 28:1  
 affective disorder, phenelzine, 28:1  
 affective disorder, sleep, 27:13  
 affective disorder, subtype, 27:13  
 affective disorder, survival analysis, 27:225  
 antidepressants, affective disorder, 28:1  
 antidepressants, nortriptyline, 28:1  
 antidepressants, phenelzine, 28:1  
 maintenance pharmacotherapy, affective disorder, 27:225

**Geriatric depression** continued

- maintenance pharmacotherapy, nortriptyline, 27:225
- maintenance pharmacotherapy, survival analysis, 27:225
- nortriptyline, affective disorder, 27:225, 28:1
- nortriptyline, antidepressants, 28:1
- nortriptyline, phenelzine, 28:1
- nortriptyline, survival analysis, 27:225
- phenelzine, affective disorder, 28:1
- phenelzine, nortriptyline, 28:1
- sleep, affective disorder, 27:13
- sleep, subtype, 27:13
- subtype, affective disorder, 27:13
- subtype, sleep, 27:13
- survival analysis, affective disorder, 27:225
- survival analysis, maintenance pharmacotherapy, 27:225
- survival analysis, nortriptyline, 27:225

**Gilles de la Tourette syndrome**

- EEG mapping, normal comparison, 29:427
- normal comparison, EEG mapping, 29:427

**Glucose**

- affective disorder, children, 29:215
- children, affective disorder, 29:215
- cholesterol, affective disorder, children, 29:215
- dexamethasone suppression test, affective disorder, children, 29:215
- diabetes mellitus, haloperidol, 29:17
- diabetes mellitus, schizophrenia, 29:17
- diabetes mellitus, tardive dyskinesia, 29:17
- haloperidol, diabetes mellitus, 29:17
- haloperidol, schizophrenia, 29:17
- haloperidol, tardive dyskinesia, 29:17
- potassium, affective disorder, children, 29:215
- schizophrenia, diabetes mellitus, 29:17
- schizophrenia, haloperidol, 29:17
- schizophrenia, tardive dyskinesia, 29:17
- sodium, affective disorder, children, 29:215
- tardive dyskinesia, diabetes mellitus, 29:17
- tardive dyskinesia, haloperidol, 29:17
- tardive dyskinesia, schizophrenia, 29:17

**Gonadotropins.** See *Luteinizing hormone***Growth hormone**

- affective disorder, Alzheimer's disease, 27:277
- affective disorder, clonidine, 27:277, 29:199
- alcoholism, computed tomography, 28:89
- alcoholism, prolactin, 28:89
- alcoholism, thyroid stimulating hormone, 28:89

**Growth hormone** continued

- alcoholism, thyrotropin releasing hormone test, 28:89
- Alzheimer's disease, affective disorder, 27:277
- Alzheimer's disease, clonidine, 27:277
- clonidine, affective disorder, 27:277, 29:199
- clonidine, Alzheimer's disease, 27:277
- clonidine, 3-methoxy-4-hydroxy-phenylglycol, 27:297
- clonidine, norepinephrine, 27:297
- clonidine, schizophrenia, 27:297
- clonidine, treatment response prediction, 27:297
- computed tomography, alcoholism, 28:89
- computed tomography, prolactin, 28:89
- computed tomography, thyroid stimulating hormone, 28:89
- computed tomography, thyrotropin releasing hormone test, 28:89
- cortisol, panic disorder, 28:351
- cortisol, prolactin, 28:351
- cortisol, syncope, 28:351
- 3-methoxy-4-hydroxyphenylglycol, clonidine, 27:297
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:297
- 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 27:297
- 3-methoxy-4-hydroxyphenylglycol, treatment response prediction, 27:297
- norepinephrine, clonidine, 27:297
- norepinephrine, 3-methoxy-4-hydroxy-phenylglycol, 27:297
- norepinephrine, schizophrenia, 27:297
- norepinephrine, treatment response prediction, 27:297
- panic disorder, cortisol, 28:351
- panic disorder, prolactin, 28:351
- panic disorder, syncope, 28:351
- prolactin, alcoholism, 28:89
- prolactin, computed tomography, 28:89
- prolactin, cortisol, 28:351
- prolactin, panic disorder, 28:351
- prolactin, syncope, 28:351
- prolactin, thyroid stimulating hormone, 28:89
- prolactin, thyrotropin releasing hormone test, 28:89
- schizophrenia, clonidine, 27:297
- schizophrenia, 3-methoxy-4-hydroxy-phenylglycol, 27:297
- schizophrenia, norepinephrine, 27:297
- schizophrenia, treatment response prediction, 27:297
- syncope, cortisol, 28:351

**Growth hormone** continued

- syncope, panic disorder, 28:351
- syncope, prolactin, 28:351
- thyroid stimulating hormone, alcoholism, 28:89
- thyroid stimulating hormone, computed tomography, 28:89
- thyroid stimulating hormone, prolactin, 28:89
- thyrotropin releasing hormone test, alcoholism, 28:89
- thyrotropin releasing hormone test, computed tomography, 28:89
- thyrotropin releasing hormone test, prolactin, 28:89
- treatment response prediction, clonidine, 27:297
- treatment response prediction, 3-methoxy-4-hydroxyphenylglycol, 27:297
- treatment response prediction, norepinephrine, 27:297
- treatment response prediction, schizophrenia, 27:297

**Haloperidol**

- blood pressure, cocaine, 27:117
- blood pressure, heart rate, 27:117
- blood pressure, subjective effects, 27:117
- blood pressure, substance abuse, 27:117
- Chinese patients, plasma levels, 30:45
- Chinese patients, schizophrenia, 30:45
- cocaine, blood pressure, 27:117
- cocaine, heart rate, 27:117
- cocaine, subjective effects, 27:117
- diabetes mellitus, glucose tolerance, 29:17
- diabetes mellitus, schizophrenia, 29:17
- diabetes mellitus, tardive dyskinesia, 29:17
- glucose tolerance, diabetes mellitus, 29:17
- glucose tolerance, schizophrenia, 29:17
- glucose tolerance, tardive dyskinesia, 29:17
- heart rate, blood pressure, 27:117
- heart rate, cocaine, 27:117
- heart rate, subjective effects, 27:117
- plasma levels, Chinese patients, 30:45
- plasma levels, schizophrenia, 30:45
- schizophrenia, Chinese patients, 30:45
- schizophrenia, diabetes mellitus, 29:17
- schizophrenia, glucose tolerance, 29:17
- schizophrenia, plasma levels, 30:45
- schizophrenia, tardive dyskinesia, 29:17
- subjective effects, blood pressure, 27:117
- subjective effects, cocaine, 27:117
- subjective effects, heart rate, 27:117
- tardive dyskinesia, diabetes mellitus, 29:17
- tardive dyskinesia, glucose tolerance, 29:17
- tardive dyskinesia, schizophrenia, 29:17

**Hamilton rating scale for depression**

- affective disorder, fluoxetine, 30:191
- affective disorder, imipramine, 30:191
- affective disorder, placebo washout, 30:191
- fluoxetine, affective disorder, 30:191
- fluoxetine, imipramine, 30:191
- fluoxetine, placebo washout, 30:191
- imipramine, affective disorder, 30:191
- imipramine, fluoxetine, 30:191
- imipramine, placebo washout, 30:191
- placebo washout, affective disorder, 30:191
- placebo washout, fluoxetine, 30:191
- placebo washout, imipramine, 30:191

**Head injury**

- cerebral blood flow, frontal lobe, 29:313
- frontal lobe, cerebral blood flow, 29:313

**Headache**

- anxiety, depressed mood, 30:95
- anxiety, migraine, 30:95
- anxiety, monoamine oxidase, 30:95
- anxiety, tribulin, 30:95
- depressed mood, migraine, 30:95
- depressed mood, monoamine oxidase, 30:95
- depressed mood, tribulin, 30:95
- migraine, anxiety, 30:95
- migraine, depressed mood, 30:95
- migraine, monoamine oxidase, 30:95
- migraine, tribulin, 30:95
- monoamine oxidase, anxiety, 30:95
- monoamine oxidase, depressed mood, 30:95
- monoamine oxidase, migraine, 30:95
- monoamine oxidase, platelet, 30:95
- monoamine oxidase, tribulin, 30:95
- tribulin, anxiety, 30:95
- tribulin, depressed mood, 30:95
- tribulin, migraine, 30:95
- tribulin, monoamine oxidase, 30:95

**Heart rate**

- blood pressure, cocaine, 27:117
- blood pressure, cortisol, 27:173
- blood pressure, eating disorders, 30:223
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, haloperidol, 27:117
- blood pressure, 3-methoxy-4-hydroxy-phenylglycol, 27:173
- blood pressure, norepinephrine, 27:173
- blood pressure, premenstrual dysphoria, 27:183
- blood pressure, stressors, 30:223
- blood pressure, subjective effects, 27:117
- blood pressure, Type A behavior, 30:223
- blood pressure, yohimbine, 27:173
- cocaine, blood pressure, 27:117

**Heart rate continued**

- cocaine, haloperidol, 27:117
- cocaine, subjective effects, 27:117
- cortisol, blood pressure, 27:173
- cortisol, generalized anxiety disorder, 27:173
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:173
- cortisol, norepinephrine, 27:173
- cortisol, yohimbine, 27:173
- eating disorders, blood pressure, 30:223
- eating disorders, stressors, 30:223
- eating disorders, Type A behavior, 30:223
- generalized anxiety disorder, blood pressure, 27:173
- generalized anxiety disorder, cortisol, 27:173
- generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173
- generalized anxiety disorder, norepinephrine, 27:173
- generalized anxiety disorder, yohimbine, 27:173
- haloperidol, blood pressure, 27:117
- haloperidol, cocaine, 27:117
- haloperidol, subjective effects, 27:117
- 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:173
- 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:173
- 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173
- norepinephrine, blood pressure, 27:173
- norepinephrine, cortisol, 27:173
- norepinephrine, generalized anxiety disorder, 27:173
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:173
- norepinephrine, yohimbine, 27:173
- premenstrual dysphoria, blood pressure, 27:183
- stressors, blood pressure, 30:223
- stressors, eating disorders, 30:223
- stressors, Type A behavior, 30:223
- subjective effects, blood pressure, 27:117
- subjective effects, cocaine, 27:117
- subjective effects, haloperidol, 27:117
- Type A behavior, blood pressure, 30:223
- Type A behavior, eating disorders, 30:223
- Type A behavior, stressors, 30:223
- yohimbine, blood pressure, 27:173

**Heart rate continued**

- yohimbine, cortisol, 27:173
- yohimbine, generalized anxiety disorder, 27:173
- yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173
- yohimbine, norepinephrine, 27:173

**5-Hydroxyindolacetic acid**

- affective disorder, cyclic adenosine monophosphate, 30:181
- affective disorder, dihydroergocryptine binding, 30:181
- affective disorder, serotonin uptake, 30:181
- cyclic adenosine monophosphate, affective disorder, 30:181
- cyclic adenosine monophosphate, dihydroergocryptine binding, 30:181
- cyclic adenosine monophosphate, serotonin uptake, 30:181
- dihydroergocryptine binding, affective disorder, 30:181
- dihydroergocryptine binding, cyclic adenosine monophosphate, 30:181
- serotonin uptake, affective disorder, 30:181

**Homovanillic acid**

- affective disorder, dexamethasone suppression test, 29:177
- dexamethasone suppression test, affective disorder, 29:177
- pharmacological treatment, schizophrenia, 28:97
- schizophrenia, pharmacological treatment, 28:97

**Huntington's disease**

- caudate nucleus, single photon emission computed tomography, 29:337
- positron emission tomography, psychiatric symptoms, 29:361
- psychiatric symptoms, positron emission tomography, 29:361
- single photon emission computed tomography, caudate nucleus, 29:337

**Hypnosis**

- autogenic training, cerebral blood flow, 29:317
- autogenic training, laterality, 29:317
- cerebral blood flow, autogenic training, 29:317
- cerebral blood flow, laterality, 29:317
- laterality, autogenic training, 29:317
- laterality, cerebral blood flow, 29:317

**Hypoglycemia**

- blood-brain barrier, electroconvulsive seizure, 29:151

**Hypoglycemia** continued  
 blood-brain barrier, rats, 29:151  
 electroconvulsive seizure, blood-brain barrier, 29:151  
 electroconvulsive seizure, rats, 29:151

**Imipramine**  
 affective disorder, circannual rhythms, 29:87, 30:21  
 affective disorder, dexamethasone suppression test, 29:87  
 affective disorder, diagnostic specificity, 30:21  
 affective disorder, fluoxetine, 30:191  
 affective disorder, Hamilton Rating Scale for Depression, 30:191  
 affective disorder, placebo washout, 30:191  
 circannual rhythms, affective disorder, 29:87, 30:21  
 circannual rhythms, dexamethasone suppression test, 29:87  
 circannual variation, platelet, 30:21  
 desipramine, frontal lobe, 30:125  
 desipramine, serotonin, 30:125  
 desipramine, suicide, 30:125  
 dexamethasone suppression test, affective disorder, 29:87  
 dexamethasone suppression test, circannual rhythms, 29:87  
 diagnostic specificity, affective disorders, 30:21  
 eating disorder, platelet binding, 30:21  
 fluoxetine, affective disorder, 30:191  
 fluoxetine, Hamilton Rating Scale for Depression, 30:191  
 fluoxetine, placebo washout, 30:191  
 frontal lobe, desipramine, 30:125  
 frontal lobe, serotonin, 30:125  
 frontal lobe, suicide, 30:125  
 genetics, platelet binding, rats, 27:287  
 Hamilton Rating Scale for Depression, affective disorder, 30:191  
 Hamilton Rating Scale for Depression, fluoxetine, 30:191  
 Hamilton Rating Scale for Depression, placebo washout, 30:191  
 panic disorder, platelet binding, 30:21  
 placebo washout, affective disorders, 30:191  
 placebo washout, fluoxetine, 30:191  
 placebo washout, Hamilton Rating Scale for Depression, 30:191  
 schizophrenia, platelet binding, 30:21  
 serotonin, desipramine, 30:125  
 serotonin, frontal lobe, 30:125  
 serotonin, suicide, 30:125

**Imipramine** continued  
 suicide, desipramine, 30:125  
 suicide, frontal lobe, 30:125  
 suicide, platelet binding, 30:21  
 suicide, serotonin, 30:125

**Immune function**  
 affective disorder, mania, 29:235  
 mania, affective disorder, 29:235

**Impulsivity**  
 aggression, serotonin, 27:5  
 Barratt Impulsivity Scale, platelet serotonin uptake, 27:5  
 serotonin, aggression, 27:5

**Indalpine**  
 clenbuterol, food restriction, rats, 27:149  
 clomipramine, food restriction, rats, 27:149  
 desipramine, food restriction, rats, 27:149  
 food restriction, rats, 27:149  
 nialamide, food restriction, rats, 27:149  
 rats, food restriction, 27:149

**Inositol**  
 lithium, red blood cell, 27:217  
 red blood cell, lithium, 27:217

**Lactate**  
 Acute Panic Inventory, affective disorder, 27:357  
 Acute Panic Inventory, panic disorder, 29:207  
 Acute Panic Inventory, somatic symptoms, 29:207  
 affective disorder, Acute Panic Inventory, 27:357  
 agoraphobia, panic disorder, 28:181  
 agoraphobia, prolactin, 28:181  
 blood gases, panic disorder, 28:171  
 panic, Acute Panic Inventory, 27:357  
 panic, affective disorder, 27:357  
 panic disorder, agoraphobia, 28:181  
 panic disorder, blood gases, 28:171  
 panic disorder, prolactin, 28:181  
 panic disorder, somatic symptoms, 29:207  
 prolactin, agoraphobia, 28:181  
 prolactin, panic disorder, 28:181  
 somatic symptoms, Acute Panic Inventory, 29:207  
 somatic symptoms, panic disorder, 29:207

**Laterality**  
 affective disorder, attention, 29:65  
 affective disorder, continuous performance test, 29:65  
 affective disorder, schizophrenia, 29:65  
 attention, affective disorder, 29:65  
 attention, computed tomography, 29:267  
 attention, continuous performance test, 29:65

**Laterality** continued

- attention, schizophrenia, 29:65, 29:267
- attention, ventricle-brain ratio, 29:267
- autogenic training, cerebral blood flow, 29:317
- autogenic training, hypnosis, 29:317
- cerebral blood flow, autogenic training, 29:317
- cerebral blood flow, hypnosis, 29:317
- cerebral blood flow, positron emission tomography, 27:325
- cerebral blood flow, schizophrenia, 27:325
- computed tomography, attention, 29:267
- computed tomography, schizophrenia, 29:247, 29:267
- computed tomography, ventricle-brain ratio, 29:267
- continuous performance test, affective disorder, 29:65
- continuous performance test, attention, 29:65
- continuous performance test, schizophrenia, 29:65
- hypnosis, autogenic training, 29:317
- hypnosis, cerebral blood flow, 29:317
- neuroleptics, parkinsonism, 30:275
- neuroleptics, schizophrenia, 30:275
- parkinsonism, neuroleptics, 30:275
- parkinsonism, schizophrenia, 30:275
- positron emission tomography, cerebral blood flow, 27:325
- positron emission tomography, schizophrenia, 27:325
- schizophrenia, affective disorder, 29:65
- schizophrenia, attention, 29:65, 29:267
- schizophrenia, cerebral blood flow, 27:325
- schizophrenia, computed tomography, 29:247, 29:267
- schizophrenia, continuous performance test, 29:65
- schizophrenia, neuroleptics, 30:275
- schizophrenia, parkinsonism, 30:275
- schizophrenia, positron emission tomography, 27:325
- schizophrenia, ventricle-brain ratio, 29:267
- ventricle-brain ratio, attention, 29:267
- ventricle-brain ratio, computed tomography, 29:267
- ventricle-brain ratio, schizophrenia, 29:267

**Learned helplessness**

- antidepressants, food intake, 27:149
- antidepressants, rats, 27:149
- antidepressants, triiodothyronine, 27:149
- food intake, antidepressants, 27:149
- food intake, rats, 27:149

**Learned helplessness** continued

- food intake, triiodothyronine, 27:149
- triiodothyronine, antidepressants, 27:149
- triiodothyronine, food intake, 27:149

**Life events**

- affective disorder, mania, 30:213
- affective disorder, stressors, 30:213
- DSM-III, *Psychiatric Epidemiology Research Interview*, 30:201
- mania, affective disorder, 30:213
- mania, stressors, 30:213
- Psychiatric Epidemiology Research Interview*, 30:201, 30:213
- stressors, affective disorder, 30:213
- stressors, mania, 30:213

**Light therapy**

- affective disorder, seasonal affective disorder, 29:29
- seasonal affective disorder, affective disorder, 29:29

**Linoleic acid**

- essential fatty acids, tardive dyskinesia, 27:313
- tardive dyskinesia, essential fatty acids, 27:313

**Lithium**

- affective disorder, ankyrin, 27:267
- affective disorder, antidepressants, 28:73
- affective disorder, bipolar, 27:267
- affective disorder, clonidine binding in platelets, 28:73
- affective disorder, red blood cell membrane, 27:267
- affective disorder, schizophrenia, 28:73
- alcoholism, prolactin, 29:55
- alcoholism, red blood cells, 29:55
- ankyrin, affective disorder, 27:267
- ankyrin, bipolar, 27:267
- ankyrin, red blood cell membrane, 27:267
- antidepressants, affective disorder, 28:73
- antidepressants, clonidine binding in platelets, 28:73
- antidepressants, schizophrenia, 28:73
- bipolar affective disorder, 27:267
- bipolar subtype, ankyrin, 27:267
- bipolar subtype, red blood cell membrane, 27:267

- clonidine, affective disorder, 28:73
- clonidine binding in platelets, affective disorder, 28:73

- clonidine binding in platelets, antidepressants, 28:73

- clonidine binding in platelets, schizophrenia, 28:73

- clonidine, schizophrenia, 28:73

**Lithium** continued

- inositol-1-phosphatase, red blood cell, 27:217
- light, pupillary response, 30:305
- light, sheep, 30:305
- prolactin, alcoholism, 29:55
- prolactin, red blood cells, 29:55
- pupillary response, light, 30:305
- pupillary response, sheep, 30:305
- rats, seizures, 30:77
- rats, theophylline, 30:77
- red blood cell, inositol-1-phosphatase, 27:217
- red blood cell membrane, affective disorder, 27:267
- red blood cell membrane, ankyrin, 27:267
- red blood cell membrane, bipolar subtype, 27:267
- red blood cells, alcoholism, 29:55
- red blood cells, prolactin, 29:55
- schizophrenia, affective disorder, 28:73
- schizophrenia, antidepressants, 28:73
- schizophrenia, clonidine, 28:73
- schizophrenia, clonidine binding in platelets, 28:73
- seizures, rats, 30:77
- seizures, theophylline, 30:77
- sheep, light, 30:305
- sheep, pupillary response, 30:305
- theophylline, rats, 30:77
- theophylline, seizures, 30:77

**Liver function**

- alcoholism, cortisol, 30:217
- alcoholism, dexamethasone suppression test, 30:217
- cortisol, alcoholism, 30:217
- cortisol, dexamethasone suppression test, 30:217
- dexamethasone suppression test, alcoholism, 30:217
- dexamethasone suppression test, cortisol, 30:217

**Locus ceruleus**

- dopamine-beta-hydroxylase, paranoid subtype, 27:31
- dopamine-beta-hydroxylase, post-mortem study, 27:31
- dopamine-beta-hydroxylase, schizophrenia, 27:31
- paranoid subtype, dopamine-beta-hydroxylase, 27:31
- paranoid subtype, post-mortem study, 27:31
- paranoid subtype, schizophrenia, 27:31
- post-mortem study, dopamine-beta-hydroxylase, 27:31

**Locus ceruleus** continued

- post-mortem study, schizophrenia, 27:31
- schizophrenia, dopamine-beta-hydroxylase, 27:31

- schizophrenia, paranoid subtype, 27:31
- schizophrenia, post-mortem study, 27:31

**Lupus Erythematosus**

- computed tomography, magnetic resonance imaging, 29:367
- computed tomography, positron emission tomography, 29:367
- magnetic resonance imaging, computed tomography, 29:367
- positron emission tomography, magnetic resonance imaging, 29:367

**Lutenizing hormone**

- eating disorders, follicle stimulating hormone, 28:11
- eating disorders, gonadotropin releasing hormone, 28:11
- eating disorders, menstrual cycle, 28:11
- follicle stimulating hormone, eating disorders, 28:11
- gonadotropin releasing hormone, eating disorders, 28:11
- gonadotropin releasing hormone, menstrual cycle, 28:11
- menstrual cycle, eating disorders, 28:11
- menstrual cycle, gonadotropin releasing hormone, 28:11

**Lymphocytes**

- butaclamol, dopamine, 30:259
- butaclamol, spiperone binding, 30:259
- dopamine, butaclamol, 30:259
- dopamine, spiperone binding, 30:259
- spiperone binding, butaclamol, 30:259
- spiperone binding, dopamine, 30:259

**Magnetic resonance imaging**

- alcoholism, computed tomography, 29:277
- alcoholism, cerebrospinal fluid volumetry, 29:277
- Alzheimer's disease, cerebral blood flow, 29:447
- Borna disease, psychiatric patients, 29:281
- cerebral blood flow, Alzheimer's disease, 29:447
- cerebral blood flow, corpus callosum, 29:453
- cerebral blood flow, schizophrenia, 29:453
- cerebrospinal fluid flow, normal pressure hydrocephalus, 29:289
- cerebrospinal fluid volumetry, alcoholism, 29:277
- cerebrospinal fluid volumetry, computed tomography, 29:277

**Magnetic resonance imaging** continued  
 computed tomography, alcoholism, 29:277  
 computed tomography, cerebrospinal fluid  
 volumetry, 29:277  
 computed tomography, diencephalic  
 lesions, 29:285  
 computed tomography, EEG focus, 29:459  
 computed tomography, lupus  
 erythematosus, 29:367  
 computed tomography, positron emission  
 tomography, 29:363, 29:367  
 computed tomography, schizophrenia,  
 29:265  
 computed tomography, seizures, 29:459  
 computed tomography, single photon  
 emission computed tomography, 29:459  
 computed tomography, thalamic  
 infarction, 29:363  
 computed tomography, ventricle-brain  
 ratio, 29:265  
 corpus callosum, cerebral blood flow,  
 29:453  
 corpus callosum, schizophrenia, 29:453  
 diencephalic lesions, computed  
 tomography, 29:285  
 EEG focus, computed tomography, 29:459  
 EEG focus, seizures, 29:459  
 EEG focus, single photon emission  
 computed tomography, 29:459  
 frontal lobe size, negative symptoms, 30:11  
 frontal lobe size, saggital morphology,  
 30:11  
 frontal lobe size, schizophrenia, 30:11  
 lupus erythematosus, computed  
 tomography, 29:367  
 lupus erythematosus, positron emission  
 tomography, 29:367  
 multiple sclerosis, neuropsychology,  
 29:293  
 multiple sclerosis, optic neuritis, 29:295  
 negative symptoms, frontal lobe size, 30:11  
 negative symptoms, saggital morphology,  
 30:11  
 negative symptoms, schizophrenia, 30:11  
 neuropsychology, multiple sclerosis,  
 29:293  
 normal pressure hydrocephalus,  
 cerebrospinal fluid flow, 29:289  
 optic neuritis, multiple sclerosis, 29:295  
 pituitary tumors, 29:283  
 positron emission tomography, computed  
 tomography, 29:363, 29:367  
 positron emission tomography, lupus  
 erythematosus, 29:367

**Magnetic resonance imaging** continued  
 positron emission tomography, thalamic  
 infarction, 29:363  
 psychiatric patients, Borna disease, 29:281  
 saggital morphology, frontal lobe size,  
 30:11  
 saggital morphology, negative symptoms,  
 30:11  
 saggital morphology, schizophrenia, 30:11  
 schizophrenia, cerebral blood flow, 29:453  
 schizophrenia, computed tomography,  
 29:265  
 schizophrenia, corpus callosum, 29:453  
 schizophrenia, frontal lobe size, 30:11  
 schizophrenia, negative symptoms, 30:11  
 schizophrenia, saggital morphology, 30:11  
 schizophrenia, temporal lobe, 29:261  
 schizophrenia, ventricle-brain ratio, 29:265  
 seizures, computed tomography, 29:459  
 seizures, EEG focus, 29:459  
 seizures, single photon emission computed  
 tomography, 29:459  
 single photon emission computed  
 tomography, computed tomography,  
 29:459  
 single photon emission computed  
 tomography, EEG focus, 29:459  
 single photon emission computed  
 tomography, seizures, 29:459  
 subcaudate tractotomy lesions, 29:291  
 temporal lobe, schizophrenia, 29:261  
 thalamic infarction, computed  
 tomography, 29:363  
 thalamic infarction, positron emission  
 tomography, 29:363  
 ventricle-brain ratio, computed  
 tomography, 29:265  
 ventricle-brain ratio, schizophrenia, 29:265  
**Magnetoencephalography**  
 auditory stimuli, evoked potentials, 29:369  
 clinical applications, comparison with  
 EEG, 29:375  
 comparison with EEG, clinical applications,  
 29:375  
 comparison with EEG, seizures, 29:377  
 evoked potentials, auditory stimuli, 29:369  
 seizures, comparison with EEG, 29:377  
**Melatonin**  
 affective disorder, light, 27:351  
 affective disorders, circadian rhythms,  
 28:263  
 affective disorders, cortisol, 28:263  
 affective disorders, norepinephrine, 28:263  
 affective disorders, temperature, 28:263

**Melatonin** continued

- affective disorders, thyroid stimulating hormone, 28:263
- circadian rhythms, affective disorder, 28:263
- circadian rhythms, cortisol, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, temperature, 28:263
- circadian rhythms, thyroid stimulating hormone, 28:263
- cortisol, affective disorder, 28:263
- cortisol, circadian rhythms, 28:263
- cortisol, norepinephrine, 28:263
- cortisol, temperature, 28:263
- cortisol, thyroid stimulating hormone, 28:263
- light, affective disorder, 27:351
- norepinephrine, affective disorder, 28:263
- norepinephrine, circadian rhythms, 28:263
- norepinephrine, cortisol, 28:263
- norepinephrine, temperature, 28:263
- norepinephrine, thyroid stimulating hormone, 28:263
- temperature, affective disorder, 28:263
- temperature, circadian rhythms, 28:263
- temperature, cortisol, 28:263
- temperature, norepinephrine, 28:263
- temperature, thyroid stimulating hormone, 28:263
- thyroid stimulating hormone, affective disorder, 28:263
- thyroid stimulating hormone, circadian rhythms, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, norepinephrine, 28:263
- thyroid stimulating hormone, temperature, 28:263

**Menstrual period**

- activity, premenstrual syndrome, 30:285
- activity, sleep, 30:285
- activity, temperature, 30:285
- eating disorders, gonadotropin releasing hormone, 28:11
- eating disorders, luteinizing hormone, 28:11
- gonadotropin releasing hormone, eating disorders, 28:11
- gonadotropin releasing hormone, luteinizing hormone, 28:11
- luteinizing hormone, eating disorders, 28:11
- luteinizing hormone, gonadotropin releasing hormone, 28:11
- premenstrual syndrome, activity, 30:285

**Menstrual period** continued

- premenstrual syndrome, sleep, 30:285
- premenstrual syndrome, temperature, 30:285
- sleep, activity, 30:285
- sleep, premenstrual syndrome, 30:285
- sleep, temperature, 30:285
- temperature, activity, 30:285
- temperature, premenstrual syndrome, 30:285
- temperature, sleep, 30:285

**Mental retardation**

- age, social group formation, 30:31
- social group formation, age, 30:31

**Mescaline**

- psychosis, single photon emission computed tomography, 29:335
- single photon emission computed tomography, psychosis, 29:335

**Metachromatic leukodystrophy**

- arylsulfatase A, schizophrenia, 30:107
- schizophrenia, arylsulfatase A, 30:107

**3-Methoxy-4-hydroxyphenylglycol**

- attention deficit disorder, conduct disorder, 27:241
- adolescents, affective disorder, 27:101
- adolescents, cortisol, 27:101
- adolescents, norepinephrine, 27:101
- affective disorder, adolescents, 27:101
- affective disorder, cortisol, 27:101
- affective disorder, norepinephrine, 27:101
- affective disorders, age of onset, 30:103
- age of onset, affective disorders, 30:103
- alprazolam, diazepam, 30:53
- alprazolam, panic disorder, 30:53
- alprazolam, treatment response, 30:53
- blood pressure, cortisol, 27:173
- blood pressure, generalized anxiety disorder, 27:173

- blood pressure, heart rate, 27:173
- blood pressure, norepinephrine, 27:173
- blood pressure, yohimbine, 27:173
- clonidine, growth hormone, 27:297
- clonidine, norepinephrine, 27:297
- clonidine, schizophrenia, 27:297
- clonidine, treatment response prediction, 27:297

- cocaine, eye movements, 29:123

- conduct disorder, attention deficit disorder, 27:241

- cortisol, adolescents, 27:101

- cortisol, affective disorder, 27:101

- cortisol, blood pressure, 27:173

- cortisol, generalized anxiety disorder, 27:173

**3-Methoxy-4-hydroxyphenylglycol**  
continued

cortisol, heart rate, 27:173  
 cortisol, norepinephrine, 27:101, 27:173  
 cortisol, yohimbine, 27:173  
 corticotropin releasing hormone,  
     gambling, 30:137  
 corticotropin releasing hormone,  
     gamma-aminobutyric acid, 30:137  
 corticotropin releasing hormone,  
     neuropeptides, 30:137  
 corticotropin releasing hormone,  
     norepinephrine, 30:137  
 diazepam, alprazolam, 30:53  
 diazepam, panic disorder, 30:53  
 diazepam, treatment response, 30:53  
 eye movements, cocaine, 29:123  
 eye movements, substance abuse, 29:123  
 gambling, corticotropin releasing hormone,  
     30:137  
 gambling, gamma-aminobutyric acid,  
     30:137  
 gambling, neuropeptides, 30:137  
 gambling, norepinephrine, 30:137  
 gamma-aminobutyric acid, corticotropin  
     releasing hormone, 30:137  
 gamma-aminobutyric acid, gambling,  
     30:137  
 gamma-aminobutyric acid, neuropeptides,  
     30:137  
 gamma-aminobutyric acid, norepinephrine,  
     30:137  
 generalized anxiety disorder, blood pressure,  
     27:173  
 generalized anxiety disorder, cortisol,  
     27:173  
 generalized anxiety disorder, heart rate,  
     27:173  
 generalized anxiety disorder,  
     norepinephrine, 27:173  
 generalized anxiety disorder, yohimbine,  
     27:173  
 growth hormone, clonidine, 27:297  
 growth hormone, norepinephrine, 27:297  
 growth hormone, schizophrenia, 27:297  
 growth hormone, treatment response  
     prediction, 27:297  
 heart rate, blood pressure, 27:173  
 heart rate, cortisol, 27:173  
 heart rate, generalized anxiety disorder,  
     27:173  
 heart rate, norepinephrine, 27:173  
 heart rate, yohimbine, 27:173  
 neuropeptides, corticotropin releasing  
     hormone, 30:137

**3-Methoxy-4-hydroxyphenylglycol**  
continued

neuropeptides, gambling, 30:137  
 neuropeptides, gamma-aminobutyric acid,  
     30:137  
 neuropeptides, norepinephrine, 30:137  
 norepinephrine, adolescents, 27:101  
 norepinephrine, affective disorder, 27:101  
 norepinephrine, blood pressure, 27:173  
 norepinephrine, clonidine, 27:297  
 norepinephrine, cortisol, 27:101, 27:173  
 norepinephrine, corticotropin releasing  
     hormone, 30:137  
 norepinephrine, gambling, 30:137  
 norepinephrine, gamma-aminobutyric  
     acid, 30:137  
 norepinephrine, generalized anxiety  
     disorder, 27:173  
 norepinephrine, growth hormone, 27:297  
 norepinephrine, heart rate, 27:173  
 norepinephrine, neuropeptides, 30:137  
 norepinephrine, schizophrenia, 27:297  
 norepinephrine, sleep deprivation, 30:155  
 norepinephrine, treatment response  
     prediction, 27:297  
 norepinephrine, yohimbine, 27:173  
 panic disorder, alprazolam, 30:53  
 panic disorder, diazepam, 30:53  
 panic disorder, treatment response, 30:53  
 schizophrenia, clonidine, 27:297  
 schizophrenia, growth hormone, 27:297  
 schizophrenia, norepinephrine, 27:297  
 schizophrenia, treatment response  
     prediction, 27:297  
 sleep deprivation, norepinephrine, 30:155  
 substance abuse, cocaine, 29:123  
 substance abuse, eye movements, 29:123  
 treatment response, alprazolam, 30:53  
 treatment response, diazepam, 30:53  
 treatment response, panic disorder, 30:53  
 treatment response prediction, clonidine,  
     27:297  
 treatment response prediction, growth  
     hormone, 27:297  
 treatment response prediction,  
     norepinephrine, 27:297  
 treatment response prediction,  
     schizophrenia, 27:297  
 yohimbine, blood pressure, 27:173  
 yohimbine, cortisol, 27:173  
 yohimbine, generalized anxiety disorder,  
     27:173  
 yohimbine, heart rate, 27:173  
 yohimbine, norepinephrine, 27:173

**Metoclopramide**

prolactin, sleep, 29:161  
 prolactin, thyrotropin releasing hormone, 29:161  
 prolactin, tryptophan, 29:161  
 prolactin, weight loss, 29:161  
 sleep, prolactin, 29:161  
 sleep, thyrotropin releasing hormone, 29:161  
 sleep, tryptophan, 29:161  
 sleep, weight loss, 29:161  
 thyrotropin releasing hormone, prolactin, 29:161  
 thyrotropin releasing hormone, sleep, 29:161  
 thyrotropin releasing hormone, tryptophan, 29:161  
 thyrotropin releasing hormone, weight loss, 29:161  
 tryptophan, prolactin, 29:161  
 tryptophan, sleep, 29:161  
 tryptophan, thyrotropin releasing hormone, 29:161  
 tryptophan, weight loss, 29:161  
 weight loss, prolactin, 29:161  
 weight loss, sleep, 29:161  
 weight loss, thyrotropin releasing hormone, 29:161  
 weight loss, tryptophan, 29:161

**Mexican-Americans**

affective disorder, Center for Epidemiologic Studies Depression Scale, 27:137  
 Center for Epidemiologic Studies Depression Scale, affective disorder, 27:137

**Migraine.** See Headache**Minnesota Multiphasic Personality Inventory**

Brief Psychiatric Rating Scale, schizoaffective disorder, 28:135  
 Brief Psychiatric Rating Scale, schizophrenia, 28:135  
 monoamine oxidase, personality, 27:81  
 monoamine oxidase, Personality Research Form, 27:81  
 monoamine oxidase, platelet, 27:81  
 monoamine oxidase, Sensation Seeking Scale, 27:81  
 personality, monoamine oxidase, 27:81  
 personality, Personality Research Form, 27:81  
 Personality Research Form, monoamine oxidase, 27:81

**Minnesota Multiphasic Personality Inventory****Inventory** continued

Personality Research Form, personality, 27:81  
 Personality Research Form, Sensation Seeking Scale, 27:81  
 personality, Sensation Seeking Scale, 27:81  
 schizoaffective disorder, Brief Psychiatric Rating Scale, 28:135  
 schizoaffective disorder, schizophrenia, 28:135  
 schizophrenia, Brief Psychiatric Rating Scale, 28:135  
 schizophrenia, schizoaffective disorder, 28:135  
 Sensation Seeking Scale, monoamine oxidase, 27:81  
 Sensation Seeking Scale, personality, 27:81  
 Sensation Seeking Scale, Personality Research Form, 27:81

**Mitral valve prolapse**

body size, panic disorder, 28:161  
 body size, triiodothyronine, 28:161  
 panic disorder, body size, 28:161  
 panic disorder, triiodothyronine, 28:161  
 triiodothyronine, body size, 28:161  
 triiodothyronine, panic disorder, 28:161

**Monoamine oxidase**

affective disorder, antisocial personality disorder, 30:265  
 affective disorder, borderline personality disorder, 30:265  
 affective disorder, personality disorder, 30:265  
 antisocial personality disorder, affective disorder, 30:265  
 antisocial personality disorder, borderline personality disorder, 30:265  
 antisocial personality disorder, personality disorder, 30:265  
 anxiety, depressed mood, 30:95  
 anxiety, headache, 30:95  
 anxiety, migraine, 30:95  
 anxiety, platelet, 30:95  
 anxiety, tribulin, 30:95  
 borderline personality disorder, affective disorder, 30:265  
 borderline personality disorder, antisocial personality disorder, 30:265  
 depressed mood, anxiety, 30:95  
 depressed mood, headache, 30:95  
 depressed mood, migraine, 30:95

**Monoamine oxidase** continued  
 depressed mood, tribulin, 30:95  
 headache, anxiety, 30:95  
 headache, depressed mood, 30:95  
 headache, tribulin, 30:95  
 migraine, anxiety, 30:95  
 migraine, depressed mood, 30:95  
 migraine, tribulin, 30:95

**Minnesota Multiphasic Personality Inventory, Personality Research Form, 27:81**

**Minnesota Multiphasic Personality Inventory, Sensation Seeking Scale, 27:81**

personality disorder, affective disorder, 30:265  
 personality disorder, antisocial personality disorder, 30:265  
 personality disorder, borderline, 30:265

**Personality Research Form, Minnesota Multiphasic Personality Inventory, 27:81**

**Personality Research Form, Sensation Seeking Scale, 27:81**

**Sensation Seeking Scale, Minnesota Multiphasic Personality Inventory, 27:81**

**Sensation Seeking Scale, Personality Research Form, 27:81**

tribulin, anxiety, 30:95  
 tribulin, depressed mood, 30:95  
 tribulin, headache, 30:95  
 tribulin, migraine, 30:95

**Multiple sclerosis**  
 magnetic resonance imaging, neuropsychology, 29:293  
 magnetic resonance imaging, optic neuritis, 29:295  
 neuropsychology, magnetic resonance imaging, 29:293  
 optic neuritis, magnetic resonance imaging, 29:295

**Neuroleptics**  
 affective symptoms, schizophrenia, 28:315  
 affective symptoms, tardive dyskinesia, 28:315  
 akathisia, propranolol, 27:1  
 anticonvulsants, plasma concentration, 28:153  
 Chinese patients, plasma levels, 30:45  
 choline, red blood cells, 29:45  
 choline, schizophrenia, 29:45  
 choline, tardive dyskinesia, 29:45  
 electroencephalography, schizophrenia, 29:395  
 eye movements, schizophrenia, 28:307  
 high dose, schizophrenia, 30:1

**Neuroleptics** continued  
 high dose, treatment response, 30:1  
 laterality, parkinsonism, 30:275  
 laterality, schizophrenia, 30:275  
 parkinsonism, laterality, 30:275  
 parkinsonism, schizophrenia, 30:275  
 plasma concentration, anticonvulsants, 28:153  
 plasma levels, Chinese patients, 30:45  
 propranolol, akathisia, 27:1  
 red blood cells, choline, 29:45  
 red blood cells, schizophrenia, 29:45  
 red blood cells, tardive dyskinesia, 29:45  
 schizophrenia, affective symptoms, 28:315  
 schizophrenia, choline, 29:45  
 schizophrenia, electroencephalography, 29:395  
 schizophrenia, eye movements, 28:307  
 schizophrenia, high dose, 30:1  
 schizophrenia, laterality, 30:275  
 schizophrenia, parkinsonism, 30:275  
 schizophrenia, red blood cells, 29:275  
 schizophrenia, tardive dyskinesia, 28:315, 29:45  
 schizophrenia, treatment response, 30:1  
 tardive dyskinesia, affective symptoms, 28:315  
 tardive dyskinesia, choline, 29:45  
 tardive dyskinesia, red blood cells, 29:45  
 tardive dyskinesia, schizophrenia, 28:315, 29:45  
 treatment response, high dose, 30:1  
 treatment response, schizophrenia, 30:1

**Neurological Evaluation Scale**  
 schizophrenia, validity data, 27:335  
 validity data, schizophrenia, 27:335

**Neuropeptides**  
 adrenocorticotrophic hormone, gambling, 30:137  
 corticotropin releasing hormone, gambling, 30:137  
 corticotropin releasing hormone, gamma-aminobutyric acid, 30:137  
 corticotropin releasing hormone, 3-methoxy-4-hydroxyphenylglycol, 30:137  
 corticotropin releasing hormone, norepinephrine, 30:137  
 gambling, corticotropin releasing hormone, 30:137  
 gambling, gamma-aminobutyric acid, 30:137  
 gambling, 3-methoxy-4-hydroxyphenylglycol, 30:137  
 gambling, norepinephrine, 30:137

**Neuropeptides** continued

- gamma-aminobutyric acid, corticotropin releasing hormone, 30:137
- gamma-aminobutyric acid, gambling, 30:137
- gamma-aminobutyric acid, 3-methoxy-4-hydroxyphenylglycol, 30:137
- gamma-aminobutyric acid, norepinephrine, 30:137
- growth hormone releasing hormone, gambling, 30:137
- 3-methoxy-4-hydroxyphenylglycol, corticotropin releasing hormone, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gambling, 30:137
- 3-methoxy-4-hydroxyphenylglycol, gamma-aminobutyric acid, 30:137
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 30:137
- neuropeptide Y, gambling, 30:137
- norepinephrine, corticotropin releasing hormone, 30:137
- norepinephrine, gambling, 30:137
- norepinephrine, gamma-aminobutyric acid, 30:137
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 30:137
- somatostatin, gambling, 30:137

**Nialamide**

- clenbuterol, food restriction, rats, 27:149
- clomipramine, food restriction, rats, 27:149
- desipramine, food restriction, rats, 27:149
- food restriction, rats, 27:149
- indalpine, food restriction, rats, 27:149
- rats, food restriction, 27:149

**Norepinephrine**

- attention deficit disorder, catecholamines, 27:241
- attention deficit disorder, conduct disorder, 27:241
- attention deficit disorder, dopamine-beta-hydroxylase, 27:241
- adolescents, affective disorder, 27:101
- adolescents, cortisol, 27:101
- adolescents, 3-methoxy-4-hydroxyphenylglycol, 27:101
- affective disorder, adolescents, 27:101
- affective disorder, circadian rhythms, 28:263
- affective disorder, cortisol, 27:101, 28:263, 29:187
- affective disorder, dexamethasone suppression test, 29:187
- affective disorder, dopamine, 29:187

**Norepinephrine** continued

- affective disorder, epinephrine, 29:187
- affective disorder, generalized anxiety disorder, 30:253
- affective disorder, melatonin, 28:263
- affective disorder, 3-methoxy-4-hydroxyphenylglycol, 27:101
- affective disorder, temperature, 28:263
- affective disorder, thyroid stimulating hormone, 28:263
- affective disorder, time sampling, 30:253
- blood pressure, cortisol, 27:173
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, heart rate, 27:173
- blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173
- blood pressure, yohimbine, 27:173
- catecholamines, attention deficit disorder, 27:241
- catecholamines, conduct disorder, 27:241
- catecholamines, dopamine-beta-hydroxylase, 27:241
- circadian rhythms, affective disorder, 28:263
- circadian rhythms, cortisol, 28:263
- circadian rhythms, melatonin, 28:263
- circadian rhythms, temperature, 28:263
- circadian rhythms, thyroid stimulating hormone, 28:263
- clonidine, growth hormone, 27:297
- clonidine, 3-methoxy-4-hydroxyphenylglycol, 27:297
- clonidine, schizophrenia, 27:297
- clonidine, treatment response prediction, 27:297
- conduct disorder, attention deficit disorder, 27:241
- conduct disorder, catecholamines, 27:241
- conduct disorder, dopamine-beta-hydroxylase, 27:241
- cortisol, adolescents, 27:101
- cortisol, affective disorder, 27:101, 28:163, 29:187
- cortisol, blood pressure, 27:173
- cortisol, circadian rhythms, 28:263
- cortisol, dexamethasone suppression test, 29:187
- cortisol, dopamine, 29:187
- cortisol, epinephrine, 29:187
- cortisol, generalized anxiety disorder, 27:173
- cortisol, heart rate, 27:173
- cortisol, melatonin, 28:263
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 7:101, 27:173

**Norepinephrine** continued

cortisol, temperature, 28:263  
 cortisol, thyroid stimulating hormone, 28:263  
 cortisol, yohimbine, 27:173  
 corticotropin releasing hormone, gambling, 30:137  
 corticotropin releasing hormone, gamma-aminobutyric acid, 30:137  
 corticotropin releasing hormone, 3-methoxy-4-hydroxyphenylglycol, 30:137  
 corticotropin releasing hormone, neuropeptides, 30:137  
 dexamethasone suppression test, affective disorder, 29:187  
 dexamethasone suppression test, cortisol, 29:187  
 dexamethasone suppression test, dopamine, 29:187  
 dexamethasone suppression test, epinephrine, 29:187  
 dopamine, affective disorder, 29:187  
 dopamine-beta-hydroxylase, attention deficit disorder, 27:241  
 dopamine-beta-hydroxylase, catecholamines, 27:241  
 dopamine-beta-hydroxylase, conduct disorder, 27:241  
 dopamine, cortisol, 29:187  
 dopamine, dexamethasone suppression test, 29:187  
 dopamine, epinephrine, 29:187  
 epinephrine, affective disorder, 29:187  
 epinephrine, cortisol, 29:187  
 epinephrine, dexamethasone suppression test, 29:187  
 epinephrine, dopamine, 29:187  
 gambling, corticotropin releasing hormone, 30:137  
 gambling, gamma-aminobutyric acid, 30:137  
 gambling, 3-methoxy-4-hydroxyphenylglycol, 30:137  
 gambling, neuropeptides, 30:137  
 gamma-aminobutyric acid, corticotropin releasing hormone, 30:137  
 gamma-aminobutyric acid, gambling, 30:137  
 gamma-aminobutyric acid, 3-methoxy-4-hydroxyphenylglycol, 30:137  
 gamma-aminobutyric acid, neuropeptides, 30:137

**Norepinephrine** continued

generalized anxiety disorder, affective disorder, 30:253  
 generalized anxiety disorder, blood pressure, 27:173  
 generalized anxiety disorder, cortisol, 27:173  
 generalized anxiety disorder, heart rate, 27:173  
 generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 generalized anxiety disorder, time sampling, 30:253  
 generalized anxiety disorder, yohimbine, 27:173  
 growth hormone, clonidine, 27:297  
 growth hormone, 3-methoxy-4-hydroxyphenylglycol, 27:297  
 growth hormone, schizophrenia, 27:297  
 growth hormone, treatment response prediction, 27:297  
 heart rate, blood pressure, 27:173  
 heart rate, cortisol, 27:173  
 heart rate, generalized anxiety disorder, 27:173  
 heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173  
 heart rate, yohimbine, 27:173  
 melatonin, affective disorder, 28:263  
 melatonin, circadian rhythms, 28:263  
 melatonin, cortisol, 28:263  
 melatonin, temperature, 28:263  
 melatonin, thyroid stimulating hormone, 28:263  
 3-methoxy-4-hydroxyphenylglycol, adolescents, 27:101  
 3-methoxy-4-hydroxyphenylglycol, affective disorder, 27:101  
 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173  
 3-methoxy-4-hydroxyphenylglycol, clonidine, 27:297  
 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:101, 27:173  
 3-methoxy-4-hydroxyphenylglycol, corticotropin releasing hormone, 30:137  
 3-methoxy-4-hydroxyphenylglycol, gambling, 30:137  
 3-methoxy-4-hydroxyphenylglycol, gamma-aminobutyric acid, 30:137  
 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173  
 3-methoxy-4-hydroxyphenylglycol, growth hormone, 27:297

**Norepinephrine** continued

- 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173
- 3-methoxy-4-hydroxyphenylglycol, neuropeptides, 30:137
- 3-methoxy-4-hydroxyphenylglycol, schizophrenia, 27:297
- 3-methoxy-4-hydroxyphenylglycol, sleep deprivation, 30:155
- 3-methoxy-4-hydroxyphenylglycol, treatment response prediction, 27:297
- 3-methoxy-4-hydroxyphenylglycol, yohimbine, 27:173
- neuropeptides, corticotropin releasing hormone, 30:137
- neuropeptides, gambling, 30:137
- neuropeptides, gamma-aminobutyric acid, 30:137
- neuropeptides, 3-methoxy-4-hydroxyphenylglycol, 30:137
- schizophrenia, clonidine, 27:297
- schizophrenia, growth hormone, 27:297
- schizophrenia, 3-methoxy-4-hydroxyphenylglycol, 27:297
- schizophrenia, treatment response prediction, 27:297
- sleep deprivation, 3-methoxy-4-hydroxyphenylglycol, 30:155
- temperature, affective disorder, 28:263
- temperature, circadian rhythms, 28:263
- temperature, cortisol, 28:263
- temperature, melatonin, 28:263
- temperature, thyroid stimulating hormone, 28:263
- thyroid stimulating hormone, affective disorder, 28:263
- thyroid stimulating hormone, circadian rhythms, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, melatonin, 28:263
- thyroid stimulating hormone, temperature, 28:263
- time sampling, affective disorder, 30:253
- time sampling, generalized anxiety disorder, 30:253
- treatment response prediction, clonidine, 27:297
- treatment response prediction, growth hormone, 27:297
- treatment response prediction, 3-methoxy-4-hydroxyphenylglycol, 27:297
- treatment response prediction, schizophrenia, 27:297

**Norepinephrine** continued

- yohimbine, blood pressure, 27:173
- yohimbine, cortisol, 27:173
- yohimbine, generalized anxiety disorder, 27:173
- yohimbine, heart rate, 27:173
- yohimbine, 3-methoxy-4-hydroxyphenylglycol, 27:173
- Nortriptyline**
- affective disorder, antidepressants, 28:1
- affective disorder, geriatric depression, 27:225, 28:1
- affective disorder, maintenance pharmacotherapy, 27:225
- affective disorder, phenelzine, 28:1
- affective disorder, survival analysis, 27:225
- antidepressants, affective disorder, 28:1
- antidepressants, geriatric depression, 28:1
- antidepressants, phenelzine, 28:1
- geriatric depression, affective disorder, 27:225, 28:1
- geriatric depression, antidepressants, 28:1
- geriatric depression, maintenance pharmacotherapy, 27:225
- geriatric depression, phenelzine, 28:1
- geriatric depression, survival analysis, 27:225
- maintenance pharmacotherapy, affective disorder, 27:225
- maintenance pharmacotherapy, geriatric depression, 27:225
- maintenance pharmacotherapy, survival analysis, 27:225
- phenelzine, affective disorder, 28:1
- phenelzine, antidepressants, 28:1
- phenelzine, geriatric depression, 28:1
- survival analysis, affective disorder, 27:225
- survival analysis, geriatric depression, 27:225
- survival analysis, maintenance pharmacotherapy, 27:225
- Nuclear magnetic resonance.** See Magnetic resonance imaging
- Obsessive-compulsive disorder**
- anxiety, depressed mood, 27:65
- anxiety, pseudocholinesterase, 27:65
- cortisol, dexamethasone suppression test, 30:243
- depressed mood, anxiety, 27:65
- depressed mood, pseudocholinesterase, 27:65
- dexamethasone suppression test, cortisol, 30:243
- evoked potentials, frontal lobe, 28:63
- evoked potentials, P300, 28:63
- frontal lobe, evoked potentials, 28:63

**Obsessive-compulsive disorder** continued

- frontal lobe, P300, 28:63
- P300, evoked potentials, 28:63
- P300, frontal lobe, 28:63
- pseudocholinesterase, anxiety, 27:65
- pseudocholinesterase, depressed mood, 27:65

**Osteoporosis**

- cortisol, eating disorders, 29:105
- cortisol, estradiol, 29:105
- eating disorders, cortisol, 29:105
- eating disorders, estradiol, 29:105
- estradiol, eating disorders, 29:105

**Panic disorder**

- Acute Panic Inventory, affective disorder, 27:357
- Acute Panic Inventory, carbon dioxide inhalation, 27:183
- Acute Panic Inventory, lactate, 27:357, 29:207
- Acute Panic Inventory, premenstrual dysphoria, 27:183
- Acute Panic Inventory, somatic symptoms, 29:207
- adenosine, caffeine, 30:231
- adenosine, posttraumatic stress disorder, 30:231
- adenosine, taste test, 30:231
- affective disorder, Acute Panic Inventory, 27:357
- affective disorder, lactate, 27:357
- agoraphobia, lactate, 28:181
- agoraphobia, prolactin, 28:181
- alprazolam, diazepam, 30:53
- alprazolam, 3-methoxy-4-hydroxy-phenylglycol, 30:53
- alprazolam, treatment response, 30:53
- anxiety, fenfluramine, 28:295
- anxiety, serotonin, 28:295
- blood gases, lactate, 28:171
- body size, mitral valve prolapse, 28:161
- body size, triiodothyronine, 28:161
- caffeine, adenosine, 30:231
- caffeine, posttraumatic stress disorder, 30:231
- caffeine, taste test, 30:231
- carbon dioxide inhalation, Acute Panic Inventory, 27:183
- carbon dioxide inhalation, premenstrual dysphoria, 27:183
- cortisol, dehydroepiandrosterone, 28:345
- cortisol, dexamethasone suppression test, 30:243
- cortisol, growth hormone, 28:351
- cortisol, prolactin, 28:351

**Panic disorder** continued

- cortisol, syncope, 28:351
- dehydroepiandrosterone, cortisol, 28:345
- dexamethasone suppression test, cortisol, 30:243
- diazepam, alprazolam, 30:53
- diazepam, 3-methoxy-4-hydroxy-phenylglycol, 30:53
- diazepam, treatment response, 30:53
- fenfluramine, anxiety, 28:295
- fenfluramine, serotonin, 28:295
- growth hormone, cortisol, 28:351
- growth hormone, prolactin, 28:351
- growth hormone, syncope, 28:351
- imipramine binding, platelet, 30:21
- lactate, Acute Panic Inventory, 27:357, 29:207
- lactate, affective disorder, 27:357
- lactate, agoraphobia, 28:181
- lactate, blood gases, 28:171
- lactate, prolactin, 28:181
- lactate, somatic symptoms, 29:207
- 3-methoxy-4-hydroxyphenylglycol, alprazolam, 30:53
- 3-methoxy-4-hydroxyphenylglycol, diazepam, 30:53
- 3-methoxy-4-hydroxyphenylglycol, treatment response, 30:53
- mitral valve prolapse, body size, 28:161
- mitral valve prolapse, triiodothyronine, 28:161
- posttraumatic stress disorder, adenosine, 30:231
- posttraumatic stress disorder, caffeine, 30:231
- posttraumatic stress disorder, taste test, 30:231
- premenstrual dysphoria, Acute Panic Inventory, 27:183
- premenstrual dysphoria, carbon dioxide inhalation, 27:183
- prolactin, agoraphobia, 28:181
- prolactin, cortisol, 28:351
- prolactin, growth hormone, 28:351
- prolactin, lactate, 28:181
- prolactin, syncope, 28:351
- serotonin, anxiety, 28:295
- serotonin, fenfluramine, 28:295
- serotonin uptake, platelet, 30:63
- somatic symptoms, Acute Panic Inventory, 29:207
- somatic symptoms, lactate, 29:207
- syncope, cortisol, 28:351
- syncope, growth hormone, 28:351
- syncope, prolactin, 28:351

**Panic disorder** continued  
 taste test, adenosine, 30:231  
 taste test, caffeine, 30:231  
 taste test, posttraumatic stress disorder, 30:231  
 treatment response, alprazolam, 30:53  
 treatment response, diazepam, 30:53  
 treatment response, 3-methoxy-4-hydroxy phenylglycol, 30:53  
 triiodothyronine, body size, 28:161  
 triiodothyronine, mitral valve prolapse, 28:161

**Parietal lobe**  
 frontal lobes, positron emission tomography, 28:119  
 frontal lobes, schizophrenia, 28:119  
 positron emission tomography, frontal lobes, 28:119  
 positron emission tomography, schizophrenia, 8:119  
 schizophrenia, frontal lobes, 28:119  
 schizophrenia, positron emission tomography, 28:119

**Parkinson's disease**  
 laterality, neuroleptics, 30:275  
 laterality, schizophrenia, 30:275  
 neuroleptics, laterality, 30:275  
 neuroleptics, schizophrenia, 30:275  
 schizophrenia, laterality, 30:275  
 schizophrenia, neuroleptics, 30:275

**Perceptual Aberration-Magical Ideation Scale**  
 attention, college students, 27:207  
 attention, Physical Anhedonia Scale, 27:207  
 attention, psychosis proneness, 27:207  
 attention, risk factors, 27:207  
 college students, attention, 27:207  
 college students, Physical Anhedonia Scale, 27:207  
 college students, psychosis proneness, 27:207  
 college students, risk factors, 27:207  
 Physical Anhedonia Scale, attention, 27:207  
 Physical Anhedonia Scale, college students, 27:207  
 Physical Anhedonia Scale, psychosis proneness, 27:207  
 Physical Anhedonia Scale, risk factors, 27:207  
 psychosis proneness, attention, 27:207  
 psychosis proneness, college students, 27:207

**Perceptual Aberration-Magical Ideation Scale** continued  
 psychosis proneness, Physical Anhedonia Scale, 27:207  
 psychosis proneness, risk factors, 27:207  
 risk factors, attention, 27:207  
 risk factors, college students, 27:207  
 risk factors, Physical Anhedonia Scale, 27:207  
 risk factors, psychosis proneness, 27:207

**Perinatal complications**  
 genetics, schizophrenia, 27:233  
 schizophrenia, genetics, 27:233

**Personality disorder**  
 affective disorder, antisocial personality disorder, 30:265  
 affective disorder, borderline personality disorder, 30:265  
 affective disorder, monoamine oxidase, platelet, 30:265  
 antisocial personality disorder, affective disorder, 30:265  
 antisocial personality disorder, borderline personality disorder, 30:265  
 antisocial personality disorder, monoamine oxidase, platelet, 30:265  
 borderline personality disorder, affective disorder, 30:265  
 borderline personality disorder, antisocial personality disorder, 30:265  
 borderline personality disorder, monoamine oxidase, platelet, 30:265  
 diagnostic criteria, self-defeating personality disorder, 30:145

**Minnesota Multiphasic Personality Inventory**, monoamine oxidase, platelet, 27:81

**Minnesota Multiphasic Personality Inventory**, Personality Research Form, 27:81

**Minnesota Multiphasic Personality Inventory**, Sensation Seeking Scale, 27:81

monoamine oxidase, affective disorder, 30:265

monoamine oxidase, antisocial personality disorder, 30:265

monoamine oxidase, borderline personality disorder, 30:265

monoamine oxidase, Minnesota Multiphasic Personality Inventory, 27:81

monoamine oxidase, personality, 27:81

monoamine oxidase, Personality Research Form, 27:81

monoamine oxidase, platelet, 27:81, 30:265

monoamine oxidase, Sensation Seeking Scale, 27:81

**Perceptual Aberration-Magical Ideation Scale** continued

- personality, monoamine oxidase, 27:81
- Personality Research Form, Minnesota Multiphasic Personality Inventory, 27:81
- Personality Research Form, monoamine oxidase, 27:81
- Personality Research Form, Sensation Seeking Scale, 27:81
- personality, Sensation Seeking Scale, 27:81
- self-defeating personality disorder, diagnostic criteria, 30:145
- Sensation Seeking Scale, Minnesota Multiphasic Personality Inventory, 27:81
- Sensation Seeking Scale, monoamine oxidase, 27:81
- Sensation Seeking Scale, Personality Research Form, 27:81

**Phenelzine**

- affective disorder, antidepressants, 28:1
- affective disorder, geriatric depression, 28:1
- affective disorder, nortriptyline, 28:1
- antidepressants, affective disorder, 28:1
- antidepressants, geriatric depression, 28:1
- antidepressants, nortriptyline, 28:1
- geriatric depression, affective disorder, 28:1
- geriatric depression, antidepressants, 28:1
- geriatric depression, nortriptyline, 28:1
- nortriptyline, affective disorder, 28:1
- nortriptyline, antidepressants, 28:1
- nortriptyline, geriatric depression, 28:1

**Phenylacetic acid**

- hostility, schizophrenia, 30:111
- paranoid subtype, hostility, 30:111
- paranoid subtype, schizophrenia, 30:111
- schizophrenia, hostility, 30:111
- schizophrenia, paranoid subtype, 30:111

**Phenylethanolamine-N-methyl-transferase**

- dopamine-beta-hydroxylase, locus ceruleus, 27:31
- schizophrenia, post-mortem study, 27:31

**Phobic disorders**

- simple phobia, subtypes, 28:25
- subtypes, simple phobia, 28:25

**Phosphatidylserine**

- Alzheimer's disease, EEG mapping, 29:411
- EEG mapping, Alzheimer's disease, 29:411
- EEG mapping, normal volunteers, 29:417

**Phosphatidylserine** continued

- normal volunteers, EEG mapping, 29:417

**Physical Anhedonia Scale**

- attention, college students, 27:207
- attention, Perceptual Aberration-Magical Ideation Scale, 27:207
- attention, psychosis proneness, 27:207
- attention, risk factors, 27:207
- college students, attention, 27:207
- college students, Perceptual Aberration-Magical Ideation Scale, 27:207
- college students, psychosis proneness, 27:207
- college students, risk factors, 27:207
- Perceptual Aberration-Magical Ideation Scale, attention, 27:207
- Perceptual Aberration-Magical Ideation Scale, college students, 27:207
- Perceptual Aberration-Magical Ideation Scale, psychosis, 27:207
- Perceptual Aberration-Magical Ideation Scale, risk factors, 27:207
- psychosis proneness, attention, 27:207
- psychosis proneness, college students, 27:207
- psychosis proneness, Perceptual Aberration-Magical Ideation, 27:207
- psychosis proneness, risk factors, 27:207
- risk factors, attention, 27:207
- risk factors, college students, 27:207
- risk factors, Perceptual Aberration-Magical Ideation Scale, 27:207
- risk factors, psychosis proneness, 27:207

**Pittsburgh Sleep Quality Index**

- affective disorders, sleep, 28:193
- sleep, affective disorders, 28:193

**Pituitary**

- magnetic resonance imaging, psychiatric symptoms, 29:283
- Placebo withdrawal affective disorder, fluoxetine, 30:191
- affective disorder, Hamilton Rating Scale for Depression, 30:191
- affective disorder, imipramine, 30:191
- fluoxetine, affective disorder, 30:191
- fluoxetine, Hamilton Rating Scale for Depression, 30:191
- Hamilton Rating Scale for Depression, affective disorder, 30:191
- Hamilton Rating Scale for Depression, fluoxetine, 30:191
- Hamilton Rating Scale for Depression, imipramine, 30:191
- imipramine, affective disorder, 30:191

**Pituitary** continued

imipramine, Hamilton Rating Scale for Depression, 30:191

**Positron emission tomography**

Alzheimer's disease, computed tomography, 29:359

Alzheimer's disease, deoxyglucose, 29:351

Alzheimer's disease, white matter, 29:359

bromospiperone, dopamine receptors, 29:357

bromospiperone, schizophrenia, 29:357

cerebral blood flow, laterality, 27:325

cerebral blood flow, schizophrenia, 27:325

computed tomography, Alzheimer's disease, 29:359

computed tomography, lupus erythematosus, 29:367

computed tomography, magnetic resonance imaging, 29:363, 29:367

computed tomography, thalamic infarction, 29:363

computed tomography, white matter, 29:359

dementia, deoxyglucose, 29:353

deoxyglucose, Alzheimer's disease, 29:351

deoxyglucose, dementia, 29:353

dopamine receptors, bromospiperone, 29:357

dopamine receptors, schizophrenia, 29:357

frontal lobes, parietal lobes, 28:119

frontal lobes, schizophrenia, 28:119

Huntington's chorea, psychiatric symptoms, 29:361

laterality, cerebral blood flow, 27:325

laterality, schizophrenia, 27:325

lupus erythematosus, computed tomography, 29:367

lupus erythematosus, magnetic resonance imaging, 29:367

magnetic resonance imaging, computed tomography, 29:363, 29:367

magnetic resonance imaging, lupus erythematosus, 29:367

magnetic resonance imaging, thalamic infarction, 29:363

parietal lobes, frontal lobes, 28:119

parietal lobes, schizophrenia, 28:119

psychiatric symptoms, Huntington's chorea, 29:361

**Positron emission tomography** continued

schizophrenia, bromospiperone, 29:357

schizophrenia, cerebral blood flow, 27:325

schizophrenia, dopamine receptors, 29:357

schizophrenia, frontal lobes, 28:119

schizophrenia, laterality, 27:325

schizophrenia, parietal lobes, 28:119

thalamic infarction, computed tomography, 29:363

thalamic infarction, magnetic resonance imaging, 29:363

white matter, Alzheimer's disease, 29:359

white matter, computed tomography, 29:359

**Posttraumatic stress disorder**

adenosine, caffeine, 30:231

adenosine, panic disorder, 30:231

adenosine, taste test, 30:231

akathisia, beta blocker, 27:1

akathisia, schizophrenia, 27:1

beta blocker, akathisia, 27:1

beta blocker, schizophrenia, 27:1

caffeine, adenosine, 30:231

caffeine, panic disorder, 30:231

caffeine, taste test, 30:231

panic disorder, adenosine, 30:231

panic disorder, caffeine, 30:231

panic disorder, taste test, 30:231

schizophrenia, akathisia, 27:1

schizophrenia, beta blocker, 27:1

taste test, adenosine, 30:231

taste test, caffeine, 30:231

taste test, panic disorder, 30:231

**Potassium**

affective disorder, children, children, affective disorder, 29:215

**Premenstrual dysphoria**

activity, menstrual cycle, 30:285

activity, sleep, 30:285

activity, temperature, 30:285

Acute Panic Inventory, carbon dioxide inhalation, 27:183

Acute Panic Inventory, panic, 27:183

blood pressure, heart rate, 27:183

carbon dioxide inhalation, Acute Panic Inventory, 27:183

carbon dioxide inhalation, panic, 27:183

heart rate, blood pressure, 27:183

menstrual cycle, activity, 30:285

menstrual cycle, sleep, 30:285

menstrual cycle, temperature, 30:285

panic, Acute Panic Inventory, 27:183

panic, carbon dioxide inhalation, 27:183

sleep, activity, 30:285

**Premenstrual dysphoria** continued

sleep, menstrual cycle, 30:285  
 sleep, temperature, 30:285  
 temperature, activity, 30:285  
 temperature, menstrual cycle, 30:285  
 temperature, sleep, 30:285

**Prolactin**

age, chlorophenylpiperazine, 29:1  
 age, cortisol, 29:1  
 age, serotonin, 29:1  
 agoraphobia, lactate, 28:181  
 agoraphobia, panic disorder, 28:181  
 alcoholism, computed tomography, 28:89  
 alcoholism, growth hormone, 28:89  
 alcoholism, lithium, 29:55  
 alcoholism, red blood cells, 29:55  
 alcoholism, thyroid stimulating hormone, 28:89  
 alcoholism, thyrotropin releasing hormone test, 28:89  
 chlorophenylpiperazine, age, 29:1  
 chlorophenylpiperazine, cortisol, 29:1  
 chlorophenylpiperazine, serotonin, 29:1  
 computed tomography, alcoholism, 28:89  
 computed tomography, growth hormone, 28:89  
 computed tomography, thyroid stimulating hormone, 28:89  
 computed tomography, thyrotropin releasing hormone test, 28:89  
 cortisol, age, 29:1  
 cortisol, chlorophenylpiperazine, 29:1  
 cortisol, growth hormone, 28:351  
 cortisol, panic disorder, 28:351  
 cortisol, serotonin, 29:1  
 cortisol, syncope, 28:351  
 growth hormone, alcoholism, 28:89  
 growth hormone, computed tomography, 28:89  
 growth hormone, cortisol, 28:351  
 growth hormone, panic disorder, 28:351  
 growth hormone, syncope, 28:351  
 growth hormone, thyroid stimulating hormone, 28:89  
 growth hormone, thyrotropin releasing hormone test, 28:89  
 lactate, agoraphobia, 28:181  
 lactate, panic disorder, 28:181  
 lithium, alcoholism, 29:55  
 lithium, red blood cells, 29:55  
 metoclopramide, sleep, 29:161  
 metoclopramide, thyrotropin releasing hormone, 29:161  
 metoclopramide, tryptophan, 29:161  
 metoclopramide, weight loss, 29:161

**Prolactin** continued

panic disorder, agoraphobia, 28:181  
 panic disorder, cortisol, 28:351  
 panic disorder, growth hormone, 28:351  
 panic disorder, lactate, 28:181  
 panic disorder, syncope, 28:351  
 red blood cells, alcoholism, 29:55  
 red blood cells, lithium, 29:55  
 serotonin, age, 29:1  
 serotonin, chlorophenylpiperazine, 29:1  
 serotonin, cortisol, 29:1  
 sleep, metoclopramide, 29:161  
 sleep, thyrotropin releasing hormone, 29:161  
 sleep, tryptophan, 29:161  
 sleep, weight loss, 29:161  
 syncope, cortisol, 28:351  
 syncope, growth hormone, 28:351  
 syncope, panic disorder, 28:351  
 thyroid stimulating hormone, alcoholism, 28:89  
 thyroid stimulating hormone, computed tomography, 28:89  
 thyroid stimulating hormone, growth hormone, 28:89  
 releasing hormone, metoclopramide, 29:161  
 thyrotropin releasing hormone, sleep, 29:161  
 thyrotropin releasing hormone test, alcoholism, 28:89  
 thyrotropin releasing hormone test, computed tomography, 28:89  
 thyrotropin releasing hormone test, growth hormone, 28:89  
 thyrotropin releasing hormone, weight loss, 29:161  
 tryptophan, metoclopramide, 29:161  
 tryptophan, sleep, 29:161  
 tryptophan, thyrotropin releasing hormone, 29:161  
 tryptophan, weight loss, 29:161  
 weight loss, metoclopramide, 29:161  
 weight loss, sleep, 29:161  
 weight loss, thyrotropin releasing hormone, 29:161  
 weight loss, tryptophan, 29:161

**Propranolol**

akathisia, neuroleptic side effect, 27:1  
 neuroleptic side effect, akathisia, 27:1

**Prostaglandins**

affective disorder, cortisol, 30:181  
 affective disorder, cyclic adenosine monophosphate, 30:181  
 affective disorder, dihydroergocryptine, 30:181

**Prolactin** continued

- cortisol, affective disorders, 30:181
- cortisol, cyclic adenosine monophosphate, 30:181
- cortisol, dihydroergocryptine, 30:181
- cyclic adenosine monophosphate, affective disorder, 30:181
- cyclic adenosine monophosphate, cortisol, 30:181
- cyclic adenosine monophosphate, dihydroergocryptine, 30:181
- dihydroergocryptine, affective disorder, 30:181
- dihydroergocryptine, cyclic adenosine monophosphate, 30:181
- dihydroergocryptine, cortisol, 30:181

**Pseudocholinesterase**

- anxiety, depressed mood, 27:65
- anxiety, obsessive-compulsive disorder, 27:65
- depressed mood, anxiety, 27:65
- depressed mood, obsessive-compulsive disorder, 27:65
- obsessive-compulsive disorder, anxiety, 27:65
- obsessive-compulsive disorder, depressed mood, 27:65

**Psychiatric Epidemiology Research Interview**

- affective disorder, life events, 30:213
- DSM-III, life events, 30:201
- life events, affective disorder, 30:213
- life events, DSM-III, 30:201

**Pupillary response**

- light, lithium, 30:305
- light, sheep, 30:305
- lithium, light, 30:305
- lithium, sheep, 30:305
- sheep, light, 30:305

**Pyratol**

- Alzheimer's disease, cerebral blood flow, 29:303
- cerebral blood flow, Alzheimer's disease, 29:303
- cognitive function, EEG mapping, 29:387
- EEG mapping, cognitive function, 29:387
- EEG mapping, evoked potentials, 29:413
- EEG mapping, P300, 29:413
- evoked potentials, EEG mapping, 29:413
- evoked potentials, P300, 29:413
- P300, EEG mapping, 29:413
- P300, evoked potentials, 29:413

**Pyruvate**

- acetazolamide, schizophrenia, 28:279
- acetazolamide, thiamine, 28:279

**Pyruvate** continued

- schizophrenia, acetazolamide, 28:279
- schizophrenia, thiamine, 28:279
- thiamine, acetazolamide, 28:279
- thiamine, schizophrenia, 28:279

**Red blood cells**

- affective disorder, ankyrin, 27:267
- affective disorder, bipolar subtype, 27:267
- affective disorder, lithium, 27:267
- alcoholism, lithium, 29:55
- alcoholism, prolactin, 29:55
- ankyrin, affective disorder, 27:267
- ankyrin, bipolar subtype, 27:267
- ankyrin, lithium, 27:267
- bipolar subtype, affective disorder, 27:267
- bipolar subtype, ankyrin, 27:267
- bipolar subtype, lithium, 27:267
- choline, neuroleptics, 29:45
- choline, schizophrenia, 29:45
- choline, tardive dyskinesia, 29:45
- inositol-1-phosphatase, lithium, 27:217
- lithium, affective disorder, 27:267
- lithium, alcoholism, 29:55
- lithium, ankyrin, 27:267
- lithium, bipolar subtype, 27:267
- lithium, inositol-1-phosphatase, 27:217
- lithium, prolactin, 29:55
- neuroleptics, choline, 29:45
- neuroleptics, schizophrenia, 29:45
- neuroleptics, tardive dyskinesia, 29:45
- prolactin, alcoholism, 29:55
- prolactin, lithium, 29:55
- schizophrenia, choline, 29:45
- schizophrenia, neuroleptics, 29:45
- schizophrenia, tardive dyskinesia, 29:45
- tardive dyskinesia, choline, 29:45
- tardive dyskinesia, neuroleptics, 29:45
- tardive dyskinesia, schizophrenia, 29:45

**Rapid eye movement (REM).** See also **Sleep**

- affective disorder, relatives of unipolars, 27:127
- affective disorder, sleep, 27:127
- relatives of unipolars, affective disorder, 27:127
- relatives of unipolars, sleep, 27:127
- sleep, affective disorder, 27:127
- sleep, relatives of unipolars, 27:127

**Rett syndrome**

- EEG mapping, theta activity, 29:425
- theta activity, EEG mapping, 29:425

**Risk factors**

- attention, college students, 27:207
- attention, Perceptual Aberration-Magical Ideation Scale, 27:207

**Risk factors** continued

- attention, Physical Anhedonia Scale, 27:207
- attention, psychosis proneness, 27:207
- college students, attention, 27:207
- college students, Physical Anhedonia Scale, 27:207
- college students, psychosis proneness, 27:207
- Perceptual Aberration-Magical Ideation Scale, attention, 27:207
- Physical Anhedonia Scale, attention, 27:207
- Physical Anhedonia Scale, college students, 27:207
- Physical Anhedonia Scale, Perceptual Aberration-Magical Ideation Scale, 27:207
- Physical Anhedonia Scale, psychosis proneness, 27:207
- psychosis proneness, attention, 27:207
- psychosis proneness, college students, 27:207
- psychosis proneness, Physical Anhedonia Scale, 27:207

**Scale for the Assessment of Negative Symptoms**

- affective flattening, schizophrenia, 27:199
- affective flattening, videotaped interviews, 27:199
- cortisol, schizophrenia, 30:69
- EEG topography, schizophrenia, 29:137
- electromechanical measures, schizophrenia, 28:145
- electromechanical measures, tardive dyskinesia, 28:145
- REM, schizophrenia, 27:359
- REM, sleep, 27:359
- schizophrenia, affective flattening, 27:199
- schizophrenia, cortisol, 30:69
- schizophrenia, EEG topography, 29:137
- schizophrenia, electromechanical measures, 28:145
- schizophrenia, REM, 27:359
- schizophrenia, sleep, 27:359
- schizophrenia, tardive dyskinesia, 28:145
- schizophrenia, videotaped interviews, 27:199
- sleep, REM, 27:359
- sleep, schizophrenia, 27:359
- tardive dyskinesia, electromechanical measures, 28:145
- tardive dyskinesia, schizophrenia, 28:145
- videotaped interviews, affective flattening, 27:199
- videotaped interviews, schizophrenia, 27:199

**Schedule for the Deficit Syndrome**

- negative symptoms, schizophrenia, 30:119
- schizophrenia, negative symptoms, 30:119

**Schizoaffective disorder**

- Brief Psychiatric Rating Scale, schizophrenia, 28:135
- Minnesota Multiphasic Personality Inventory, schizophrenia, 28:135
- schizophrenia, Brief Psychiatric Rating Scale, 28:135
- schizophrenia, Minnesota Multiphasic Personality Inventory, 28:135

**Schizophrenia**

- acetazolamide, pyruvate dehydrogenase, 28:279
- acetazolamide, thiamine, 28:279
- affective disorder, antidepressants, 28:73
- affective disorder, attention, 29:65
- affective disorder, clonidine binding in platelets, 28:73
- affective disorder, continuous performance test, 29:65
- affective disorder, laterality, 29:65
- affective disorder, lithium, 28:73
- affective flattening, Scale for the Assessment of Negative Symptoms, 27:199
- affective flattening, videotaped interviews, 27:199
- affective symptoms, neuroleptics, 28:315
- affective symptoms, tardive dyskinesia, 28:315
- akathisia, beta blocker, 27:1
- akathisia, posttraumatic stress disorder, 27:1
- alpha, EEG, 30:313
- alpha, photic driving, 30:313
- alpha, thalamus, 30:313
- antidepressants, affective disorder, 28:73
- antidepressants, clonidine binding in platelets, 28:73
- antidepressants, lithium, 28:73
- arachnoid cyst, EEG mapping, 29:421
- arachnoid cyst, evoked potentials, 29:421
- arachnoid cyst, P300, 29:421
- arylsulfatase A, metachromatic leucodystrophy, 30:107
- attention, affective disorder, 29:65
- attention, clinical stabilization, 28:31
- attention, computed tomography, 29:267
- attention, continuous performance test, 29:65
- attention, eye movements, 28:31
- attention, laterality, 29:65, 29:267
- attention, ventricle-brain ratio, 29:267
- beta blocker, akathisia, 27:1
- beta blocker, posttraumatic stress disorder, 27:1

**Schizophrenia** continued

Brief Psychiatric Rating Scale, schizoaffective disorder, 28:135  
 bromospiperone, dopamine receptors, 29:357  
 bromospiperone, positron emission tomography, 29:357  
 cerebral blood flow, corpus callosum, 29:453  
 cerebral blood flow, frontal lobe reduction, 29:331  
 cerebral blood flow, laterality, 27:325  
 cerebral blood flow, magnetic resonance imaging, 29:453  
 cerebral blood flow, positron emission tomography, 27:325  
 cerebral blood flow, single photon emission computed tomography, 29:331  
 Chinese patients, haloperidol, 30:45  
 Chinese patients, plasma levels, 30:45  
 choline, neuroleptics, 29:45  
 choline, red blood cells, 29:45  
 choline, tardive dyskinesia, 29:45  
 clinical stabilization, attention, 28:31  
 clinical stabilization, eye movements, 28:31  
 clonidine, affective disorder, 28:73  
 clonidine, antidepressants, 28:73  
 clonidine binding in platelets, affective disorder, 28:73  
 clonidine binding in platelets, antidepressants, 28:73  
 clonidine binding in platelets, lithium, 28:73  
 clonidine, growth hormone, 27:297  
 clonidine, lithium, 28:73  
 clonidine, 3-methoxy-4-hydroxyphenylglycol, 27:297  
 clonidine, norepinephrine, 27:297  
 clonidine, treatment response prediction, 27:297  
 computed tomography, attention, 29:267  
 computed tomography, electroencephalogram, 29:137  
 computed tomography, frontal lobe, 29:137  
 computed tomography, laterality, 29:247, 29:267  
 computed tomography, limbic system, 29:255  
 computed tomography, magnetic resonance imaging, 29:265  
 computed tomography, ventricle-brain ratio, 29:257, 29:265, 29:267  
 computed tomography, Wisconsin Card Sort Test, 29:137  
 continuous performance test, affective disorder, 29:65  
 continuous performance test, attention, 29:65  
 continuous performance test, laterality, 29:65

**Schizophrenia** continued

corpus callosum, cerebral blood flow, 29:453  
 corpus callosum, magnetic resonance imaging, 29:453  
 cortisol, dexamethasone suppression test, 30:69  
 cortisol, negative symptoms, 30:69  
 cortisol, Scale for the Assessment of Negative Symptoms, 30:69  
 dementia, EEG mapping, 29:391  
 dementia, evoked potentials, 29:391  
 dementia, P300, 29:391  
 dermatoglyphics, genetics, 29:37  
 dermatoglyphics, twins, 29:37  
 dexamethasone suppression test, cortisol, 30:69  
 dexamethasone suppression test, negative symptoms, 30:69  
 diabetes mellitus, glucose tolerance, 29:17  
 diabetes mellitus, haloperidol, 29:17  
 diabetes mellitus, tardive dyskinesia, 29:17  
 dopamine-beta-hydroxylase, locus ceruleus, 27:31  
 dopamine-beta-hydroxylase, paranoid subtype, 27:31  
 dopamine-beta-hydroxylase, post-mortem study, 27:31  
 dopamine receptors, bromospiperone, 29:357  
 dopamine receptors, positron emission tomography, 29:357  
 EEG, alpha, 30:313  
 EEG mapping, arachnoid cyst, 29:421  
 EEG mapping, dementia, 29:391  
 EEG mapping, evoked potentials, 29:391, 29:421  
 EEG mapping, P300, 29:391, 29:421  
 EEG mapping, temporal lobe beta, 29:419  
 EEG, photic driving, 30:313  
 EEG, thalamus, 30:313  
 EEG topography, Scale for the Assessment of Negative Symptoms, 29:137  
 electroencephalogram, computed tomography, 29:137  
 electroencephalogram, frontal lobe, 29:137  
 electroencephalogram, neuroleptics, 29:395  
 electroencephalogram, Wisconsin Card Sort Test, 29:137  
 electromechanical measures, tardive dyskinesia, 28:145  
 evoked potentials, arachnoid cyst, 29:421  
 evoked potentials, dementia, 29:391

**Schizophrenia** continued

evoked potentials, EEG mapping, 29:391, 29:421  
 evoked potentials, P300, 29:391, 29:421  
 evoked potentials, tardive dyskinesia, 28:117  
 eye movements, attention, 28:31  
 eye movements, clinical stabilization, 28:31  
 eye movements, neuroleptics, 28:307  
 frontal lobe, computed tomography, 29:137  
 frontal lobe, electroencephalogram, 29:137  
 frontal lobe reduction, cerebral blood flow, 29:331  
 frontal lobe reduction, single photon emission computed tomography, 29:331  
 frontal lobe size, magnetic resonance imaging, 30:11  
 frontal lobe size, negative symptoms, 30:11  
 frontal lobe size, saggital morphology, 30:11  
 frontal lobe, Wisconsin Card Sort Test, 29:137  
 frontal lobes, parietal lobes, 28:119  
 frontal lobes, positron emission tomography, 28:119  
 gender, 28:243  
 gender, genetics, 28:243  
 gender, heterogeneity, 28:243  
 genetics, 28:243  
 genetics, dermatoglyphics, 29:37  
 genetics, gender, 28:243  
 genetics, heterogeneity, 28:243  
 genetics, perinatal complications, 27:233  
 genetics, twins, 29:37  
 glucose tolerance, diabetes mellitus, 29:17  
 glucose tolerance, haloperidol, 29:17  
 glucose tolerance, tardive dyskinesia, 29:17  
 growth hormone, clonidine, 27:297  
 growth hormone, 3-methoxy-4-hydroxy-phenylglycol, 27:297  
 growth hormone, norepinephrine, 27:297  
 growth hormone, treatment response prediction, 27:297  
 haloperidol, Chinese patients, 30:45  
 haloperidol, diabetes mellitus, 29:17  
 haloperidol, glucose tolerance, 29:17  
 haloperidol, plasma levels, 30:45  
 haloperidol, tardive dyskinesia, 29:17  
 heterogeneity, 28:243  
 heterogeneity, gender, 28:243  
 heterogeneity, genetics, 28:243  
 high dose, neuroleptics, 30:1  
 high dose, treatment response, 30:1

**Schizophrenia** continued

homovanillic acid, pharmacological treatment, 28:97  
 hostility, paranoid subtype, 30:111  
 hostility, phenylacetic acid, 30:111  
 imipramine binding, platelet, 30:21  
 laterality, affective disorder, 29:65  
 laterality, attention, 29:65, 29:267  
 laterality, cerebral blood flow, 27:325  
 laterality, computed tomography, 29:247, 29:267  
 laterality, continuous performance test, 29:65  
 laterality, neuroleptics, 30:275  
 laterality, parkinsonism, 30:275  
 laterality, positron emission tomography, 27:325  
 laterality, ventricle-brain ratio, 29:267  
 limbic system, computed tomography, 29:255  
 lithium, affective disorder, 28:73  
 lithium, antidepressants, 28:73  
 lithium, clonidine, 28:73  
 lithium, clonidine binding in platelets, 28:73  
 locus ceruleus, dopamine-beta-hydroxylase, 27:31  
 locus ceruleus, paranoid subtype, 27:31  
 locus ceruleus, post-mortem study, 27:31  
 magnetic resonance imaging, cerebral blood flow, 29:453  
 magnetic resonance imaging, computed tomography, 29:265  
 magnetic resonance imaging, corpus callosum, 29:453  
 magnetic resonance imaging, frontal lobe size, 30:11  
 magnetic resonance imaging, negative symptoms, 30:11  
 magnetic resonance imaging, saggital morphology, 30:11  
 magnetic resonance imaging, temporal lobe, 29:261  
 magnetic resonance imaging, ventricle-brain ratio, 29:265  
 metachromatic leucodystrophy, arylsulfatase A, 30:107  
 3-methoxy-4-hydroxyphenylglycol, clonidine, 27:297  
 3-methoxy-4-hydroxyphenylglycol, growth hormone, 27:297  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:297  
 3-methoxy-4-hydroxyphenylglycol, treatment response prediction, 27:297

**Schizophrenia** continued

Minnesota Multiphasic Personality Inventory, schizoaffective disorder, 28:135  
 negative symptoms, cortisol, 30:69  
 negative symptoms, dexamethasone suppression test, 30:69  
 negative symptoms, frontal lobe size, 30:11  
 negative symptoms, magnetic resonance imaging, 30:11  
 negative symptoms, saggital morphology, 30:11  
 negative symptoms, Schedule for the Deficit Syndrome, 30:119  
 neuroleptics, affective symptoms, 28:315  
 neuroleptics, choline, 29:45  
 neuroleptics, electroencephalography, 29:395  
 neuroleptics, eye movements, 28:307  
 neuroleptics, high dose, 30:1  
 neuroleptics, laterality, 30:275  
 neuroleptics, parkinsonism, 30:275  
 neuroleptics, red blood cells, 29:45  
 neuroleptics, tardive dyskinesia, 28:315, 29:45  
 neuroleptics, treatment response, 30:1  
**Neurological Evaluation Scale**, validity data, 27:335  
 norepinephrine, clonidine, 27:297  
 norepinephrine, growth hormone, 27:297  
 norepinephrine, 3-methoxy-4-hydroxy-phenylglycol, 27:297  
 norepinephrine, treatment response prediction, 27:297  
 P300, arachnoid cyst, 29:421  
 P300, dementia, 29:391  
 P300, EEG mapping, 29:391, 29:421  
 P300, evoked potentials, 29:391, 29:421  
 paranoid subtype, dopamine-beta-hydroxylase, 27:31  
 paranoid subtype, hostility, 30:111  
 paranoid subtype, locus ceruleus, 27:31  
 paranoid subtype, phenylacetic acid, 30:111  
 paranoid subtype, post-mortem study, 27:31  
 parietal lobes, frontal lobes, 28:119  
 parietal lobes, positron emission tomography, 28:119  
 parkinsonism, laterality, 30:275  
 parkinsonism, neuroleptics, 30:275  
 perinatal complications, genetics, 27:233  
 pharmacological treatment, homovanillic acid, 28:97  
 phenylacetic acid, hostility, 30:111

**Schizophrenia** continued

phenylacetic acid, paranoid subtype, 30:111  
 phenylethanolamine-N-methyltransferase, post-mortem study, 27:31  
 photic driving, alpha, 30:313  
 photic driving, EEG, 30:313  
 photic driving, thalamus, 30:313  
 plasma levels, Chinese patients, 30:45  
 plasma levels, haloperidol, 30:45  
 platelet, imipramine binding, 30:21  
 positron emission tomography, bromospiperone, 29:357  
 positron emission tomography, cerebral blood flow, 27:325  
 positron emission tomography, dopamine receptors, 29:357  
 positron emission tomography, frontal lobes, 28:119  
 positron emission tomography, laterality, 27:325  
 positron emission tomography, parietal lobes, 28:119  
 post-mortem study, dopamine-beta-hydroxylase, 27:31  
 post-mortem study, locus ceruleus, 27:31  
 post-mortem study, paranoid subtype, 27:31  
 post-mortem study, phenylethanolamine-N-methyltransferase, 27:31  
 posttraumatic stress disorder, akathisia, 27:1  
 posttraumatic stress disorder, beta blocker, 27:1  
 pyruvate dehydrogenase, acetazolamide, 28:279  
 pyruvate dehydrogenase, thiamine, 28:279  
 red blood cells, choline, 29:45  
 red blood cells, neuroleptics, 29:45  
 red blood cells, tardive dyskinesia, 29:45  
**REM, Scale for the Assessment of Negative Symptoms**, 27:359  
 REM, sleep, 27:359  
 saggital morphology, frontal lobe size, 30:11  
 saggital morphology, magnetic resonance imaging, 30:11  
 saggital morphology, negative symptoms, 30:11  
**Scale for the Assessment of Negative Symptoms**, affective flattening, 27:199  
**Scale for the Assessment of Negative Symptoms**, cortisol, 30:69  
**Scale for the Assessment of Negative Symptoms**, EEG topography, 29:137

**Schizophrenia** continued

- Scale for the Assessment of Negative Symptoms, REM, 27:359
- Scale for the Assessment of Negative Symptoms, sleep, 27:359
- Scale for the Assessment of Negative Symptoms, tardive dyskinesia, 28:315
- Scale for the Assessment of Negative Symptoms, videotaped interviews, 27:199
- Schedule for the Deficit Syndrome, negative symptoms, 30:119
- schizoaffective disorder, Brief Psychiatric Rating Scale, 28:135
- schizoaffective disorder, Minnesota Multiphasic Personality Inventory, 28:135
- sleep, REM, 27:359
- sleep, Scale for the Assessment of Negative Symptoms, 27:359
- single photon emission computed tomography, cerebral blood flow, 29:331
- single photon emission computed tomography, frontal lobe reduction, 29:331
- tardive dyskinesia, affective symptoms, 28:315
- tardive dyskinesia, choline, 29:45
- tardive dyskinesia, diabetes mellitus, 29:17
- tardive dyskinesia, electromechanical measures, 28:145
- tardive dyskinesia, evoked potentials, 28:117
- tardive dyskinesia, glucose tolerance, 29:17
- tardive dyskinesia, haloperidol, 29:17
- tardive dyskinesia, neuroleptics, 28:315, 29:45
- tardive dyskinesia, red blood cells, 29:45
- tardive dyskinesia, Scale for the Assessment of Negative Symptoms, 28:145
- temporal lobe beta, EEG mapping, 29:419
- temporal lobe, magnetic resonance imaging, 29:261
- thalamus, alpha, 30:313
- thalamus, EEG, 30:313
- thalamus, photic driving, 30:313
- thiamine, acetazolamide, 28:279
- thiamine, pyruvate dehydrogenase, 28:279
- treatment response, high dose, 30:1

**Schizophrenia** continued

- treatment response, neuroleptics, 30:1
- treatment response prediction, clonidine, 27:297
- treatment response prediction, growth hormone, 27:297
- treatment response prediction, 3-methoxy-4-hydroxyphenylglycol, 27:297
- treatment response prediction, norepinephrine, 27:297
- twins, dermatoglyphics, 29:37
- twins, genetics, 29:37
- validity data, Neurological Evaluation Scale, 27:335
- ventricle-brain ratio, attention, 29:267
- ventricle-brain ratio, computed tomography, 29:257, 29:265, 29:267
- ventricle-brain ratio, laterality, 29:267
- ventricle-brain ratio, magnetic resonance imaging, 29:265
- videotaped interviews, affective flattening, 27:199
- videotaped interviews, Scale for the Assessment of Negative Symptoms, 27:199
- Wisconsin Card Sort Test, computed tomography, 29:137
- Wisconsin Card Sort Test, electroencephalogram, 29:137
- Wisconsin Card Sort Test, frontal lobe, 29:137

**Seasonal affective disorder**

- affective disorder, cluster analysis, 28:227
- affective disorder, light therapy, 29:29
- affective disorder, statistics, 28:227
- affective disorder, temperature, 28:323
- cluster analysis, affective disorder, 28:227
- cluster analysis, statistics, 28:227
- light therapy, affective disorder, 29:29
- statistics, affective disorder, 28:227
- statistics, cluster analysis, 28:227
- temperature, affective disorder, 28:323

**Seizures**

- comparison with EEG, magneto-encephalography, 29:377
- computed tomography, EEG focus, 29:459
- computed tomography, magnetic resonance imaging, 29:459
- computed tomography, single photon emission computed tomography, 29:459
- EEG focus, computed tomography, 29:459
- EEG focus, magnetic resonance imaging, 29:459
- EEG focus, single photon emission computed tomography, 29:459

**Seizures** continued

- lithium, rats, 30:77
- lithium, theophylline, 30:77
- magnetic resonance imaging, computed tomography, 29:459
- magnetic resonance imaging, EEG focus, 29:459
- magnetic resonance imaging, single photon emission computed tomography, 29:459
- magnetoencephalography, comparison with EEG, 29:377
- rats, lithium, 30:77
- rats, theophylline, 30:77
- single photon emission computed tomography, computed tomography, 29:459
- single photon emission computed tomography, EEG focus, 29:459
- single photon emission computed tomography, magnetic resonance imaging, 29:459
- theophylline, lithium, 30:77
- theophylline, rats, 30:77

**Sensation Seeking Scale**

- Minnesota Multiphasic Personality Inventory, monoamine oxidase, 27:81
- Minnesota Multiphasic Personality Inventory, Personality Research Form, 27:81
- monoamine oxidase, Minnesota Multiphasic Personality Inventory, 27:81
- monoamine oxidase, Personality Research Form, 27:81
- monoamine oxidase, platelet, 27:81
- personality, monoamine oxidase, 27:81
- Personality Research Form, Minnesota Multiphasic Personality Inventory, 27:81
- Personality Research Form, monoamine oxidase, 27:81

**Serotonin**

- affective disorders, cyclic adenosine monophosphate, 30:181
- affective disorders, dihydroergocryptine binding, 30:181
- affective disorders, 5-hydroxyindolacetic acid, 30:181
- age, chlorophenylpiperazine, 29:1
- age, cortisol, 29:1
- age, prolactin, 29:1
- aggression, impulsivity, 27:5
- anxiety, fenfluramine, 28:295
- anxiety, panic disorder, 28:295
- cyclic adenosine monophosphate, affective disorder, 30:181

**Serotonin** continued

- cyclic adenosine monophosphate, dihydroergocryptine binding, 30:181
- cyclic adenosine monophosphate, 5-hydroxyindolacetic acid, 30:181
- chlorophenylpiperazine, age, 29:1
- chlorophenylpiperazine, cortisol, 29:1
- chlorophenylpiperazine, prolactin, 29:1
- circannual rhythm, platelet uptake, 27:5
- cortisol, age, 29:1
- cortisol, chlorophenylpiperazine, 29:1
- cortisol, prolactin, 29:1
- desipramine, frontal lobe, 30:125
- desipramine, imipramine binding, 30:125
- desipramine, suicide, 30:125
- dihydroergocryptine binding, affective disorder, 30:181
- dihydroergocryptine binding, cyclic adenosine monophosphate, 30:181
- dihydroergocryptine binding, 5-hydroxyindolacetic acid, 30:181
- fenfluramine, anxiety, 28:295
- fenfluramine, panic disorder, 28:295
- frontal lobe, desipramine, 30:125
- frontal lobe, imipramine binding, 30:125
- frontal lobe, suicide, 30:125
- 5-hydroxyindolacetic acid, affective disorders, 30:181
- 5-hydroxyindolacetic acid, cyclic adenosine monophosphate, 30:181
- 5-hydroxyindolacetic acid, dihydroergocryptine binding, 30:181
- imipramine binding, desipramine, 30:125
- imipramine binding, frontal lobe, 30:125
- imipramine binding, suicide, 30:125
- impulsivity, aggression, 27:5
- panic disorder, anxiety, 28:295
- panic disorder, fenfluramine, 28:295
- platelet, aggression, 27:5
- platelet, panic disorder, 30:63
- platelet uptake, circannual rhythm, 27:5
- prolactin, age, 29:1
- prolactin, chlorophenylpiperazine, 29:1
- prolactin, cortisol, 29:1
- suicide, desipramine, 30:125
- suicide, frontal lobe, 30:125
- suicide, imipramine binding, 30:125

**Sleep deprivation**

- activity, menstrual cycle, 30:285
- activity, premenstrual syndrome, 30:285
- activity, temperature, 30:285
- affective disorder, bipolar depression, 27:23
- affective disorder, circadian rhythm, 27:23

**Sleep deprivation** continued

affective disorder, clomipramine, 28:47, 30:165  
 affective disorder, geriatric depression, 27:13  
 affective disorder, interview behavior, 28:47  
 affective disorder, naps, 27:253  
 affective disorder, Pittsburgh Sleep Quality Index, 28:193  
 affective disorder, relatives of unipolars, 27:127  
 affective disorder, REM latency, 27:127  
 affective disorder, subtype, 27:13  
 affective disorder, temperature, 27:23  
 affective disorder, thyroid stimulating hormone, 29:231  
 affective disorder, triiodothyronine, 29:231  
 bipolar depression, affective disorder, 27:23  
 bipolar depression, circadian rhythms, 27:23  
 bipolar depression, temperature, 27:23  
 circadian rhythms, affective disorder, 27:23  
 circadian rhythms, bipolar depression, 27:23  
 circadian rhythms, temperature, 27:23  
 clomipramine, affective disorder, 28:47, 30:165  
 clomipramine, interview behavior, 28:47  
 EEG mapping, K complex, 29:435  
 geriatric depression, affective disorder, 27:13  
 geriatric depression, subtype, 27:13  
 interview behavior, affective disorder, 28:47  
 interview behavior, clomipramine, 28:47  
 K complex, EEG mapping, 29:435  
 menstrual cycle, activity, 30:285  
 menstrual cycle, premenstrual syndrome, 30:285  
 menstrual cycle, temperature, 30:285  
 metoclopramide, prolactin, 29:161  
 metoclopramide, thyrotropin releasing hormone, 29:161  
 metoclopramide, tryptophan, 29:161  
 metoclopramide, weight loss, 29:161  
 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 30:155  
 naps, affective disorder, 27:253  
 norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 30:155

**Sleep Deprivation** continued

Pittsburgh Sleep Quality Index, affective disorder, 28:193  
 premenstrual syndrome, activity, 30:285  
 premenstrual syndrome, menstrual cycle, 30:285  
 premenstrual syndrome, temperature, 30:285  
 prolactin, metoclopramide, 29:161  
 prolactin, thyrotropin releasing hormone, 29:161  
 prolactin, tryptophan, 29:161  
 prolactin, weight loss, 29:161  
 relatives of unipolars, affective disorder, 27:127  
 relatives of unipolars, REM latency, 27:127  
 REM latency, affective disorder, 27:127  
 REM latency, relatives of unipolars, 27:127  
 REM, Scale for the Assessment of Negative Symptoms, 27:359  
 REM, schizophrenia, 27:359  
 Scale for the Assessment of Negative Symptoms, REM, 27:359  
 Scale for the Assessment of Negative Symptoms, schizophrenia, 27:359  
 schizophrenia, REM, 27:359  
 schizophrenia, Scale for the Assessment of Negative Symptoms, 27:359  
 subtype, affective disorder, 27:13  
 subtype, geriatric depression, 27:13  
 temperature, activity, 30:285  
 temperature, affective disorder, 27:23  
 temperature, bipolar depression, 27:23  
 temperature, circadian rhythms, 27:23  
 temperature, menstrual cycle, 30:285  
 temperature, premenstrual syndrome, 30:285  
 thyroid stimulating hormone, affective disorder, 29:231  
 thyroid stimulating hormone, triiodothyronine, 29:231  
 thyrotropin releasing hormone, metoclopramide, 29:161  
 thyrotropin releasing hormone, prolactin, 29:161  
 thyrotropin releasing hormone, tryptophan, 29:161  
 thyrotropin releasing hormone, weight loss, 29:161  
 triiodothyronine, affective disorder, 29:231  
 triiodothyronine, thyroid stimulating hormone, 29:231

**Sleep deprivation** continued  
 tryptophan, metoclopramide, 29:161  
 tryptophan, prolactin, 29:161  
 tryptophan, thyrotropin releasing hormone, 29:161  
 tryptophan, weight loss, 29:161  
 weight loss, metoclopramide, 29:161  
 weight loss, prolactin, 29:161  
 weight loss, thyrotropin releasing hormone, 29:161  
 weight loss, tryptophan, 29:161

**Social group size**  
 age, mental retardation, 30:31  
 mental retardation, ethology, 30:31

**Sodium**  
 affective disorder, children, 29:215  
 children, affective disorder, 29:215

**Single photon emission computed tomography**  
 affective disorder, cerebral blood flow, 29:323, 29:331  
 Alzheimer's disease, cerebral blood flow, 29:347  
 Alzheimer's disease, computed tomography, 29:445  
 Alzheimer's disease, dementia, 29:445  
 Alzheimer's disease, EEG mapping, 29:449  
 brain death, children, 29:343  
 brain tumors, cerebral blood flow, 29:341  
 caudate nucleus, Huntington's chorea, 29:337  
 cerebral blood flow, affective disorder, 29:323, 29:331  
 cerebral blood flow, Alzheimer's disease, 29:347  
 cerebral blood flow, brain tumors, 29:341  
 cerebral blood flow, dementia, 29:327  
 cerebral blood flow, frontal lobe reduction, 29:331  
 cerebral blood flow, schizophrenia, 29:331  
 cerebral ischemia, computed tomography, 29:457  
 children, brain death, 29:343  
 computed tomography, Alzheimer's disease, 29:445  
 computed tomography, cerebral ischemia, 29:457  
 computed tomography, dementia, 29:445  
 computed tomography, EEG focus, 29:459  
 computed tomography, magnetic resonance imaging, 29:459  
 computed tomography, seizures, 29:459  
 dementia, Alzheimer's disease, 29:445  
 dementia, cerebral blood flow, 29:327  
 dementia, computed tomography, 29:445

**Single photon emission computed tomography** continued  
 EEG focus, computed tomography, 29:459  
 EEG focus, magnetic resonance imaging, 29:459  
 EEG focus, seizures, 29:459  
 EEG mapping, Alzheimer's disease, 29:449  
 frontal lobe reduction, cerebral blood flow, 29:331  
 frontal lobe reduction, schizophrenia, 29:331  
 Huntington's chorea, caudate nucleus, 29:337  
 magnetic resonance imaging, computed tomography, 29:459  
 magnetic resonance imaging, EEG focus, 29:459  
 magnetic resonance imaging, seizures, 29:459  
 mescaline, psychosis, 29:335  
 psychosis, mescaline, 29:335  
 schizophrenia, cerebral blood flow, 29:331  
 schizophrenia, frontal lobe reduction, 29:331  
 seizures, computed tomography, 29:459  
 seizures, EEG focus, 29:459  
 seizures, magnetic resonance imaging, 29:459

**Spiperone**  
 butaclamol, dopamine, 30:259  
 butaclamol, lymphocytes, 30:259  
 dopamine, butaclamol, 30:259  
 dopamine, lymphocytes, 30:259  
 lymphocytes, butaclamol, 30:259  
 lymphocytes, dopamine, 30:258

**Statistics**  
 affective disorder, cluster analysis, 28:227  
 affective disorder, seasonal affective disorder, 28:227  
 binary data, correlated data, 28:41  
 binary data, matched pair data, 28:41  
 cluster analysis, affective disorder, 28:227  
 cluster analysis, seasonal affective disorder, 28:227  
 correlated data, binary data, 28:41  
 correlated data, matched pair data, 28:41  
 matched pair data, binary data, 28:41  
 matched pair data, correlated data, 28:41  
 seasonal affective disorder, affective disorder, 28:227  
 seasonal affective disorder, cluster analysis, 28:227

**Stressors**  
 affective disorder, life events, 30:213  
 affective disorder, mania, 30:213

**Stressors** continued

- Axis IV, diagnostic criteria, 30:201
- Axis IV, DSM-III, 30:201
- blood pressure, eating disorders, 30:223
- blood pressure, heart rate, 30:223
- blood pressure, Type A behavior, 30:223
- diagnostic criteria, Axis IV, 30:201
- diagnostic criteria, DSM-III, 30:201
- DSM-III, Axis IV, 30:201
- DSM-III, diagnostic criteria, 30:201
- eating disorders, blood pressure, 30:223
- eating disorders, heart rate, 30:223
- eating disorders, Type A behavior, 30:223
- heart rate, blood pressure, 30:223
- heart rate, eating disorders, 30:223
- heart rate, Type A behavior, 30:223
- life events, affective disorder, 30:213
- life events, mania, 30:213
- mania, affective disorder, 30:213
- mania, life events, 30:213
- Type A behavior, blood pressure, 30:223
- Type A behavior, eating disorders, 30:223
- Type A behavior, heart rate, 30:223

**Stroke**

- computed tomography, embolic mechanisms, 29:273
- embolic mechanisms, computed tomography, 29:273

**Substance abuse**

- affective disorder, cocaine, 28:105, 28:335
- affective disorder, comorbidity, 28:105, 28:335
- alcoholism, cocaine, 29:113
- alcoholism, comorbidity, 29:113
- alcoholism, genetics, 29:113
- amantadine, bromocriptine, 29:11
- amantadine, cocaine, 29:11
- amantadine, withdrawal, 29:11
- blood pressure, cocaine, 27:117
- blood pressure, haloperidol, 27:117
- blood pressure, heart rate, 27:117
- blood pressure, subjective effects, 27:117
- bromocriptine, amantadine, 29:11
- bromocriptine, cocaine, 29:11
- bromocriptine, withdrawal, 29:11
- cocaine, affective disorder, 28:105, 28:335
- cocaine, alcoholism, 29:113
- cocaine, amantadine, 29:11
- cocaine, blood pressure, 27:117
- cocaine, bromocriptine, 29:11
- cocaine, comorbidity, 28:105, 28:335, 29:113
- cocaine, eye movements, 29:123
- cocaine, genetics, 29:113
- cocaine, haloperidol, 27:117

**Substance abuse** continued

- cocaine, heart rate, 27:117
- cocaine, 3-methoxy-4-hydroxyphenylglycol, 29:123
- cocaine, subjective effects, 27:117
- cocaine, withdrawal, 29:11
- comorbidity, affective disorder, 28:105, 28:335
- comorbidity, alcoholism, 29:113
- comorbidity, cocaine, 28:105, 28:335, 29:113
- comorbidity, genetics, 29:113
- eye movements, cocaine, 29:123
- eye movements, 3-methoxy-4-hydroxy-phenylglycol, 29:123
- genetics, alcoholism, 29:113
- genetics, cocaine, 29:113
- genetics, comorbidity, 29:113
- haloperidol, blood pressure, 27:117
- haloperidol, cocaine, 27:117
- haloperidol, heart rate, 27:117
- haloperidol, subjective effects, 27:117
- heart rate, blood pressure, 27:117
- heart rate, cocaine, 27:117
- heart rate, haloperidol, 27:117
- heart rate, subjective effects, 27:117
- 3-methoxy-4-hydroxyphenylglycol, cocaine, 29:123
- 3-methoxy-4-hydroxyphenylglycol, eye movements, 29:123
- subjective effects, blood pressure, 27:117
- subjective effects, cocaine, 27:117
- subjective effects, haloperidol, 27:117
- subjective effects, heart rate, 27:117
- withdrawal, amantadine, 29:11
- withdrawal, bromocriptine, 29:11
- withdrawal, cocaine, 29:11

**Suicide**

- Albert Einstein College of Medicine Suicide Intent Scale, affective disorder, 27:71
- affective disorder, Albert Einstein College of Medicine Suicide Intent Scale, 27:71
- depressed mood, impulsivity, 27:71
- depressed mood, seriousness of attempt, 27:71
- desipramine, frontal lobe, 30:125
- desipramine, imipramine binding, 30:125
- desipramine, serotonin, 30:125
- frontal lobe, desipramine, 30:125
- frontal lobe, imipramine binding, 30:125
- frontal lobe, serotonin, 30:125
- imipramine binding, desipramine, 30:125
- imipramine binding, frontal lobe, 30:125
- imipramine binding, platelet, 30:21

**Suicide** continued

- imipramine binding, serotonin, 30:125
- impulsivity, depressed mood, 27:71
- impulsivity, seriousness of attempt, 27:71
- risk factors, violence, 28:215
- seriousness of attempt, depressed mood, 27:71
- seriousness of attempt, impulsivity, 27:71
- serotonin, desipramine, 30:125
- serotonin, frontal lobe, 30:125
- serotonin, imipramine binding, 30:125
- violence, risk factors, 28:215

**Syncope**

- cortisol, growth hormone, 28:351
- cortisol, panic disorder, 28:351
- cortisol, prolactin, 28:351
- growth hormone, panic disorder, 28:351
- growth hormone, prolactin, 28:351
- panic disorder, cortisol, 28:351
- panic disorder, growth hormone, 28:351
- panic disorder, prolactin, 28:351
- prolactin, panic disorder, 28:351

**Tardive dyskinesia**

- Abnormal Involuntary Movement Scale, electromechanical measures, 27:193
- Abnormal Involuntary Movement Scale, observer ratings, 27:193
- affective symptoms, neuroleptics, 28:315
- affective symptoms, schizophrenia, 28:315
- choline, neuroleptics, 29:45
- choline, red blood cells, 29:45
- choline, schizophrenia, 29:45
- diabetes mellitus, glucose tolerance, 29:17
- diabetes mellitus, haloperidol, 29:17
- diabetes mellitus, schizophrenia, 29:17
- electromechanical measures, Abnormal Involuntary Movement Scale, 27:193
- electromechanical measures, observer ratings, 27:193
- electromechanical measures, Scale for the Assessment of Negative Symptoms, 28:145
- electromechanical measures, schizophrenia, 28:145
- essential fatty acids, linoleic acid, 27:313
- evoked potentials, schizophrenia, 28:117
- glucose tolerance, diabetes mellitus, 29:17
- glucose tolerance, haloperidol, 29:17
- glucose tolerance, schizophrenia, 29:17
- haloperidol, diabetes mellitus, 29:17
- haloperidol, glucose tolerance, 29:17
- haloperidol, schizophrenia, 29:17
- linoleic acid, essential fatty acids, 27:313
- neuroleptics, affective symptoms, 28:315
- neuroleptics, choline, 29:45
- neuroleptics, red blood cells, 29:45

**Tardive dyskinesia** continued

- neuroleptics, schizophrenia, 28:315, 29:45
- observer ratings, Abnormal Involuntary Movement Scale, 27:193
- observer ratings, electromechanical measures, 27:193
- red blood cells, choline, 29:45
- red blood cells, neuroleptics, 29:45
- red blood cells, schizophrenia, 29:45
- Scale for the Assessment of Negative Symptoms, electromechanical measures, 28:145
- Scale for the Assessment of Negative Symptoms, schizophrenia, 28:145
- schizophrenia, affective symptoms, 28:315
- schizophrenia, choline, 29:45
- schizophrenia, diabetes mellitus, 29:17
- schizophrenia, electromechanical measures, 28:145
- schizophrenia, evoked potentials, 28:117
- schizophrenia, glucose tolerance, 29:17
- schizophrenia, haloperidol, 29:17
- schizophrenia, neuroleptics, 28:315, 29:45
- schizophrenia, red blood cells, 29:45
- schizophrenia, Scale for the Assessment of Negative Symptoms, 28:145

**Temperature**

- activity, menstrual cycle, 30:285
- activity, premenstrual syndrome, 30:285
- activity, sleep, 30:285
- affective disorder, bipolar depression, 27:23
- affective disorder, circadian rhythms, 27:23, 28:263
- affective disorder, cortisol, 28:263
- affective disorder, melatonin, 28:263
- affective disorder, norepinephrine, 28:263
- affective disorder, seasonal affective disorder, 28:323
- affective disorder, sleep, 27:23
- affective disorder, thyroid stimulating hormone, 28:263
- bipolar depression, affective disorder, 27:23
- bipolar depression, circadian rhythms, 27:23
- bipolar depression, sleep, 27:23
- circadian rhythms, affective disorder, 27:23, 28:263
- circadian rhythms, bipolar depression, 27:23
- circadian rhythms, cortisol, 28:263
- circadian rhythms, melatonin, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, sleep, 27:23

**Temperature** continued

- circadian rhythms, thyroid stimulating hormone, 28:263
- cortisol, affective disorder, 28:263
- cortisol, circadian rhythms, 28:263
- cortisol, melatonin, 28:263
- cortisol, norepinephrine, 28:263
- cortisol, thyroid stimulating hormone, 28:263
- melatonin, affective disorder, 28:263
- melatonin, circadian rhythms, 28:263
- melatonin, cortisol, 28:263
- melatonin, norepinephrine, 28:263
- melatonin, thyroid stimulating hormone, 28:263
- menstrual cycle, activity, 30:285
- menstrual cycle, premenstrual syndrome, 30:285
- menstrual cycle, sleep, 30:285
- norepinephrine, affective disorder, 28:263
- norepinephrine, circadian rhythms, 28:263
- norepinephrine, cortisol, 28:263
- norepinephrine, melatonin, 28:263
- norepinephrine, thyroid stimulating hormone, 28:263
- premenstrual syndrome, activity, 30:285
- premenstrual syndrome, menstrual cycle, 30:285
- premenstrual syndrome, sleep, 30:285
- seasonal affective disorder, affective disorder, 28:323
- sleep, activity, 30:285
- sleep, affective disorder, 27:23
- sleep, bipolar depression, 27:23
- sleep, circadian rhythms, 27:23
- sleep, menstrual cycle, 30:285
- sleep, premenstrual syndrome, 30:285
- thyroid stimulating hormone, affective disorder, 28:263
- thyroid stimulating hormone, circadian rhythms, 28:263
- thyroid stimulating hormone, cortisol, 28:263
- thyroid stimulating hormone, melatonin, 28:263
- thyroid stimulating hormone, norepinephrine, 28:263

**Theophylline**

- lithium, rats, 30:77
- lithium, seizures, 30:77
- rats, lithium, 30:77
- seizures, lithium, 30:77
- seizures, rats, 30:77

**Thiamine**

- acetazolamide, pyruvate dehydrogenase, 28:279
- acetazolamide, schizophrenia, 28:279
- pyruvate dehydrogenase, acetazolamide, 28:279
- pyruvate dehydrogenase, schizophrenia, 28:279
- schizophrenia, acetazolamide, 28:279
- schizophrenia, pyruvate dehydrogenase, 28:279

**Thyroid stimulating hormone**

- affective disorder, circadian rhythms, 28:263
- affective disorder, cortisol, 28:263
- affective disorder, melatonin, 28:263
- affective disorder, norepinephrine, 28:263
- affective disorder, sleep deprivation, 29:231
- affective disorder, temperature, 28:263
- affective disorder, triiodothyronine, 29:231
- alcoholism, computed tomography, 28:89
- alcoholism, growth hormone, 28:89
- alcoholism, prolactin, 28:89
- alcoholism, thyrotropin releasing hormone test, 28:89
- circadian rhythms, affective disorder, 28:263
- circadian rhythms, cortisol, 28:263
- circadian rhythms, melatonin, 28:263
- circadian rhythms, norepinephrine, 28:263
- circadian rhythms, temperature, 28:263
- computed tomography, alcoholism, 28:89
- computed tomography, growth hormone, 28:89
- computed tomography, prolactin, 28:89
- computed tomography, thyrotropin releasing hormone test, 28:89
- cortisol, affective disorder, 28:263
- cortisol, circadian rhythms, 28:263
- cortisol, melatonin, 28:263
- cortisol, norepinephrine, 28:263
- cortisol, temperature, 28:263
- growth hormone, alcoholism, 28:89
- growth hormone, computed tomography, 28:89
- growth hormone, prolactin, 28:89
- growth hormone, thyrotropin releasing hormone test, 28:89
- melatonin, affective disorder, 28:263
- melatonin, circadian rhythms, 28:263
- melatonin, cortisol, 28:263
- melatonin, norepinephrine, 28:263

**Thyroid Stimulating Hormone** continued  
 melatonin, temperature, 28:263  
 norepinephrine, affective disorder, 28:263  
 norepinephrine, circadian rhythms, 28:263  
 norepinephrine, cortisol, 28:263  
 norepinephrine, melatonin, 28:263  
 norepinephrine, temperature, 28:263  
 prolactin, alcoholism, 28:89  
 prolactin, computed tomography, 28:89  
 prolactin, growth hormone, 28:89  
 prolactin, thyrotropin releasing hormone test, 28:89  
 sleep deprivation, affective disorder, 29:231  
 sleep deprivation, triiodothyronine, 29:231  
 temperature, affective disorder, 28:263  
 temperature, circadian rhythms, 28:263  
 temperature, cortisol, 28:263  
 temperature, melatonin, 28:263  
 temperature, norepinephrine, 28:263  
 thyrotropin releasing hormone test, alcoholism, 28:89  
 thyrotropin releasing hormone test, computed tomography, 28:89  
 thyrotropin releasing hormone test, growth hormone, 28:89  
 thyrotropin releasing hormone test, prolactin, 28:89  
 triiodothyronine, affective disorder, 29:231  
 triiodothyronine, sleep deprivation, 29:231

**Thyrotropin releasing hormone**  
 alcoholism, computed tomography, 28:89  
 alcoholism, growth hormone, 28:89  
 alcoholism, prolactin, 28:89  
 alcoholism, thyroid stimulating hormone, 28:89  
 computed tomography, alcoholism, 28:89  
 computed tomography, growth hormone, 28:89  
 computed tomography, prolactin, 28:89  
 computed tomography, thyroid stimulating hormone, 28:89  
 growth hormone, alcoholism, 28:89  
 growth hormone, computed tomography, 28:89  
 growth hormone, prolactin, 28:89  
 growth hormone, thyroid stimulating hormone, 28:89  
 metoclopramide, prolactin, 29:161  
 metoclopramide, sleep, 29:161  
 metoclopramide, tryptophan, 29:161  
 metoclopramide, weight loss, 29:161  
 prolactin, alcoholism, 28:89

**Thyrotropin releasing hormone** continued  
 prolactin, computed tomography, 28:89  
 prolactin, growth hormone, 28:89  
 prolactin, metoclopramide, 29:161  
 prolactin, sleep, 29:161  
 prolactin, thyroid stimulating hormone, 28:89  
 prolactin, tryptophan, 29:161  
 prolactin, weight loss, 29:161  
 sleep, metoclopramide, 29:161  
 sleep, prolactin, 29:161  
 sleep, tryptophan, 29:161  
 sleep, weight loss, 29:161  
 thyroid stimulating hormone, alcoholism, 28:89  
 thyroid stimulating hormone, computed tomography, 28:89  
 thyroid stimulating hormone, growth hormone, 28:89  
 thyroid stimulating hormone, prolactin, 28:89  
 tryptophan, metoclopramide, 29:161  
 tryptophan, prolactin, 29:161  
 tryptophan, sleep, 29:161  
 tryptophan, weight loss, 29:161  
 weight loss, metoclopramide, 29:161  
 weight loss, prolactin, 29:161  
 weight loss, sleep, 29:161  
 weight loss, tryptophan, 29:161

**Tribulin**  
 anxiety, depressed mood, 30:95  
 anxiety, headache, 30:95  
 anxiety, migraine, 30:95  
 anxiety, monoamine oxidase, 30:95  
 depressed mood, anxiety, 30:95  
 depressed mood, headache, 30:95  
 depressed mood, migraine, 30:95  
 depressed mood, monoamine oxidase, 30:95  
 headache, anxiety, 30:95  
 headache, depressed mood, 30:95  
 headache, monoamine oxidase, 30:95  
 migraine, anxiety, 30:95  
 migraine, depressed mood, 30:95  
 migraine, monoamine oxidase, 30:95  
 monoamine oxidase, anxiety, 30:95  
 monoamine oxidase, depressed mood, 30:95  
 monoamine oxidase, headache, 30:95  
 monoamine oxidase, migraine, 30:95  
 monoamine oxidase, platelet, 30:95

**Triiodothyronine**  
 affective disorder, sleep deprivation, 29:231

**Triiodothyronine** continued

- affective disorder, thyroid stimulating hormone, 29:231
- antidepressants, food intake, 27:149
- antidepressants, learned helplessness, 27:149
- antidepressants, rats, 27:149
- beta-hydroxybutyric acid, computed tomography, 27:39
- beta-hydroxybutyric acid, cortisol, 27:39
- beta-hydroxybutyric acid, eating disorders, 27:39
- beta-hydroxybutyric acid, ventricle-brain ratio, 27:39
- body size, mitral valve prolapse, 28:161
- body size, panic disorder, 28:161
- computed tomography, beta-hydroxybutyric acid, 27:39
- computed tomography, cortisol, 27:39
- computed tomography, eating disorders, 27:39
- computed tomography, ventricle-brain ratio, 27:39
- cortisol, beta-hydroxybutyric acid, 27:39
- cortisol, computed tomography, 27:39
- cortisol, eating disorders, 27:39
- cortisol, ventricle-brain ratio, 27:39
- eating disorders, beta-hydroxybutyric acid, 27:39
- eating disorders, computed tomography, 27:39
- eating disorders, cortisol, 27:39
- eating disorders, ventricle-brain ratio, 27:39
- food intake, antidepressants, 27:149
- food intake, learned helplessness, 27:149
- food intake, rats, 27:149
- learned helplessness, antidepressants, 27:149
- learned helplessness, food intake, 27:149
- learned helplessness, rats, 27:149
- mitral valve prolapse, body size, 28:161
- mitral valve prolapse, panic disorder, 28:161
- panic disorder, body size, 28:161
- panic disorder, mitral valve prolapse, 28:161
- rats, antidepressants, 27:149
- rats, food intake, 27:149
- rats, learned helplessness, 27:149
- sleep deprivation, affective disorder, 29:231
- sleep deprivation, thyroid stimulating hormone, 29:231

**Triiodothyronine** continued

- thyroid stimulating hormone, affective disorder, 29:231
- thyroid stimulating hormone, sleep deprivation, 29:231
- ventricle-brain ratio, beta-hydroxybutyric acid, 27:39
- ventricle-brain ratio, computed tomography, 27:39
- ventricle-brain ratio, cortisol, 27:39
- ventricle-brain ratio, eating disorders, 27:39

**Tryptophan**

- metoclopramide, prolactin, 29:161
- metoclopramide, sleep, 29:161
- metoclopramide, thyrotropin releasing hormone, 29:161
- metoclopramide, weight loss, 29:161
- prolactin, metoclopramide, 29:161
- prolactin, sleep, 29:161
- prolactin, thyrotropin releasing hormone, 29:161
- prolactin, weight loss, 29:161
- sleep, metoclopramide, 29:161
- sleep, prolactin, 29:161
- sleep, thyrotropin releasing hormone, 29:161
- sleep, weight loss, 29:161
- thyrotropin releasing hormone, metoclopramide, 29:161
- thyrotropin releasing hormone, prolactin, 29:161
- thyrotropin releasing hormone, sleep, 29:161
- thyrotropin releasing hormone, weight loss, 29:161
- weight loss, metoclopramide, 29:161
- weight loss, prolactin, 29:161
- weight loss, sleep, 29:161
- weight loss, thyrotropin releasing hormone, 29:161

**Type A and B personality**

- blood pressure, eating disorders, 30:223
- blood pressure, stressors, 30:223
- eating disorders, blood pressure, 30:223
- eating disorders, heart rate, 30:223
- eating disorders, stressors, 30:223
- heart rate, eating disorders, 30:223
- heart rate, stressors, 30:223
- stressors, eating disorders, 30:223

**Ventricle-brain ratio**

- affective disorders, computed tomography, 29:271
- affective disorders, symptomatology, 29:271

**Venticle-brain ratio** continued

- attention, computed tomography, 29:267
- attention, laterality, 29:267
- attention, schizophrenia, 29:267
- beta-hydroxybutyric acid, computed tomography, 27:39
- beta-hydroxybutyric acid, cortisol, 27:39
- beta-hydroxybutyric acid, eating disorders, 27:39
- beta-hydroxybutyric acid, triiodothyronine, 27:39
- computed tomography, affective disorders, 29:271
- computed tomography, attention, 29:267
- computed tomography, beta-hydroxybutyric acid, 27:39
- computed tomography, cortisol, 27:39
- computed tomography, eating disorders, 27:39
- computed tomography, laterality, 29:267
- computed tomography, magnetic resonance imaging, 29:265
- computed tomography, schizophrenia, 29:257, 29:265, 29:267
- computed tomography, symptomatology, 29:271
- computed tomography, triiodothyronine, 27:39
- cortisol, beta-hydroxybutyric acid, 27:39
- cortisol, computed tomography, 27:39
- cortisol, eating disorders, 27:39
- cortisol, triiodothyronine, 27:39
- eating disorders, beta-hydroxybutyric acid, 27:39
- eating disorders, computed tomography, 27:39
- eating disorders, cortisol, 27:39
- eating disorders, triiodothyronine, 27:39
- laterality, attention, 29:267
- laterality, computed tomography, 29:267
- laterality, schizophrenia, 29:267
- magnetic resonance imaging, computed tomography, 29:265
- magnetic resonance imaging, schizophrenia, 29:265
- schizophrenia, attention, 29:267
- schizophrenia, computed tomography, 29:257, 29:265, 29:267
- schizophrenia, laterality, 29:267
- schizophrenia, magnetic resonance imaging, 29:265
- symptomatology, affective disorder, 29:271
- symptomatology, computed tomography, 29:271

**Venticle-brain ratio** continued

- triiodothyronine, beta-hydroxybutyric acid, 27:39
- triiodothyronine, computed tomography, 27:39
- triiodothyronine, cortisol, 27:39
- triiodothyronine, eating disorders, 27:39

**Violence**

- risk factors, suicide, 28:215
- suicide, risk factors, 28:215
- Visual analogue scale
- affective disorder, circadian rhythms, 27:89
- affective disorder, global vigor and affect, 27:89
- circadian rhythms, affective disorder, 27:89
- circadian rhythms, global vigor and affect, 27:89
- global vigor and affect, affective disorder, 27:89
- global vigor and affect, circadian rhythms, 27:89

**Wisconsin Card Sort Test**

- computed tomography, electroencephalogram, 29:137
- computed tomography, frontal lobe, 29:137
- computed tomography, schizophrenia, 29:137
- electroencephalogram, frontal lobe, 29:137
- electroencephalogram, schizophrenia, 29:137
- frontal lobe, computed tomography, 29:137
- frontal lobe, electroencephalogram, 29:137
- frontal lobe, schizophrenia, 29:137
- schizophrenia, frontal lobe, 29:137

**Weight loss**

- metoclopramide, prolactin, 29:161
- metoclopramide, sleep, 29:161
- metoclopramide, thyrotropin releasing hormone, 29:161
- metoclopramide, tryptophan, 29:161
- prolactin, sleep, 29:161
- prolactin, thyrotropin releasing hormone, 29:161
- prolactin, tryptophan, 29:161
- sleep, metoclopramide, 29:161
- sleep, prolactin, 29:161
- sleep, thyrotropin releasing hormone, 29:161
- sleep, tryptophan, 29:161
- thyrotropin releasing hormone, metoclopramide, 29:161
- thyrotropin releasing hormone, prolactin, 29:161

**Weight loss** continued

- thyrotropin releasing hormone, sleep, 29:161
- thyrotropin releasing hormone, tryptophan, 29:161
- tryptophan, prolactin, 29:161
- tryptophan, sleep, 29:161
- tryptophan, thyrotropin releasing hormone, 29:161

**Yohimbine**

- blood pressure, cortisol, 27:173
- blood pressure, generalized anxiety disorder, 27:173
- blood pressure, heart rate, 27:173
- blood pressure, 3-methoxy-4-hydroxyphenylglycol, 27:173
- blood pressure, norepinephrine, 27:173
- cortisol, blood pressure, 27:173
- cortisol, generalized anxiety disorder, 27:173
- cortisol, heart rate, 27:173
- cortisol, 3-methoxy-4-hydroxyphenylglycol, 27:173
- cortisol, norepinephrine, 27:173
- generalized anxiety disorder, blood pressure, 27:173
- generalized anxiety disorder, cortisol, 27:173

**Yohimbine** continued

- generalized anxiety disorder, heart rate, 27:173
- generalized anxiety disorder, 3-methoxy-4-hydroxyphenylglycol, 27:173
- generalized anxiety disorder, norepinephrine, 27:173
- heart rate, cortisol, 27:173
- heart rate, generalized anxiety disorder, 27:173
- heart rate, 3-methoxy-4-hydroxyphenylglycol, 27:173
- heart rate, norepinephrine, 27:173
- 3-methoxy-4-hydroxyphenylglycol, blood pressure, 27:173
- 3-methoxy-4-hydroxyphenylglycol, cortisol, 27:173
- 3-methoxy-4-hydroxyphenylglycol, generalized anxiety disorder, 27:173
- 3-methoxy-4-hydroxyphenylglycol, heart rate, 27:173
- 3-methoxy-4-hydroxyphenylglycol, norepinephrine, 27:173
- norepinephrine, generalized anxiety disorder, 27:173
- norepinephrine, heart rate, 27:173
- norepinephrine, 3-methoxy-4-hydroxyphenylglycol, 27:173

